WO2024041661A1 - 细胞周期蛋白调节剂 - Google Patents
细胞周期蛋白调节剂 Download PDFInfo
- Publication number
- WO2024041661A1 WO2024041661A1 PCT/CN2023/115312 CN2023115312W WO2024041661A1 WO 2024041661 A1 WO2024041661 A1 WO 2024041661A1 CN 2023115312 W CN2023115312 W CN 2023115312W WO 2024041661 A1 WO2024041661 A1 WO 2024041661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- ring
- optionally substituted
- group
- mmol
- Prior art date
Links
- 102000016736 Cyclin Human genes 0.000 title abstract description 11
- 108050006400 Cyclin Proteins 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 345
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 230000008685 targeting Effects 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 5
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 549
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 249
- 238000006243 chemical reaction Methods 0.000 description 162
- 239000000243 solution Substances 0.000 description 150
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 126
- 239000007787 solid Substances 0.000 description 121
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 110
- 239000000203 mixture Substances 0.000 description 108
- -1 antibodies Proteins 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 230000015572 biosynthetic process Effects 0.000 description 57
- 238000003786 synthesis reaction Methods 0.000 description 57
- 238000005481 NMR spectroscopy Methods 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 49
- 239000011541 reaction mixture Substances 0.000 description 48
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 48
- 239000012267 brine Substances 0.000 description 43
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- 238000004440 column chromatography Methods 0.000 description 32
- 239000012074 organic phase Substances 0.000 description 32
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 31
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 30
- 102100036876 Cyclin-K Human genes 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 101000713127 Homo sapiens Cyclin-K Proteins 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 25
- 239000012044 organic layer Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 239000003480 eluent Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000003818 flash chromatography Methods 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000004698 Polyethylene Substances 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000009739 binding Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000010791 quenching Methods 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000003292 glue Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 10
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 108091007914 CDKs Proteins 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 7
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 239000012295 chemical reaction liquid Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000001064 degrader Substances 0.000 description 7
- 230000000593 degrading effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
- 230000026374 cyclin catabolic process Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940125953 molecular glue degrader Drugs 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 description 3
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 229940050176 methyl chloride Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 2
- 102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 108010049990 CD13 Antigens Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 102100029756 Cadherin-6 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 description 2
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 description 2
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 description 2
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010056045 K cadherin Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 102000000717 Lysine methyltransferases Human genes 0.000 description 2
- 108050008120 Lysine methyltransferases Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 description 2
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 description 2
- 102100028949 Serine/threonine-protein kinase TAO2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108050001286 Somatostatin Receptor Proteins 0.000 description 2
- 102000011096 Somatostatin receptor Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 2
- 102100039094 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MEXAGTSTSPYCEP-NUBCRITNSA-N (2r)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@@H](N)C(O)=O MEXAGTSTSPYCEP-NUBCRITNSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- TUMYZSXRMYKNMG-UHFFFAOYSA-N 2,6-dichloro-9-(1-methylpyrazol-4-yl)purine Chemical compound ClC1=NC(=C2N=CN(C2=N1)C=1C=NN(C=1)C)Cl TUMYZSXRMYKNMG-UHFFFAOYSA-N 0.000 description 1
- GRIMHSVOCZYGST-UHFFFAOYSA-N 2,6-dichloro-9-(3-fluorophenyl)purine Chemical compound FC1=CC=CC(N2C3=NC(Cl)=NC(Cl)=C3N=C2)=C1 GRIMHSVOCZYGST-UHFFFAOYSA-N 0.000 description 1
- TZGZJNYRHVQXOG-ZDUSSCGKSA-N 2-[(2S)-1-benzylpiperazin-2-yl]ethanol Chemical compound OCC[C@H]1CNCCN1CC1=CC=CC=C1 TZGZJNYRHVQXOG-ZDUSSCGKSA-N 0.000 description 1
- DSSFSAGQNGRBOR-LURJTMIESA-N 2-[(2s)-piperazin-2-yl]ethanol Chemical compound OCC[C@H]1CNCCN1 DSSFSAGQNGRBOR-LURJTMIESA-N 0.000 description 1
- RVZLNAFRTQWDFX-UHFFFAOYSA-N 2-[4-(aminomethyl)phenyl]phenol Chemical compound C1=CC(CN)=CC=C1C1=CC=CC=C1O RVZLNAFRTQWDFX-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- MLISZBPTIMZRFF-UHFFFAOYSA-N 3-hydroxy-4-phenylbenzonitrile Chemical compound OC1=CC(C#N)=CC=C1C1=CC=CC=C1 MLISZBPTIMZRFF-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- QNZKGZMRMGIXKO-UHFFFAOYSA-N 4-(2-hydroxyphenyl)benzonitrile Chemical compound OC1=CC=CC=C1C1=CC=C(C#N)C=C1 QNZKGZMRMGIXKO-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- YORLKVKBZRVNMZ-UHFFFAOYSA-N 4-bromobutoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCCBr YORLKVKBZRVNMZ-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- YXNDIZORRBESDA-UHFFFAOYSA-N 5-(aminomethyl)-2-phenylphenol Chemical compound OC1=CC(CN)=CC=C1C1=CC=CC=C1 YXNDIZORRBESDA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 101100168911 Arabidopsis thaliana CUL4 gene Proteins 0.000 description 1
- 101100021996 Arabidopsis thaliana CYP97C1 gene Proteins 0.000 description 1
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101150075175 Asgr1 gene Proteins 0.000 description 1
- 102100020998 Aspartate beta-hydroxylase domain-containing protein 1 Human genes 0.000 description 1
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108010073466 Bombesin Receptors Proteins 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010085074 Brevican Proteins 0.000 description 1
- 102100032312 Brevican core protein Human genes 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- YKZJACNAOMFBCS-INIZCTEOSA-N C(C1=CC=CC=C1)N1[C@H](CN(CC1)C(=O)OC(C)(C)C)CCO Chemical compound C(C1=CC=CC=C1)N1[C@H](CN(CC1)C(=O)OC(C)(C)C)CCO YKZJACNAOMFBCS-INIZCTEOSA-N 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 102100024220 CD180 antigen Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 101150031358 COLEC10 gene Proteins 0.000 description 1
- 102000015367 CRBN Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 description 1
- 102000012698 DDB1 Human genes 0.000 description 1
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 1
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 1
- 102100038605 Death-associated protein kinase 2 Human genes 0.000 description 1
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 101100168913 Dictyostelium discoideum culD gene Proteins 0.000 description 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 1
- 102100029638 Dual serine/threonine and tyrosine protein kinase Human genes 0.000 description 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 1
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 1
- 102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 101150097734 EPHB2 gene Proteins 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055179 EphA4 Receptor Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 101150078651 Epha4 gene Proteins 0.000 description 1
- 101150025643 Epha5 gene Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100021600 Ephrin type-A receptor 10 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 1
- 102100021604 Ephrin type-A receptor 6 Human genes 0.000 description 1
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 1
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100026130 Extracellular tyrosine-protein kinase PKDCC Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 1
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 description 1
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 description 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710155270 Glycerate 2-kinase Proteins 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 101150112082 Gpnmb gene Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000783987 Homo sapiens Aspartate beta-hydroxylase domain-containing protein 1 Proteins 0.000 description 1
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 1
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 description 1
- 101100499854 Homo sapiens DPEP1 gene Proteins 0.000 description 1
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 description 1
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101000865739 Homo sapiens Dual serine/threonine and tyrosine protein kinase Proteins 0.000 description 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 description 1
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 1
- 101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 description 1
- 101000898673 Homo sapiens Ephrin type-A receptor 10 Proteins 0.000 description 1
- 101000898696 Homo sapiens Ephrin type-A receptor 6 Proteins 0.000 description 1
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 description 1
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 1
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 description 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
- 101001045553 Homo sapiens Hemogen Proteins 0.000 description 1
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101000889893 Homo sapiens Inactive serine/threonine-protein kinase TEX14 Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001002695 Homo sapiens Integrin-linked protein kinase Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 description 1
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 1
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 1
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 1
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 1
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 description 1
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 description 1
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101000826079 Homo sapiens SRSF protein kinase 3 Proteins 0.000 description 1
- 101000648174 Homo sapiens Serine/threonine-protein kinase 10 Proteins 0.000 description 1
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 description 1
- 101000701401 Homo sapiens Serine/threonine-protein kinase 38 Proteins 0.000 description 1
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101001038337 Homo sapiens Serine/threonine-protein kinase LMTK1 Proteins 0.000 description 1
- 101001038335 Homo sapiens Serine/threonine-protein kinase LMTK2 Proteins 0.000 description 1
- 101001038341 Homo sapiens Serine/threonine-protein kinase LMTK3 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001123812 Homo sapiens Serine/threonine-protein kinase Nek11 Proteins 0.000 description 1
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
- 101000601456 Homo sapiens Serine/threonine-protein kinase Nek3 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 description 1
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 description 1
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 description 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 description 1
- 101000864806 Homo sapiens Serine/threonine-protein kinase Sgk2 Proteins 0.000 description 1
- 101000838579 Homo sapiens Serine/threonine-protein kinase TAO1 Proteins 0.000 description 1
- 101000662993 Homo sapiens Serine/threonine-protein kinase TNNI3K Proteins 0.000 description 1
- 101000989953 Homo sapiens Serine/threonine-protein kinase haspin Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000637847 Homo sapiens Serine/threonine-protein kinase tousled-like 2 Proteins 0.000 description 1
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000772231 Homo sapiens Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000772239 Homo sapiens Testis-specific serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101000892986 Homo sapiens Tyrosine-protein kinase FRK Proteins 0.000 description 1
- 101001026790 Homo sapiens Tyrosine-protein kinase Fes/Fps Proteins 0.000 description 1
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 description 1
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 1
- 101000727826 Homo sapiens Tyrosine-protein kinase RYK Proteins 0.000 description 1
- 101000661459 Homo sapiens Tyrosine-protein kinase STYK1 Proteins 0.000 description 1
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
- 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 description 1
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 description 1
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 description 1
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 1
- 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102100040173 Inactive serine/threonine-protein kinase TEX14 Human genes 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102100034845 KiSS-1 receptor Human genes 0.000 description 1
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 239000012819 MDM2-Inhibitor Substances 0.000 description 1
- 108010066373 MLK-like mitogen-activated protein triple kinase Proteins 0.000 description 1
- 101150078127 MUSK gene Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 1
- 102100033116 Mitogen-activated protein kinase kinase kinase 20 Human genes 0.000 description 1
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 description 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102100037603 P2X purinoceptor 5 Human genes 0.000 description 1
- 101710189969 P2X purinoceptor 5 Proteins 0.000 description 1
- 101700056750 PAK1 Proteins 0.000 description 1
- 101150001863 PKDCC gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 description 1
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100022938 Protein shisa-2 homolog Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 102100023017 SRSF protein kinase 3 Human genes 0.000 description 1
- 101100168914 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pcu4 gene Proteins 0.000 description 1
- 102100028900 Serine/threonine-protein kinase 10 Human genes 0.000 description 1
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100030515 Serine/threonine-protein kinase 33 Human genes 0.000 description 1
- 102100030514 Serine/threonine-protein kinase 38 Human genes 0.000 description 1
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100040293 Serine/threonine-protein kinase LMTK1 Human genes 0.000 description 1
- 102100040292 Serine/threonine-protein kinase LMTK2 Human genes 0.000 description 1
- 102100040291 Serine/threonine-protein kinase LMTK3 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100028775 Serine/threonine-protein kinase Nek11 Human genes 0.000 description 1
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
- 102100037706 Serine/threonine-protein kinase Nek3 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 description 1
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 description 1
- 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 description 1
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 1
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102100037670 Serine/threonine-protein kinase TNNI3K Human genes 0.000 description 1
- 102100029332 Serine/threonine-protein kinase haspin Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102100032014 Serine/threonine-protein kinase tousled-like 2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 108091007283 TRIM24 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 102100029355 Testis-specific serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100026159 Tomoregulin-1 Human genes 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100022011 Transcription intermediary factor 1-alpha Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100040959 Tyrosine-protein kinase FRK Human genes 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- 102100037333 Tyrosine-protein kinase Fes/Fps Human genes 0.000 description 1
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 description 1
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
- 102100029759 Tyrosine-protein kinase RYK Human genes 0.000 description 1
- 102100037781 Tyrosine-protein kinase STYK1 Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 description 1
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 1
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SIRSTRHGFGFVME-YFKPBYRVSA-N [(2s)-piperazin-2-yl]methanol Chemical compound OC[C@@H]1CNCCN1 SIRSTRHGFGFVME-YFKPBYRVSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000003636 chemical group Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000053842 human bromodomain and extra-terminal domain Human genes 0.000 description 1
- 108700009340 human bromodomain and extra-terminal domain Proteins 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960005540 iRGD Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108010067366 proto-oncogene protein c-fes-fps Proteins 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 231100000336 radiotoxic Toxicity 0.000 description 1
- 230000001690 radiotoxic effect Effects 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- FPQSSQQQKLJLPA-VIFPVBQESA-N tert-butyl (3s)-3-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@@H](CCO)C1 FPQSSQQQKLJLPA-VIFPVBQESA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Definitions
- the invention belongs to the field of medicinal chemistry, and specifically relates to a cell cycle protein regulator.
- molecular glue degraders achieve the purpose of killing cancer cells by destroying target proteins through the ubiquitin-proteasome system.
- the multiple myeloma drug lenalidomide is a molecular glue degrader that recruits E3 ubiquitin ligase to tag target proteins in cells and subsequently degrades it.
- molecular glues act as catalysts to drive target ubiquitination and induce degradation, which is a new strategy that can inactivate targets that are difficult to treat with traditional pharmacological methods.
- Molecular glue also cleverly avoids the limitations of traditional inhibitors, turning some targets from "undruggable" to "druggable”.
- the cell cycle is the basic process of cell life activities, which controls cells from the stationary phase to the growth and proliferation phase.
- Cyclin-dependent kinases (CDKs) and cyclins are core molecules in the entire cell cycle regulatory mechanism. In normal cells, the activity of cyclins is tightly controlled by their cell cycle-specific transcription and protein degradation, as well as by some CDK inhibitory proteins. In addition to promoting cell division, cyclins are also responsible for regulating various cellular functions. This mechanism is operated by cyclins and their catalytic partners, cyclin-dependent kinases (CDKs). However, these influencing factors are often out of control in human cancer, leading to abnormal activation of cell cycle proteins. Abnormal activity of the cell cycle machinery is present in essentially all types of tumors and is a driving force for tumorigenesis. Targeting a specific cell cycle protein may become an effective anti-cancer strategy.
- CDK inhibitors there are very few CDK inhibitors on the market, and all of them are CDK4/6 inhibitors. However, it is difficult for inhibitors that selectively target other CDK families to meet the required specificity. Almost all of them are multi-target inhibitors, which exhibit unacceptable toxicity in clinical practice, thus preventing their clinical application.
- kinase inhibitors can lead to the removal of kinase subunits, they maintain the integrity of cell cycle proteins and may trigger compensatory mechanisms. Degradation of the kinase may result in longer-lasting effects than its inhibition.
- CyclinK cyclin K
- CR8 is first of all a multi-kinase inhibitor that can inhibit the activity of multiple cyclins in the CDK family, resulting in toxicity that limits its clinical application.
- its activity in degrading CyclinK is also very average, which limits the use of its catalytic amount.
- the purpose of the present invention is to provide a cyclin degrading agent with higher activity or a novel cyclin modulating agent.
- R 1 is each independently H or C 1-4 alkyl
- n1 1, 2 or 3;
- Ring Ar 1 is selected from the following group: C 6-10 aromatic ring, 5 to 10 membered heteroaromatic ring, 5 to 10 membered bridged ring;
- Ring Cr 1 is selected from the group consisting of: H, C 3-10 carbocyclyl, 3 to 10 membered heterocyclyl, C 6-10 aryl, and 5 to 10 membered heteroaryl;
- R a and R b are each independently selected from the group consisting of: H, R e or R; or R a and R b are formed together with ring Ar 1 and ring Cr 1 in,
- X 7 is each independently selected from the group consisting of -O-, -S-, -N(R c )-, -C(R c ) 2 -, -C(R c ) 2 -C(R c ) 2 - ;
- Subscripts n5 and n6 are each independently 0, 1, 2 or 3;
- Each R e is independently selected from the group consisting of: hydroxyl, C 1-6 alkyl, -OC 1-6 alkyl, -OC 1-6 alkylene -R f ;
- R f is selected from the following group: -CN, -OH, -NH 2 , -NH(C 1-6 alkyl), -N(C 1-6 alkyl) 2 ;
- Subscripts n3 and n4 are each independently 0, 1, 2, 3 or 4;
- R 2 is selected from the following group: H, CN, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3 -8 cycloalkyl, optionally substituted 3 to 8-membered heterocyclyl;
- X 1 , X 2 and X 6 are each independently N or C(R c );
- X 3 , X 4 and X 5 are each independently N or C;
- M 1 is selected from the following group: None, X 8 , (M 4 ) s ; where,
- X 8 is N(R c ) or C(R c ) 2 ;
- M 4 is each independently selected from the group consisting of O, S, C(O)O, C(O), N(R c ) and C 1-4 alkylene;
- s is 1, 2 or 3;
- M 2 is none or a ring as shown in formula A;
- X 9 is the position connected to M 1
- X 10 is the position connected to M 3
- X 9 is N or C (R m )
- X 10 is selected from the following group: O, S, N or C ( R m ) ; X 11 and , and m1+m2 ⁇ 2;
- R m is each independently R c or R m1 ;
- Each R m1 is independently selected from the group consisting of: hydroxyl, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 hydroxyalkyl, optionally substituted C 1-6 haloalkyl; or, two R m1 together form a single bond, an optionally substituted C 1-4 alkylene group or an optionally substituted 1 to 4-membered heteroalkylene group;
- M 3 is selected from the following group: None, R 3 , -NH-R 3 ; wherein,
- R 3 is selected from the following group: H, optionally substituted C 1-6 alkyl, optionally substituted C 1-6- hydroxyalkyl, optionally substituted C 1-6- haloalkyl;
- R c is each independently H or C 1-4 alkyl
- the optional substitution means that one or more (such as 1, 2, 3 or 4) hydrogens in the group are substituted by the substituent R, and R is selected from the following group: D, Halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, -CN , -OR', -NO 2 , - NR'R", -SR', -OC(O)R', -C(O)R', -CO 2 R', -CONR', -OC(O)NR'R", -NR"C( O)R', -NR"-C(O)NR'R", -NR"C(O) 2 R', -S(O)R', -S(O) 2 R', -S(O ) 2 NR'R", -NR"S(O) 2 R', C 3-10 cycloalkyl optionally substituted
- Each R' is independently H, D, optionally substituted by one or more R'", a group selected from the following group: C 1-6 alkyl, C 3-10 cycloalkyl, 4 to 10 Membered heterocycloalkyl, C 6-10 aryl, 5 to 10 membered heteroaryl, -C 1-4 alkylene -C 3-10 cycloalkyl, -C 1-4 alkylene -4 to 10 One-membered heterocycloalkyl, -C 1-4 alkylene-C 6-10 aryl-C 1-4 alkylene-5 to 10-membered heteroaryl;
- Each R" is selected from the group consisting of H, D, C 1-4 alkyl, C 1-4 haloalkyl, and C 3-4 cycloalkyl;
- Each R"' is independently selected from the group consisting of: D, halogen, hydroxyl, nitro, CN, C 1-6 alkyl, C 1-6 haloalkyl.
- the compound is not CR8 as shown below:
- ring Ar 1 is selected from the following group: C 6-10 aromatic ring, 5 to 10 membered heteroaromatic ring.
- ring Ar 1 is selected from the following group: benzene ring, 5- to 10-membered heteroaromatic ring.
- Ring Ar 1 is selected from the following group:
- * represents the position connected to ring Cr 1 ;
- X a , X b , X c and X d are each independently CH and N;
- X g is selected from the following group: NH, O, S;
- X h , Xi and X j is each independently -CH 2 - or -CH 2 -CH 2 -.
- Ring Ar 1 is selected from the following group:
- * represents the position connected to ring Cr 1 ;
- X a , X b , X c and X d are each independently CH and N;
- X g is selected from the following group: NH, O, S.
- Ring Ar 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- * represents the position connected to ring Cr 1 .
- the carbocyclic ring is a saturated or unsaturated carbocyclic ring containing 1 or 2 double bonds.
- the C 3-10 carbocyclic ring is a C 4-10 carbocyclic ring; preferably, it is a C 4-6 carbocyclic ring.
- the 3- to 10-membered heterocyclyl group is a saturated 3- to 10-membered heterocyclyl group.
- the 3- to 10-membered heterocyclyl group is a 4- to 10-membered heterocyclyl group; preferably, it is a 4- to 6-membered heterocyclyl group.
- ring Cr 1 is selected from the following group:
- X d and X e are each independently N or CH; X f is NH, S, O; X g is N or CH.
- Ring Cr 1 is Ring Ar 2 ; and Ring Ar 2 is selected from the group consisting of: C 6-10 aryl, and 5 to 10 membered heteroaryl.
- ring Ar 2 is selected from the following group:
- X d and X e are each independently -N- or -CH-; X f is -NH-, -S-, -O-; X g is N or CH.
- Ring Ar 2 is In another preferred embodiment, Ring Ar 2 is phenyl.
- ring Ar 2 is not a nitrogen-containing heteroaryl group (wherein, the nitrogen-containing heteroaryl group has 1 or 2 nitrogen heteroatoms on the ring and does not contain other heteroaryls.
- atomic heteroaryl groups such as pyridyl, pyrazolyl, imidazolyl and pyrazinyl).
- n3 is 0 (that is, ring Ar 1 is unsubstituted); or, n3 is 1, 2, 3 or 4 (that is, ring Ar 1 is substituted by 1, 2, 3 or 4 R a ), and R a is each independently selected from the group consisting of: D, halogen, C 1-6 alkyl, C 1-6 haloalkyl.
- n3 is 0. In another preferred example, n3 is 1, and R a is Re .
- n4 is 0 (that is, ring Cr 1 is unsubstituted); or, n4 is 1, 2, 3 or 4 (that is, ring Cr 1 is substituted by 1, 2, 3 or 4 R b ), and R b is each independently selected from the group consisting of: D, halogen, C 1-6 alkyl, C 1-6 haloalkyl.
- n4 is 0. In another preferred example, n4 is 1, and R b is Re .
- n3 is 0 (that is, ring Ar 1 is unsubstituted); or, n3 is 1, 2, 3 or 4 (that is, ring Ar 1 is substituted by 1, 2, 3 or 4 R a ), and R a is each independently selected from the group consisting of: D, halogen, C 1-6 alkyl, C 1-6 haloalkyl.
- X 1 is N
- X 2 is CR c
- X 3 is C
- X 4 is C
- X 5 is N and X 6 is CR c
- X 1 is CR c
- X 2 is CR c
- X 3 is CR c
- X 4 is N
- X 5 is C and X 6 is CR c
- X 1 is N
- X 2 is CR c
- X 3 is CR c
- X 4 is N
- X 5 is C and X 6 is CR c .
- X 1 is CR c
- X 2 is CR c
- X 3 is CR c
- X 4 is N
- X 5 is N and X 6 is CR c
- X 1 is CR c
- X 2 is CR c
- X 3 is N
- X 4 is CR c
- X 5 is C and X 6 is CR c
- X 1 is CR c
- X 2 is N
- X 3 is N
- X 4 is CR c
- X 5 is C and X 6 is CR c
- X 1 is N
- X 2 is CR c
- X 3 is N
- X 4 is CR c
- X 5 is C and X 6 is CR c .
- R c are all H.
- X 1 is N, X 2 is CH, X 3 is C, X 4 is C, X 5 is N and X 6 is CH.
- X 1 is CH, X 2 is CH, X 3 is CH, X 4 is N, X 5 is C and X 6 is CH.
- X 1 is N, X 2 is CH, X 3 is CH, X 4 is N, X 5 is C and X 6 is CH.
- X 1 is CH, X 2 is CH, X 3 is CH, X 4 is N, X 5 is C and X 6 is CH.
- X 1 is CH, X 2 is CH, X 3 is CH, X 4 is N, X 5 is N and X 6 is CH.
- X 1 is CH, X 2 is CH, X 3 is N, X 4 is CH, X 5 is C and X 6 is CH.
- X 1 is CH, X 2 is N, X 3 is N, X 4 is CH, X 5 is C and X 6 is CH.
- X 1 is N, X 2 is CH, X 3 is N, X 4 is CH, X 5 is C and X 6 is CH.
- X 1 is N, X 2 is CH, X 3 is N, X 4 is CH, X 5 is C and X 6 is CH.
- R 2 is optionally substituted C 1-6 alkyl. In another preferred embodiment, R 2 is C 1-6 alkyl. In another preferred embodiment, R 2 is selected from the following group: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.
- two R m1 together form a C 1-4 alkylene group.
- 2 ⁇ m1+m2 ⁇ 4 that is, the ring represented by formula A is a 4- to 6-membered ring.
- M 3 when X 10 is O or S, M 3 is none; when X 10 is N or C (R m ), M 3 is R 3 -- or -NH-R 3 .
- M 1 is None or X 8 .
- M 1 is none
- M 3 is -NH-R 3
- M 2 is none.
- R 3 is optionally substituted C 1-6- hydroxyalkyl.
- M 1 is none
- M 3 is none or R 3
- M 2 is a ring as shown in formula A.
- n1 and m2 are each independently 1 or 2. In another preferred example, m1 and m2 are both 2.
- X 9 is N.
- R 3 is H.
- X 10 is N, M 3 is R 3 , and R 3 is H or C 1-6 alkyl. In another preferred embodiment, X 10 is N, M 3 is R 3 , and R 3 is H.
- X 11 and X 12 are each independently -C(R m ) 2 -.
- At most two R m in X 11 and X 12 are R m1 , and the remaining R m are R c (preferably, the remaining R m for H).
- M 1 is none, M 3 is none or R 3 , and M 2 is a ring of formula A; and, in formula A, X 9 is N or C (R m ), and X 10 is selected from the following Group: O , S, N or C(R m ) ; X 11 and m2 are both 2).
- M 1 is none, M 3 is R 3 , and M 2 is a ring of formula A; and, in formula A, X 9 is N or C (R m ), X 10 is N; X 11 and _ _
- M 1 is None
- M 3 is R 3
- R 3 is H
- M 2 is a ring of formula A; and, in formula A, X 9 is N, X 10 is N; X 11 and _ _
- m3 is 0, 1 or 2.
- the compound is represented by formula I-1
- each group is as defined before.
- M 1 is : O and C 1-4 alkylene; s is 1, 2 or 3; and at most one M 4 is O.
- M 1 is X 8
- M 3 is None or R 3
- M 2 is a ring as shown in Formula A.
- X 8 is N(R c ).
- R 3 is H.
- n1 and m2 are each independently 1, 2 or 3. In another preferred example, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4.
- X 10 is N or C (R c ), M 3 is R 3 , and R 3 is H or C 1-6 alkyl. In another preferred example, X 10 is N or CH, M 3 is R 3 , and R 3 is H.
- X 10 is N, M 3 is R 3 , and R 3 is H or C 1-6 alkyl. In another preferred embodiment, X 10 is N, M 3 is R 3 , and R 3 is H.
- only one R m in X 11 and X 12 is R m1 , and the remaining R m is R c (preferably, the remaining R m is H).
- M 1 is X 8
- M 3 is R 3
- M 2 is a ring as shown in formula A
- X 9 is N or C ( R m ), is N or C(R m );
- X 11 and 2 or 3 preferably, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- M 1 is X 8
- M 3 is R 3
- M 2 is a ring as shown in formula A
- X 9 is N or C ( R m ), is N ; X 11 and or 3 and m1+m2 ⁇ 4).
- M 1 is X 8 , X 8 is N(R c ); M 3 is R 3 , and R 3 is H, and M 2 is a ring of formula A; in formula A, (R m ), X 10 is N; X 11 and X 12 are each independently -C(R m ) 2 -; subscripts m1 and m2 are each independently 1, 2 or 3 (preferably, m1 and Each is independently 1, 2 or 3 and m1+m2 ⁇ 4).
- the subscripts m1 and m2 are each independently 1, 2 or 3 (preferably, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- each group is as defined before.
- M 1 is none
- M 3 is -NH-R 3
- M 2 is a ring represented by formula A.
- n1 and m2 are each independently 1, 2 or 3. In another preferred example, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4.
- R 3 is H.
- X 9 is N.
- X 10 is C(R m ). In another preferred example, X 10 is C(R c ). In another preferred example, X 10 is CH.
- X 11 and X 12 are each independently -C(R m ) 2 -. In another preferred example, X 11 and X 12 are each independently -C(R c ) 2 -. In another preferred example, X 11 and X 12 are each independently -CH 2 -.
- M 1 is none, M 3 is -NH-R 3 , and M 2 is a ring as shown in formula A; and, in formula A, X 9 is N or C (R m ), X 10 is C (R m ) ; X 11 and Ground is 1, 2 or 3 and m1+m2 ⁇ 4).
- M 1 is none, M 3 is -NH-R 3 , and M 2 is a ring as shown in formula A; and, in formula A, X 9 is N, X 10 is C (R m ) ; X 11 and 3 and m1+m2 ⁇ 4).
- M 1 is none, M 3 is -NH-R 3 , and M 2 is a ring as shown in formula A; and, in formula A, X 9 is N, X 10 is C (R c ) ; X 11 and 3 and m1+m2 ⁇ 4).
- the subscripts m1 and m2 are each independently 1, 2 or 3 (preferably, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- each group is as defined before.
- M 1 is X 8
- M 3 is -NH-R 3
- M 2 is a ring represented by formula A.
- X 8 is N(R c ).
- R 3 is H.
- n1 and m2 are each independently 1, 2 or 3. In another preferred example, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4.
- X 9 is C(R m ); preferably, X 9 is C(R c ); preferably, X 9 is CH.
- X 10 is C(R m ); preferably, X 10 is C(R c ); preferably, X 10 is CH.
- X 11 and X 12 are each independently -C(R m ) 2 -. In another preferred example, X 11 and X 12 are each independently -C(R c ) 2 -. In another preferred example, X 11 and X 12 are each independently -CH 2 -.
- M 1 is 2 ;
- X 9 is C(R c )
- X 10 is C(R c );
- X 11 and X 12 are each independently -C(R c ) 2 -; the subscripts m1 and m2 are each independently 1, 2 or 3 (preferably, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- M 1 is X 8
- M 3 is -NH-R 3
- M 2 is a ring shown in formula A
- X 8 is N(R c );
- X 9 is C(R c )
- X 10 is C(R c ) ;
- m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- M 1 is X 8
- M 3 is -NH-R 3
- M 2 is a ring as shown in formula A
- X 8 is NH
- X 9 is CH
- X 10 is CH
- X 11 and And m1+m2 ⁇ 4).
- the subscripts m1 and m2 are each independently 1, 2 or 3 (preferably, m1 and m2 are each independently 1, 2 or 3 and m1+m2 ⁇ 4).
- each group is as defined before.
- the compound is a compound of formula I-1, wherein, for m3 is 0, 1 or 2.
- R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , 12 , M 1 , M 2 , M 3 , M 4 , subscript n1, subscript n3, subscript n4, subscript n5, subscript n6, subscript m1, subscript m2, subscript m3, subscript s, Ar 1 , Ar 2 , Cr 1 , Ra , R b , R c , Re , R f , R m , R m1 , R, R', R" and R'" are each independently an example compound or table.
- the compound is a compound selected from Table A1, A2, A3 and Table A4.
- composition which pharmaceutical composition includes:
- a compound represented by formula (I) or a drug thereof as described in the first aspect is provided.
- a method for treating cancer comprising the step of: administering a safe and effective amount of a compound represented by formula (I) as described in the first aspect or a pharmaceutical thereof to a subject in need. with an acceptable salt.
- a method for degrading cyclin K comprising the steps of: treating an object with a compound represented by formula (I) as described in the first aspect, so that Degradation of Cyclin K.
- the object is a cell.
- the subject is HepG2 cells.
- the method is non-therapeutic in vitro.
- a conjugate or a pharmaceutically acceptable salt thereof is provided.
- the conjugate is composed of a compound represented by formula (I) and a polypeptide as described in the first aspect. elements or targeting ligands.
- the conjugate is represented by formula II M D -M L -MP (II)
- M D is a moiety derived from a compound of formula (I) as described in the first aspect
- M L is none or a connecting part used to connect M D and M P ;
- MP is a moiety derived from a polypeptide element or a targeting ligand.
- the targeting ligand refers to a small molecule capable of binding to extracellular receptors.
- polypeptide elements include (but are not limited to): polypeptides, antibodies, antibody fragments, fusion proteins, or combinations thereof.
- MP is selected from the group consisting of polypeptides, antibodies, antibody fragments, fusion proteins, or small molecule ligand moieties capable of binding to extracellular receptors.
- the antibodies include (but are not limited to): nanobodies, small molecule antibodies (minibodies), antibody fragments (such as scFv, Fab), double antibodies (Dibody), monoclonal antibodies (mAb ), or a combination thereof.
- the targets of the polypeptide include but are not limited to: EGFR, FGFR, SSTR1-14, GnRH, TRPV1-6, RGD, iRGD, EphA2, or combinations thereof.
- the targets that the small molecule ligand can bind include (but are not limited to): FR, HSP90, PSMA, ASGPR, and combinations thereof.
- the antibody can bind to an antigen or receptor selected from the following group (for example, with one (i.e., monofunctional antibody) or two (i.e., bifunctional antibody) selected from the following group) or more Multiple (i.e. multifunctional antibodies) antigen and/or receptor binding): DLL3, EDAR, CLL1, BMPR1B, E16, STEAP1, 0772P, MPF, 5T4, NaPi2b, Sema 5b, PSCAhlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD22, CD79b, CD19, CD37, CD38, CD138, FcRH2, B7-H4, HER2, NCA, MDP, IL20R ⁇ , Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD79a , CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2,
- the targeting ligand can also bind to receptors that can be targeted by specific small molecules, such as folic acid, HSP90, glucose transporter 1 (G LUT1), ammonia Aminopeptidase N (APN), low-density lipoprotein receptor-related protein 1 (LRP1), prostate-specific membrane antigen (PSMA), integrated Receptors such as ⁇ v ⁇ 3, bombesin receptor, somatostatin receptor (SSTR), tumor hypoxic microenvironment, and carbonic anhydrase IX (CAIX).
- specific small molecules such as folic acid, HSP90, glucose transporter 1 (G LUT1), ammonia Aminopeptidase N (APN), low-density lipoprotein receptor-related protein 1 (LRP1), prostate-specific membrane antigen (PSMA), integrated Receptors such as ⁇ v ⁇ 3, bombesin receptor, somatostatin receptor (SSTR), tumor hypoxic microenvironment, and carbonic anhydrase IX (CAI
- a pharmaceutical composition which pharmaceutical composition includes:
- a method for treating cancer comprising the step of administering a safe and effective amount of the conjugate as described in the sixth aspect or a pharmaceutically acceptable salt thereof to a subject in need.
- Figure 1 shows the immunohistochemical staining (IHC) results of compounds CR-8, UB-018, UB-022, and UB-027.
- Figure 2 shows the effects of CR-8 and compounds of the present invention on cyclin K degradation in HEK293 cells.
- bonds represented by dashed lines in each structural formula represent attachment positions to other moieties.
- alkyl by itself or as part of another substituent refers to a straight or branched chain hydrocarbon group having the specified number of carbon atoms (i.e., C 1-6 means 1-6 carbons ).
- the alkyl group has 1 to 4 carbon atoms, that is, C 1-4 alkyl group.
- alkyl groups include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, N-octyl et al.
- alkenyl refers to an unsaturated alkyl group having one or more double bonds.
- the alkenyl group has 2 to 4 carbon atoms, that is, C 2-4 alkenyl group.
- alkynyl refers to an unsaturated alkyl group having one or more triple bonds.
- the alkynyl group has 2 to 4 carbon atoms, that is, C 2-4 alkynyl group.
- unsaturated alkyl groups include, but are not limited to: vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3 -(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl and higher homologues and isomers.
- heteroalkyl by itself or in combination with other terms refers to an alkyl group as previously defined in which one or more (eg, 1 or 2) carbon atoms are selected from, for example, O, N,
- a stable linear or branched group is formed by replacing heteroatoms of Si and S, in which the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatoms are optionally quaternized.
- the atoms O, N and S can be located at any internal position of the heteroalkyl group.
- the heteroatom Si can be located anywhere on the heteroalkyl group, including where the alkyl group is attached to the rest of the molecule.
- alkylene by itself or as part of another substituent refers to a divalent group derived from an alkane, such as -CH2- .
- alkane such as -CH2- .
- heteroalkylene by itself or as part of another substituent refers to a divalent group derived from heteroalkyl.
- carbocyclyl or “carbocycle” refers to a ring having the specified number of ring atoms (e.g., C 3-10 carbocyclyl, C 4-10 carbocyclyl, C 4-6 carbon Hydrocarbon ring (base) that is fully saturated or has one or two double bonds between the ring tops.
- the term also includes bicyclic and polycyclic hydrocarbon rings, such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and the like.
- heterocyclyl or “heterocycle” refers to a carbocyclic ring containing 1 to 5 heteroatoms selected from N, O and S, in which the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally oxidized. Be quaternized.
- the heterocyclic ring(base) may be a monocyclic, bicyclic or polycyclic ring system, preferably a monocyclic ring.
- heterocycle(s) include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide , piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone , 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, etc.
- Heterocycles may be attached to the remainder of the molecule via ring carbons or heteroatoms.
- cycloalkyl refers to a hydrocarbon ring having the specified number of ring atoms (eg, C 3-6 cycloalkyl) and being fully saturated. Cycloalkyl groups may be monovalent or divalent.
- alkoxy is used in its conventional sense to refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
- halo or halogen by itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom.
- terms such as “haloalkyl” are intended to include mono- or polyhaloalkyl groups.
- C 1-4 haloalkyl is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- aryl means a polyunsaturated (usually aromatic) hydrocarbyl group, which may be a single ring or multiple rings (up to three rings) fused together or covalently linked.
- heteroaryl refers to an aryl group (or ring) containing 1 to 5 heteroatoms selected from N, O, and S, in which the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atoms are optionally quaternized. .
- a heteroaryl group can be attached to the rest of the molecule through a heteroatom.
- Non-limiting examples of aryl groups include phenyl, naphthyl, and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolyl, Quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benziso Oxazolyl, isobenzofuryl (isobenzofuryl), isoindolyl, indanyl, benzotriazinyl, thienopyridyl, thienopyrimidinyl, pyrazopyrimidinyl, imidazopyridine, benzene Thiazolyl, benzofuranyl, benzothienyl, indolyl, quinoly
- alkyl alkyl
- aryl heteroaryl
- alkyl alkyl
- heteroaryl aliphatic Groups
- R' and R" are connected to the same nitrogen atom, they can be Nitrogen atoms combine to form 3-, 4-, 5-, 6- or 7-membered rings.
- -NR'R" is intended to include 1-pyrrolidinyl and 4-morpholinyl.
- acyl used alone or as part of another group, refers to the group in which the group is closest to the point of attachment.
- heteroatom is intended to include oxygen (O), nitrogen (N), sulfur (S), and silicon (Si).
- a bond from a substituent (generally an R group) to the center of an aromatic ring will be understood to mean a bond providing a connection at any available vertex of the aromatic ring.
- this description also includes on-ring linkages fused to aromatic rings.
- a bond drawn to the center of the indobenzene moiety would represent a bond to any available vertex of the six- or five-membered ring moiety of the indole.
- a moiety derived from means that an active substance (e.g., a polypeptide element such as an antibody or a targeting ligand) is subjected to certain means (e.g., reacting a reactive group on it, or introducing a reactive group The part or fragment of the active substance that remains after reacting) so that the active substance forms a linking group with other parts, which part or fragment retains the function of the active substance (such as the ability to target the desired receptor).
- specific “derivatized” linking groups include, but are not limited to: -NH-, -CONH-, -CO-, -S-S-, etc.
- salts are intended to include salts of the active compounds prepared with relatively nontoxic acids or bases, depending on the particular substituents on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, solventless or in a suitable inert solvent.
- salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, iron, ferrous iron, lithium, magnesium, manganese, manganese, potassium, sodium, zinc, and the like.
- Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary, and tertiary amines, including substituted amines, cyclic amines, naturally occurring amines, and the like, such as arginine, betaine, caffeine, Choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- Ethyl piperidine, glucamine, glucosamine, Histidine, hypamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
- arginine betaine
- caffeine Choline
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, solventless or in a suitable inert solvent.
- pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogen carbonic acid, phosphoric acid, monohydrogen phosphoric acid, dihydrogen phosphoric acid, sulfuric acid, monohydrogen sulfuric acid, Hydroiodic acid, or phosphorous acid, etc.; and salts derived from relatively non-toxic organic acids, such as acetic acid, propionic acid, isobutyric acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumarate Acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc
- salts of amino acids such as arginine salts, and the like
- salts of organic acids such as glucuronic acid or galactunoric acid.
- Certain specific compounds of the present invention contain both basic and acidic functional groups, thereby converting the compounds into base or acid addition salts.
- the neutral form of the compound can be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties (such as solubility in polar solvents), but otherwise, those salts are equivalent to the parent form of the compound for the purposes of this invention. of.
- the present invention provides compounds in prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the invention.
- prodrugs can be converted to compounds of the invention by chemical or biochemical methods in an ex vivo environment. For example, a prodrug can be slowly converted to a compound of the invention when placed in a transdermal patch reservoir containing appropriate enzymes or chemical reagents.
- Certain compounds of the invention may exist in unsolvated as well as solvated forms, including hydrated forms. Solved forms are generally equivalent to the unsolvated forms and are intended to be included within the scope of this invention. Certain compounds of the present invention may exist in polymorphic or amorphous forms. In general, all physical forms are equivalent for the applications contemplated by this invention and are intended to be included within the scope of this invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separated enantiomers body) should be included in the scope of the present invention.
- compounds provided herein have a defined stereochemistry (denoted as R or S, or have dashed or wedge-shaped bonds)
- those compounds will be understood by those skilled in the art to be substantially free of other isomers (e.g., at least 80% , 90%, 95%, 98%, 99% and up to 100% free of other isomers).
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the isotope atoms that make up such compounds.
- the unnatural ratio of a certain isotope can be defined as the amount from the naturally found amount of the atom in question to 100% of that atom.
- the compounds may incorporate radioactive isotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C), or non-radioactive isotopes, such as deuterium ( 2 H) or carbon-13 ( 13 C ).
- radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C)
- non-radioactive isotopes such as deuterium ( 2 H) or carbon-13 ( 13 C ).
- Such isotopic variants may provide additional uses in addition to those described herein.
- isotopic variants of the compounds of the present invention may have additional uses, including, but not limited to, as diagnostic and/or imaging agents, or as cytotoxic/radiotoxic therapeutics. Additionally, isotopic variants of the compounds of the present invention may have altered pharmacokinetic and pharmacodynamic characteristics, thereby contributing to increased safety, tolerability, or efficacy during treatment. All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be included within the scope of the invention.
- CDK cyclin-dependent kinases
- CDK12 plays a role similar to that of a CRBN substrate receptor.
- the surface of CDK12 interacts with the 2-pyridine moiety of CR8.
- the presence and correct orientation of CR8 increase the gain-of-function of CR8, leading to the degradation of cyclin K. That is, CR8-phenylpyridine gives it the activity of molecular glue, induces the degradation of cyclin K, and increases the toxicity of CR8.
- the compound with the structure represented by formula (I-1) has a pyridine substituent (or other nitrogen-containing heteroaromatic ring substituent) or whether it has a pyridine substituent (or other nitrogen-containing heteroaromatic ring substituent). It still has an excellent effect of inducing the degradation of cell cycle proteins such as cyclin K, and based on this, the inventors provide a series of novel cell cycle protein regulators (more specifically, molecular glue degraders).
- each group is as defined in the first aspect.
- a compound represented by formula (I-1), formula (I-2), formula (I-3) or formula (I-4) or a pharmaceutically acceptable salt thereof is provided ;
- each group is as defined before.
- a molecular glue degrading agent as shown in any of the following is provided
- n2 is 2-4 (that is, the ring where n2 is located is a 4 to 6-membered ring), ring Ar 1 may also be optionally substituted by n3 R a substituents (not shown), and ring Cr 1 may also be optionally substituted by n3 R a substituents (not shown).
- n4 R b substituents are substituted (not shown); R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 8 , X 9 , subscript n1, n3, n4, Ar 1 , Cr 1 , Ra and R b are as defined elsewhere herein.
- n2 is 2-4 (that is, the ring where n2 is located is a 4 to 6-membered ring); Ring Ar 1 may also be optionally substituted by n3 R a substituents (not shown) and Ring Ar 2 may also be optionally substituted by n4 R b substituents substituted (not shown);; R 1 , R 2 , R 3 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 8 , X 9 , subscript n1 , n3, n4, Ar 1 , Cr 1 , R a and R b are as defined elsewhere herein.
- compound of the invention refers to a compound of formula (I).
- the term also includes compounds of formula I Various crystalline forms of the substance, or pharmaceutically acceptable salts.
- the active ingredient may also be a conjugate formed between a compound represented by formula (I) and an antibody or polypeptide.
- compositions and methods of administration are provided.
- the compound of the present invention Since the compound of the present invention has excellent activity in inducing the degradation of cyclin K (Cyclin K), the compound of the present invention and its various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, As well as pharmaceutical compositions containing the compound of the present invention as the main active ingredient, or the conjugates formed by the compound of the present invention and antibodies or polypeptides can be used to treat or prevent Cyclin K (Cyclin K)-related or Cyclin K (Cyclin K)-related diseases. ) is involved in the disease. According to the prior art, the compounds of the present invention can be used to treat the following diseases: cancer, etc.
- the pharmaceutical composition of the present invention contains a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier within a safe and effective amount.
- the “safe and effective dose” refers to the amount of compound that is sufficient to significantly improve the condition without causing serious side effects.
- “Pharmaceutically acceptable carrier” refers to one or more compatible solid or liquid filler or gel substances that are suitable for human use and must be of sufficient purity and low enough toxicity. "Compatibility” here refers to the ability of each component of the composition to be blended with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds.
- Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid , magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
- cellulose and its derivatives such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- gelatin such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- solid lubricants such as
- administration mode of the compounds or pharmaceutical compositions of the present invention is not particularly limited.
- Representative administration modes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration. .
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or compatibilizers, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) Humectants, For example, glycerol; (d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) retarder, such as paraffin; (f) Absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl mono
- Solid dosage forms such as tablets, dragees, capsules, pills and granules may be prepared using coatings and shell materials such as enteric casings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxy substances. If necessary, the active compounds can also be in microencapsulated form with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
- liquid dosage forms may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1 ,3-butanediol, Dimethylformamide as well as oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
- inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1 ,3-butanediol, Dimethylform
- compositions may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
- Suspensions may contain, in addition to the active compound, suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances and the like.
- suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances and the like.
- compositions for parenteral injection may contain physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
- Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants.
- the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
- the compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
- a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, and the dosage when administered is a pharmaceutically effective dosage.
- a mammal such as a human
- the daily dose is usually 1 to 2000 mg, preferably 20 to 500 mg.
- the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the skill of a skilled physician.
- polypeptide element includes peptide segments (eg, short peptides of 3-20 aa) or proteins. Additionally, the term includes intact proteins or fragments thereof. Preferred polypeptide elements include antibodies (such as intact antibodies, single-chain antibodies, Nanobodies, antibody fragments), especially against tumor cell markers (such as tumor markers located on the surface of tumor cells, such as receptors on the cell surface) or against inflammation. Antibodies to inflammatory factors such as those associated with autoimmune diseases.
- antibody or "immunoglobulin” is a heterotetrameric protein of approximately 150,000 daltons with the same structural characteristics, consisting of two identical light chains (L) and two identical heavy chains (H) Composition. Each light chain is connected to the heavy chain by a covalent disulfide bond, and the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable domain (VH) at one end, followed by multiple constant domains.
- VH variable domain
- Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite to the first constant region of the heavy chain, and the variable region of the light chain is opposite to the variable region of the heavy chain. .
- Special amino acid residues form the interface between the variable regions of the light and heavy chains.
- single domain antibody and “nanobody” have the same meaning and refer to cloning the variable region of the heavy chain of an antibody to construct a single domain antibody consisting of only one heavy chain variable region, which is fully functional The smallest antigen-binding fragment.
- the variable region of the antibody heavy chain is cloned to construct a single-domain antibody consisting of only one heavy chain variable region.
- variable means that certain portions of the variable regions of an antibody differ in sequence and contribute to the binding and specificity of each particular antibody to its particular antigen. However, variability is not evenly distributed throughout the antibody variable region. It is concentrated in three segments in the variable regions of the light and heavy chains called complementarity determining regions (CDRs) or hypervariable regions. The more conserved part of the variable region is called the framework region (FR).
- CDRs complementarity determining regions
- FR framework region
- the variable regions of the natural heavy and light chains each contain four FR regions, which are roughly in a ⁇ -sheet configuration and are connected by three CDRs forming a connecting loop. In some cases, Form a partially folded structure.
- the CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain form the antigen-binding site of the antibody. Constant regions are not directly involved in the binding of the antibody to the antigen, but they exhibit different effector functions, such as involvement in antibody-dependent cytotoxicity of the antibody.
- the "light chains" of vertebrate antibodies can be assigned to one of two distinct classes (termed kappa and lambda) based on the amino acid sequence of their constant regions.
- Immunoglobulins can be divided into different classes based on the amino acid sequence of their heavy chain constant region.
- the heavy chain constant regions corresponding to different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known to those in the art.
- variable regions which are separated into four framework regions (FR), four
- FR framework regions
- the amino acid sequence of FR is relatively conservative and does not directly participate in the binding reaction.
- CDRs form a cyclic structure, and the ⁇ -sheets formed by the FRs between them are close to each other in spatial structure.
- the CDRs on the heavy chain and the CDRs on the corresponding light chain constitute the antigen-binding site of the antibody. You can determine which amino acids constitute the FR or CDR region by comparing the amino acid sequences of antibodies of the same type.
- polypeptide elements may include not only complete antibodies, but also fragments of antibodies with immunological activity (such as Fab or (Fab') 2 fragments; antibody heavy chains; or antibody light chains) or antibodies formed with other sequences. fusion protein. Therefore, the present invention also includes fragments, derivatives and analogs of said antibodies.
- Targeting ligands are small molecules capable of binding to a target protein of interest.
- the targeting ligand may be (or be derived from) the target molecule.
- target molecules include but are not limited to: folic acid, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting human BET bromodomain-containing proteins, targeted Compounds for the cytoplasmic signaling protein FKBP12, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, targeting the aryl hydrocarbon receptor (AHR) and targeting the tumor anaerobic microenvironment compound of.
- AHR aryl hydrocarbon receptor
- the targeting ligand is capable of binding a kinase, a BET bromodomain-containing protein, a cytoplasmic signaling protein (e.g., FKBP12), a nuclear protein, a histone deacetylase, a lysine methyltransferase, Proteins that regulate angiogenesis, proteins that regulate immune response, aryl hydrocarbon receptors (AHRs), estrogen receptors, androgen receptors, glucocorticoid receptors, or transcription factors (eg, SMARCA4, SMARCA2, TRIM24).
- a cytoplasmic signaling protein e.g., FKBP12
- FKBP12 cytoplasmic signaling protein
- a nuclear protein e.g., a histone deacetylase
- a lysine methyltransferase e.g., Proteins that regulate angiogenesis, proteins that regulate immune response, aryl hydrocarbon receptors (AHRs), estrogen receptors, androgen
- kinases to which the targeting ligand is capable of binding include, but are not limited to: tyrosine kinases (e.g., AATK, ABL, ABL2, ALK, AXL, BLK, BMX, BTK, CSF1R, CSK, DDR1, DDR2 , EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FER, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR , FLT1, FLT3, FLT4, FRK, FYN, GSG2, HCK, HRAS, HSP90, IGF1R, ILK, INSR, INSRR, IRAK4, ITK, JAK1, JAK2, JAK3, KDR, KIT, K RA S, KSP, KSR1, LCK , LM
- kinase 2 protein kinase A, protein kinase B, protein kinase C, Raf kinase, CaM kinase, AKT1, AKT2, AKT3, ALK1, ALK2, ALK3, ALK4, AuroraA, AuroraB, AuroraC, CHK1, CHK2, CLK1, CLK2, CLK3, DAPK1, DAPK2, DAPK3, DMPK, ERK1, ERK2, ERK5, GCK, GSK3, HIPK, KHS1, LKB1, LOK, MAPKAPK2, MAPKAPK, MEK, MNK1, MSSK1, MST1, MST2, MST4, NDR, NEK2, NEK3, NEK6, NEK7, NEK9, NEK11, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PIM1, PIM2, PLK1, RIP2, RIP5, RSK1, RSK2, SGK2, SGK3, SIK1, STK33, TAO1,
- the compound of the present invention has an excellent effect of inducing the degradation of cyclin K (Cyclin K).
- the compounds of the present invention may be prepared, isolated or obtained by any method apparent to those skilled in the art.
- the compounds of the present invention can also be prepared according to the exemplary preparation schemes provided below (such as the methods in the Examples). Reaction conditions, steps and reactants not provided in the exemplary preparation schemes will be obvious and known to those skilled in the art.
- the symbols and conventions used in these procedures, schemes, and examples, regardless of whether a particular abbreviation is specifically defined, have meanings well known to those skilled in the art. Specifically, but not limited to, the following abbreviations may be used in the examples and throughout the specification: g (gram); mg (milligram); mL (millilitre); ⁇ L (microliter); millimeter (millimol); ⁇ M (micron).
- UB-025c (3.0g, 12mmol), anhydrous DCM (15mL) solution and Et 3 N (1.82g, 18mmol) were added to the reaction bottle.
- the mixture was cooled to 0°C and a solution of UB-025d (1.89 g, 14.3 mmol) in 5 mL of anhydrous DCM was slowly added.
- the reaction was stirred at room temperature for 1 hour.
- the brown solution was washed twice with 1 M HCl solution, twice with saturated NaHCO solution, and once with brine.
- UB-037c (121.2 mg, 0.23 mmol), hydrochloric acid in 1,4-dioxane (4 mL), and dichloromethane (8.0 mL) at room temperature. The solution was then stirred at room temperature for 2 hours. The reaction mixture was filtered, and the filter cake was washed with dichloromethane (5 mL), neutralized with saturated aqueous sodium bicarbonate solution, and extracted with dichloromethane (3*50 mL).
- the synthesis method of UB-061 is similar to the synthesis of UB-041.
- Reagents RPMI-1640 medium, McCoy's5A medium, IMDM medium, MEM medium, L-15 medium, fetal bovine serum, cyan-chain double antibody, trypsin, etc., 2-mercaptoethanol, NEAA, pyruvate, etc. .
- Cells for testing are routinely cultured, and cells are passaged for at least 2 generations before plating.
- 25uL1000 HT-29, N87, SKOV3, Colo-205 and MDA-MB-231 cells were seeded on the black wall Add 25uL of compounds of different concentrations to a transparent bottom 384-well plate and incubate overnight at 37°C and 5% CO2 .
- 25uL1500 H82 and H69 cells were seeded in a black wall transparent bottom 384-well plate, 25uL of compounds of different concentrations were added and the cells were cultured for 72 hours at 37°C and 5% CO2 . Equilibrate the 384-well plate at room temperature and add 25 ⁇ L Cell to each well. Reagent, shake and mix on a horizontal shaking shaker for 2 minutes to lyse the cells, incubate at room temperature for 10 minutes to stabilize the luminescence signal, and then use Envision to detect the chemiluminescence signal.
- Min, Max and Slope represent the minimum value, maximum value and slope respectively.
- the results are shown in Table 1.
- the compounds of the present invention were subjected to cell inhibition experiments on multiple tumor cell lines. The results showed that most compounds showed strong cell killing effects in multiple tumor cells and have anti-tumor effects. potential for drug development.
- reaction enhancement solution add 100 ⁇ L of reaction enhancement solution and incubate at 37°C for 20 minutes; wash with PBS buffer for 3 minutes ⁇ 3 times.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种细胞周期蛋白调节剂。具体地,本发明提供了一种如式(I)所示的化合物或其药学上可接受的盐。
Description
本发明属于药物化学领域,具体涉及一种细胞周期蛋白调节剂。
不像大多数传统药物直接抑制分子标靶的作用,分子胶降解剂(molecular glue degrader)则是通过泛素-蛋白酶体系统(ubiquitin-proteasome system)破坏标靶蛋白来达成杀死癌细胞的目的。比如,多发性骨髓瘤药物来那度胺(lenalidomide)就是一种分子胶降解剂,通过招募E3泛素连接酶(ubiquitin ligase)来标记细胞中的目标蛋白,并随后降解它。与传统意义上的小分子抑制剂不同,分子胶水以催化剂的方式驱动靶标泛素化并诱导降解,是能够使传统药理学方法难以治疗的靶点失活的新策略。分子胶水也巧妙地避开了传统抑制剂的局限性,使得一部分靶点从“无成药性”变为“有成药性”。
细胞周期是细胞生命活动的基本过程,它控制着细胞从静止期转向生长增殖期。细细胞周期蛋白依赖激酶(CDKs)和细胞周期蛋白(Cyclins)是整个细胞周期调控机制中的核心分子。在正常细胞中,细胞周期蛋白的活性受到其细胞周期特异性转录和蛋白质降解的严格控制,以及一些CDK抑制蛋白的影响。细胞周期蛋白除了促进细胞分裂外,还肩负调节各种细胞功能的责任。这种机制由细胞周期蛋白及其催化搭档细胞周期蛋白依赖激酶(CDKs)共同运行。但这些影响因素在人类癌症中经常失控,导致细胞周期蛋白的异常激活。细胞周期机制活动异常基本上在所有类型的肿瘤中都存在,这也是肿瘤发生的驱动力。靶向某个特定细胞周期蛋白可能成为一种有效的抗癌策略。
迄今为止,已上市的CDK抑制剂很少,且均为CDK4/6抑制剂。而选择性靶向其他CDK家族的抑制剂,很难做到满足要求的特异性,几乎都为多靶点抑制剂,临床上表现出不可接收的毒性,从而阻止了其临床应用。另外,激酶抑制剂虽能导致激酶亚基的去除,但同时保持细胞周期蛋白的完整性,可能触发代偿机制。而激酶的降解可能导致比其抑制作用更持久的效果。
虽然分子胶降解剂非常理想,临床效果好也很受欢迎,但迄今为止发现的分子胶降解剂仍寥寥可数,且多为偶然发现。CR8作为被新发现的细胞周期素K(CyclinK)降解剂,其首先是一个多激酶抑制剂,能抑制CDK家族中多个周期蛋白的活性,从而带来的毒性限制了其临床应用。除了选择性欠佳,其降解CyclinK的活性也很一般,限制了其催化量的使用。
综上所述,本领域迫切需要开发一类具有更高活性和/或更低毒性的细胞周期蛋白调节剂如细胞周期蛋白降解剂。
发明内容
本发明的目的就是提供具有更高活性的细胞周期蛋白降解剂,或者新型细胞周期蛋白调节剂。
在本发明的第一方面中,提供了一种如式(I)所示的化合物或其药学上可接受的盐,
其中,
R1各自独立地为H或C1-4烷基;
下标n1为1、2或3;
环Ar1选自下组:C6-10芳环、5至10元杂芳环、5至10元桥环;
环Cr1选自下组:H、C3-10碳环基、3至10元杂环基、C6-10芳基、和5至10元杂芳基;
Ra和Rb各自独立地选自下组:H、Re或R;或者Ra和Rb与环Ar1和环Cr1共同形成其中,
X7各自独立地选自下组:-O-、-S-、-N(Rc)-、-C(Rc)2-、-C(Rc)2-C(Rc)2-;
下标n5和n6各自独立地为0、1、2或3;
Re各自独立地选自下组:羟基、C1-6烷基、-O-C1-6烷基、-O-C1-6亚烷基-Rf;
其中,Rf选自下组:-CN、-OH、-NH2、-NH(C1-6烷基)、-N(C1-6烷基)2;
下标n3和n4各自独立地为0、1、2、3或4;
R2选自下组:H、CN、任选取代的C1-6烷基、任选取代的C2-6烯基、任选取代的C2-6炔基、任选取代的C3-8环烷基、任选取代的3至8元杂环基;
X1、X2和X6各自独立地为N或C(Rc);
X3、X4和X5各自独立地为N或C;
M1选自下组:无、X8、(M4)s;其中,
X8为N(Rc)或C(Rc)2;
M4各自独立地选自下组:O、S、C(O)O、C(O)、N(Rc)和C1-4亚烷基;
s为1、2或3;
M2为无或如式A所示的环;
式A中,X9是与M1连接的位置,X10是与M3连接的位置;X9为N或C(Rm),X10选自下组:O、S、N或C(Rm);X11和X12各自独立地选自下组:-C(Rm)2-、-N(Rm)-;下标m1和m2各自独立地为0、1、2或3,并且m1+m2≥2;
其中,Rm各自独立地为Rc或Rm1;其中,
Rm1各自独立地选自下组:羟基、任选取代的C1-6烷基、任选取代的C1-6羟基烷基、任选取代的C1-6卤代烷基;或者,两个Rm1共同形成单键、任选取代的C1-4亚烷基或任选取代的1至4元杂亚烷基;
M3选自下组:无、R3、-NH-R3;其中,
R3选自下组:H、任选取代的C1-6烷基、任选取代的C1-6-羟烷基、任选取代的C1-6-卤代烷基;
Rc各自独立地为H或C1-4烷基;
除非特别定义,所述任选取代是指未取代的或基团中一个或多个(如1、2、3或4个)氢被取代基R所取代,并且R选自下组:D、卤素、C1-6烷基、C1-6卤代烷基、C1-6羟烷基、C2-6烯基、C2-6炔基、-CN、-OR'、-NO2、-NR'R"、-SR'、-OC(O)R'、-C(O)R'、-CO2R'、-CONR'、-OC(O)NR'R"、-NR"C(O)R'、-NR"-C(O)NR'R"、-NR"C(O)2R'、-S(O)R'、-S(O)2R'、-S(O)2NR'R"、-NR"S(O)2R'、任选被一个或多个R'"所取代的C3-10环烷基、任选被一个或多个R'"所取代的4至10元杂环烷基、任选被一个或多个R'"所取代的C6-10芳基、任选被一个或多个R'"所取代的5至10元杂芳基、任选被一个或多个R'"所取代的-C1-4亚烷基-C3-10环烷基、任选被一个或多个R'"所取代的-C1-4亚烷基-4至10元杂环烷基、任选被一个或多个R'"所取代的-C1-4亚烷基-C6-10芳基、任选被一个或多个R'"所取代的-C1-4亚烷基-5至10元杂芳基;
各个R'各自独立地为H、D、任选被一个或多个R'"所取代的选自下组的基团:C1-6烷基、C3-10环烷基、4至10元杂环烷基、C6-10芳基、5至10元杂芳基、-C1-4亚烷基-C3-10环烷基、-C1-4亚烷基-4至10元杂环烷基、-C1-4亚烷基-C6-10芳基-C1-4亚烷基-5至10元杂芳基;
各个R"选自下组:H、D、C1-4烷基、C1-4卤代烷基、和C3-4环烷基;
各个R"'独立地选自下组:D、卤素、羟基、硝基、CN、C1-6烷基、C1-6卤代烷基。
在另一优选例中,所述化合物不为如下所示的CR8:
在另一优选例中,R1为H。在另一优选例中,n1=1。在另一优选例中,R1为H,且n1=1。
在另一优选例中,环Ar1选自下组:C6-10芳环、5至10元杂芳环。
在另一优选例中,环Ar1选自下组:苯环、5至10元杂芳环。
在另一优选例中,环Ar1选自下组:
其中,*代表与环Cr1连接的位置;Xa、Xb、Xc和Xd各自独立地为CH和N;Xg选自下组:NH、O、S;Xh、Xi和Xj各自独立为-CH2-或-CH2-CH2-。
在另一优选例中,为
在另一优选例中,环Ar1中,为
在另一优选例中,环Ar1选自下组:
其中,*代表与环Cr1连接的位置;Xa、Xb、Xc和Xd各自独立地为CH和N;Xg选自下组:NH、O、S。
在另一优选例中,环Ar1为
其中,*代表与环Cr1连接的位置。
在另一优选例中,为其中*代表与环Cr1连接的位置
在另一优选例中,环Cr1中,所述碳环为饱和的或含1或2个双键的不饱和的碳环。
在另一优选例中,环Cr1中,所述C3-10碳环为C4-10碳环;较佳地,为C4-6碳环。
在另一优选例中,环Cr1中,所述3至10元杂环基为饱和的3至10元杂环基。
在另一优选例中,环Cr1中,所述3至10元杂环基为4至10元杂环基;较佳地,为4至6元杂环基。
在另一优选例中,环Cr1选自下组:
其中,Xd和Xe各自独立地为N或CH;Xf为NH、S、O;Xg为N或CH。
在另一优选例中,为
在另一优选例中,环Cr1为环Ar2;并且环Ar2选自下组:C6-10芳基、和5至10元杂芳基。
在另一优选例中,环Ar2选自下组:
其中,Xd和Xe各自独立地为-N-或-CH-;Xf为-NH-、-S-、-O-;Xg为N或CH。
在另一优选例中,环Ar2为在另一优选例中,环Ar2为苯基。
在另一优选例中,当M2为无时,环Ar2不为含氮杂芳基(其中,所述含氮杂芳基为环上具有1或2个氮杂原子且不含其他杂原子的杂芳基,如吡啶基、吡唑基、咪唑基和吡嗪基)。
在另一优选例中,当M2为无时,环Ar2不为
在另一优选例中,n3为0(即环Ar1是未取代的);或者,n3为1、2、3或4(即环Ar1被1、2、3或4个Ra所取代),且Ra各自独立地选自下组:D、卤素、C1-6烷基、C1-6卤代烷基。
在另一优选例中,n3为0。在另一优选例中,n3为1,且Ra为Re。
在另一优选例中,n4为0(即环Cr1是未取代的);或者,n4为1、2、3或4(即环Cr1被1、2、3或4个Rb所取代),且Rb各自独立地选自下组:D、卤素、C1-6烷基、C1-6卤代烷基。
在另一优选例中,n4为0。在另一优选例中,n4为1,且Rb为Re。
在另一优选例中,n3为0(即环Ar1是未取代的);或者,n3为1、2、3或4(即环Ar1被1、2、3或4个Ra所取代),且Ra各自独立地选自下组:D、卤素、C1-6烷基、C1-6卤代烷基。
在另一优选例中,当M2为无时,不为
在另一优选例中,为
在另一优选例中,X1为N,X2为CRc,X3为C,X4为C,X5为N且X6为CRc。在另一优选例中,X1为CRc,X2为CRc,X3为CRc,X4为N,X5为C且X6为CRc。在另一优选例中,X1为N,X2为CRc,X3为CRc,X4为N,X5为C且X6为CRc。在另一优选例中,X1为CRc,X2为CRc,X3为CRc,X4为N,X5为N且X6为CRc。在另一优选例中,X1为CRc,X2为CRc,X3为N,X4为CRc,X5为C且X6为CRc。在另一优选例中,X1为CRc,X2为N,X3为N,X4为CRc,X5为C且X6为CRc。在另一优选例中,X1为N,X2为CRc,X3为N,X4为CRc,X5为C且X6为CRc。
在另一优选例中,Rc均为H。
在另一优选例中,X1为N,X2为CH,X3为C,X4为C,X5为N且X6为CH。在另一优选例中,X1为CH,X2为CH,X3为CH,X4为N,X5为C且X6为CH。在另一优选例中,X1为N,X2为CH,X3为CH,X4为N,X5为C且X6为CH。在另一优选例中,X1为CH,X2为CH,X3为CH,X4为N,X5为N且X6为CH。在另一优选例中,X1为CH,X2为CH,X3为N,X4为CH,X5为C且X6为CH。在另一优选例中,X1为CH,X2为N,X3为N,X4为CH,X5为C且X6为CH。在另一优选例中,X1为N,X2为CH,X3为N,X4为CH,X5为C且X6为CH。
在另一优选例中,
选自下组:
在另一优选例中,
为
在另一优选例中,R2为任选取代的C1-6烷基。在另一优选例中,R2为C1-6烷基。在另一优选例中,R2为选自下组:甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基。
在另一优选例中,式A中,当两个Rm1位于同一碳原子上时,两个Rm1共同形成任选取代的C2-4亚烷基或任选取代的2至4元亚杂烷基(即如式A所示的环为螺环)。
在另一优选例中,式A中,当两个Rm1位于位于相邻两个环原子上时,两个Rm1共同形成任选取代的C1-4亚烷基或任选取代的1至4元亚杂烷基(即如式A所示的环为并环)。
在另一优选例中,式A中,当两个Rm1位于至少间隔一个环原子的两个环原子上时,两个Rm1共同形成单键、任选取代的C1-3亚烷基或任选取代的1至3元亚杂烷基(即如式A所示的环为并环)。
在另一优选例中,两个Rm1共同形成C1-4亚烷基。
在另一优选例中,2≤m1+m2≤4(即如式A所示的环为4至6元环)。
在另一优选例中,X10为O或S时,M3为无;X10为N或C(Rm)时,M3为R3--或-NH-R3。
在另一优选例中,M1为无或X8。
在另一优选例中,M1为无,M3为-NH-R3,且M2为无。
在另一优选例中,R3任选取代的C1-6-羟烷基。
在另一优选例中,为
在另一优选例中,M1为无,M3为无或R3,且M2为如式A所示的环。
在另一优选例中,m1和m2各自独立地为1或2。在另一优选例中,m1和m2均为2。
在另一优选例中,X9为N。
在另一优选例中,R3为H。
在另一优选例中,X10为N,M3为R3,且R3为H或C1-6烷基。在另一优选例中,X10为N,M3为R3,且R3为H。
在另一优选例中,X11和X12各自独立地为-C(Rm)2-。
在另一优选例中,X11和X12中至多只有两个Rm为Rm1,其余Rm为Rc(较佳地,其余Rm
为H)。
在另一优选例中,M1为无,M3为无或R3,且M2为式A环;并且,式A中,X9为N或C(Rm),X10选自下组:O、S、N或C(Rm);X11和X12各自独立为-C(Rm)2-;下标m1和m2各自独立地为1或2(较佳地下标m1和m2均为2)。
在另一优选例中,M1为无,M3为R3,且M2为式A环;并且,式A中,X9为N或C(Rm),X10为N;X11和X12各自独立地为C(Rm)2-;下标m1和m2各自独立地为1或2(较佳地下标m1和m2均为2)。
在另一优选例中,M1为无,M3为R3,且R3为H,且M2为式A环;并且,式A中,X9为N,X10为N;X11和X12各自独立地为-C(Rm)2-;下标m1和m2各自独立地为1或2(较佳地下标m1和m2均为2)。
在另一优选例中,为
在另一优选例中,为其中,m3为0、1或2。
在另一优选例中,选自下组:
在另一优选例中,所述的化合物如式I-1所示
其中,各基团如前定义。
在另一优选例中,M1为X8或(M4)s,M3为无或R3,且M2为如式A所示的环;其中,M4各自独立地选自下组:O和C1-4亚烷基;s为1、2或3;且至多一个M4为O。
在另一优选例中,M1为X8,M3为无或R3,且M2为如式A所示的环。
在另一优选例中,X8为N(Rc)。
在另一优选例中,R3为H。
在另一优选例中,m1和m2各自独立地为1、2或3。在另一优选例中,m1和m2各自独立地为1、2或3并且m1+m2≤4。
在另一优选例中,X10为N或C(Rc),M3为R3,且R3为H或C1-6烷基。在另一优选例中,X10为N或CH,M3为R3,且R3为H。
在另一优选例中,X10为N,M3为R3,且R3为H或C1-6烷基。在另一优选例中,X10为N,M3为R3,且R3为H。
在另一优选例中,X11和X12中只有1个Rm为Rm1,其余Rm为Rc(较佳地,其余Rm为H)。
在另一优选例中,M1为X8,M3为R3,且M2为如式A所示的环;并且,式A中,X9为N或C(Rm),X10为N或C(Rm);X11和X12各自独立地选自下组:-C(Rm)2-、-N(Rm)-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为X8,M3为R3,且M2为如式A所示的环;并且,式A中,X9为N或C(Rm),X10为N;X11和X12各自独立地为-C(Rm)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为X8,X8为N(Rc);M3为R3,且R3为H,且M2为式A环;式A中,X9为C(Rm),X10为N;X11和X12各自独立地为-C(Rm)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,为
在另一优选例中,为其中,下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,选自下组:
在另一优选例中,所述的化合物如式I-2所示
其中,各基团如前定义。
在另一优选例中,M1为无,M3为-NH-R3,且M2为如式A所示的环。
在另一优选例中,m1和m2各自独立地为1、2或3。在另一优选例中,m1和m2各自独立地为1、2或3并且m1+m2≤4。
在另一优选例中,R3为H。
在另一优选例中,X9为N。
在另一优选例中,X10为C(Rm)。在另一优选例中,X10为C(Rc)。在另一优选例中,X10为CH。
在另一优选例中,X11和X12各自独立地为-C(Rm)2-。在另一优选例中,X11和X12各自独立地为-C(Rc)2-。在另一优选例中,X11和X12各自独立地为-CH2-。
在另一优选例中,M1为无,M3为-NH-R3,且M2为如式A所示的环;并且,式A中,X9为N或C(Rm),X10为C(Rm);X11和X12各自独立为-C(Rm)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为无,M3为-NH-R3,且M2为如式A所示的环;并且,式A中,X9为N,X10为C(Rm);X11和X12各自独立为-C(Rm)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为无,M3为-NH-R3,且M2为如式A所示的环;并且,式A中,X9为N,X10为C(Rc);X11和X12各自独立为-C(Rc)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,为
在另一优选例中,为其中,下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,选自下组:
在另一优选例中,所述的化合物如式I-3所示
其中,各基团如前定义。
在另一优选例中,M1为X8,M3为-NH-R3,且M2为如式A所示的环。
在另一优选例中,X8为N(Rc)。
在另一优选例中,R3为H。
在另一优选例中,m1和m2各自独立地为1、2或3。在另一优选例中,m1和m2各自独立地为1、2或3并且m1+m2≤4。
在另一优选例中,X9为C(Rm);较佳地,X9为C(Rc);较佳地,X9为CH。
在另一优选例中,X10为C(Rm);较佳地,X10为C(Rc);较佳地,X10为CH。
在另一优选例中,X11和X12各自独立地为-C(Rm)2-。在另一优选例中,X11和X12各自独立地为-C(Rc)2-。在另一优选例中,X11和X12各自独立地为-CH2-。
在另一优选例中,M1为X8,M3为-NH-R3,且M2为如式A所示的环;并且,X8为N(Rc)或C(Rc)2;式A中,X9为C(Rc),X10为C(Rc);X11和X12各自独立为-C(Rc)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为X8,M3为-NH-R3,且M2为如式A所示的环;并且,X8为N(Rc);式A中,X9为C(Rc),X10为C(Rc);X11和X12各自独立为-C(Rc)2-;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,M1为X8,M3为-NH-R3,且M2为如式A所示的环;并且,X8为NH;式A中,X9为CH,X10为CH;X11和X12各自独立为-CH2-;;下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,为
在另一优选例中,为其中,下标m1和m2各自独立地为1、2或3(较佳地,m1和m2各自独立地为1、2或3并且m1+m2≤4)。
在另一优选例中,选自下组:
在另一优选例中,所述的化合物如式I-4所示
其中,各基团如前定义。
在另一优选例中,化合物所述化合物为式I-1化合物,其中,为m3为0、1或2。
在另一优选例中,R1、R2、R3、X1、X2、X3、X4、X5、X6、X7、X8、X9、X10、X11、X12、M1、M2、M3、M4、下标n1、下标n3、下标n4、下标n5、下标n6、下标m1、下标m2、下标m3、下标s、Ar1、Ar2、Cr1、Ra、Rb、Rc、Re、Rf、Rm、Rm1、R、R'、R"和R'"各自独立地为实施例化合物或表A1、A2、A3和表A4中具体化合物中对应基团。
在另一优选例中,所述的化合物为选自表A1、A2、A3和表A4的化合物。
在本发明的第二方面中,提供了一种药物组合物,所述的药物组合物包括:
(i)如第一方面所述的化合物或其药学上可接受的盐;以及
(ii)药学上可以接受的载体。
在本发明的第三方面中,提供了一种如第一方面所述的如式(I)所示的化合物或其药
学上可接受的盐在制备用于治疗癌症的药物中的用途。
在本发明的第四方面中,提供了一种治疗癌症的方法,包括步骤:向有需要的对象施用安全有效量的如第一方面所述的如式(I)所示的化合物或其药学上可接受的盐。
在本发明的第五方面中,提供了一种降解细胞周期素K(Cyclin K)的方法,包括步骤:用如第一方面所述的如式(I)所示的化合物处理对象,从而使细胞周期素K(Cyclin K)降解。
在另一优选例中,所述的对象是细胞。
在另一优选例中,所述的对象是HepG2细胞。
在另一优选例中,所述的方法是体外非治疗性的。
在本发明的第六方面中,提供了一种偶联物或其药学上可接受的盐,所述偶联物是由如第一方面所述的如式(I)所示的化合物与多肽元件或靶向配体形成的偶联物。
在另一优选例中,所述偶联物如式II所示
MD-ML-MP (II)
MD-ML-MP (II)
其中,
MD是衍生自如第一方面所述的如式(I)所示的化合物的部分;
ML为无或用于连接MD和MP的连接部分;
MP为衍生自多肽元件或靶向配体的部分。
在另一优选例中,所述靶向配体是指能够结合细胞外受体的小分子。
在另一优选例中,多肽元件包括(但不限于):多肽、抗体、抗体片段、融合蛋白,或其组合。
在另一优选例中,MP选自下组:多肽、抗体、抗体片段、融合蛋白,或能够结合细胞外受体的小分子配体部分。
在另一优选例中,所述抗体包括(但不限于):纳米抗体(nanobody)、小分子抗体(minibody)、抗体片段(如scFv,Fab)、双抗(Dibody)、单克隆抗体(mAb),或其组合。
在另一优选例中,所述多肽(如靶向多肽)的靶标包括但不局限于:EGFR、FGFR、SSTR1-14、GnRH、TRPV1-6、RGD、iRGD、EphA2,或其组合。
在另一优选例中,所述的小分子配体可结合的靶标包括(但不限于):FR、HSP90、PSMA、ASGPR,其组合。
在另一优选例中,所述抗体可与选自下组的抗原或受体结合(例如,与选自下组的一种(即单功能抗体)或两种(即双功能抗体)或更多种(即多功能抗体)抗原和/或受体结合):DLL3、EDAR、CLL1、BMPR1B、E16、STEAP1、0772P、MPF、5T4,NaPi2b、Sema 5b、PSCAhlg、ETBR、MSG783、STEAP2、TrpM4、CRIPTO、CD21、CD22、CD79b、CD19、CD37、CD38、CD138、FcRH2、B7-H4、HER2、NCA、MDP、IL20Rα、短小蛋白聚(Brevican)、EphB2R、ASLG659、PSCA、GEDA、BAFF-R、CD79a、CXCR5、HLA-DOB、P2X5、CD72、LY64、FcRH1、IRTA2、TENB2、PMEL17、TMEFF1、GDNF-Ra1、Ly6E、TMEM46、Ly6G6D、LGR5、RET、LY6K、GPR19、GPR54、ASPHD1、酪氨酸酶(Tyrosinase)、TMEM118、GPR172A、MUC1、CD70、CD71、MUC16、methothelin、FOLR1、TroP1-2、gpNMB、EGFR、ENPP3、PSMA、CA6、GPC-3、PTK7、CD44、CD56、TIM-1、钙粘素-6(Cadherin-6)、ASG-15ME、ASG-22ME、CanAg、AXL、CEACAM5、EphA4、cMet、FGFR2、FGFR3、CD123、Her3、LAMP1、LRRC15、TDGF1、CD66、CD25、BCMA、GCC、Noch3、cMet、EGFR和CD33,或者诸如CD70、Trop2、PD-L1、CD47、CLDN-18.2的受体。
在另一优选例中,所述靶向配体还可与可以被特异性小分子靶向的受体结合,如叶酸,HSP90、葡萄糖转运蛋白-1(glucose transporter 1)(G LUT1)、氨肽酶(aminopeptidase N)(APN)、低密度脂蛋白受体相关蛋白1(low-density lipoprotein receptor-related protein 1)(LRP1),前列腺特异性肽(prostate-specific membrane antigen)(PSMA),整合素αvβ3、铃蟾素(bombesin receptor)、生长抑素受体(somatostatin receptor)(SSTR)、肿瘤乏氧微环境,以及碳酸酐酶IX(CAIX)等受体。
在本发明的第七方面中,提供了一种药物组合物,所述的药物组合物包括:
(i)如第六方面所述的偶联物或其药学上可接受的盐;以及
(ii)药学上可以接受的载体。
在本发明的第八方面中,提供了一种如第六方面所述的偶联物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
在本发明的第九方面中,提供了一种治疗癌症的方法,包括步骤:向有需要的对象施用安全有效量如第六方面所述的偶联物或其药学上可接受的盐。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
图1显示了化合物CR-8、UB-018、UB-022、UB-027的免疫组织化学染色(IHC)结果。
图2显示了HEK293细胞中CR-8以及本发明化合物对细胞周期素K降解效果。
发明人在广泛而深入地研究之后,意外地发现一类具有新颖结构的化合物(如本文中式(I)、式(I-1)、式(I-2)、式(I-3)或式(I-4)所示的化合物,尤其是当Cr1环上不存在N原子时),通过修饰母核其他位置的官能团,也具有优异的诱导细胞周期素K(Cyclin K)降解的效果。基于此,本发明人完成了本发明。
术语
除非另有说明,各结构式中以虚线表示的键代表与其他部分连接的位置。
如本文所用,除非另有定义,术语“烷基”本身或作为另一取代基的一部分是指具有指定碳原子数的直链或支链烃基(即,C1-6表示1-6个碳)。较佳地,烷基具体1~4个碳即C1-4烷基。烷基的例子包括但不限于:甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、正戊基、正己基、正庚基、正辛基等。术语“烯基”指具有一个或多个双键的不饱和烷基。较佳地,烯基具体2~4个碳即C2-4烯基。类似地,术语“炔基”指具有一个或多个三键的不饱和烷基。较佳地,炔基具体2~4个碳即C2-4炔基。此类不饱和烷基的例子包括但不限于:乙烯基、2-丙烯基、巴豆基、2-异戊烯基、2-(丁二烯基)、2,4-戊二烯基、3-(1,4-戊二烯基)、乙炔基、1-和3-丙炔基、3-丁炔基和更高级的同系物和异构体。
除非另有说明,术语“杂烷基”本身或与其它术语组合是指的如前所定义的烷基中一个或多个(如1或2个)碳原子被诸如人选自O、N、Si和S的杂原子所替换所形成的稳定的直链或支链基团,且其中氮和硫原子可选地被氧化,氮杂原子可任选地被季铵化。杂
原子O、N和S可以位于杂烷基的任何内部位置。杂原子Si可以位于杂烷基的任何位置,包括烷基连接到分子其余部分的位置。
术语“亚烷基”本身或作为另一取代基的一部分是指衍生自烷烃的二价基团,例如-CH2-。优选地,在本申请中,具有1、2、3或4个碳原子(即C1-4亚烷基)。
术语“杂亚烷基”本身或作为另一取代基的一部分是指由杂烷基衍生的二价基团。
如本文所用,术语“碳环基”或“碳环”是指具有指定环原子数(例如,C3-10碳环(基)、C4-10碳环(基)、C4-6碳环(基))并且完全饱和的或在环顶之间具有一个或二个双键的烃环(基)。该术语也包括双环和多环烃环,例如双环[2.2.1]庚烷、双环[2.2.2]辛烷等。术语“杂环基”或“杂环”是指含有1至5个选自N、O和S的杂原子的碳环(基),其中氮和硫原子任选被氧化,且氮原子任选被季铵化。杂环(基)可以是单环、双环或多环体系,优选单环。杂环(基)的非限制性例子包括吡咯烷、咪唑烷、吡唑烷、丁内酰胺、戊内酰胺、咪唑烷酮、乙内酰脲、二氧戊环、苯邻二甲酰亚胺、哌啶、1,4-二恶烷、吗啉、硫代吗啉、硫代吗啉-S-氧化物、硫代吗啉-S,S-氧化物、哌嗪、吡喃、吡啶酮、3-吡咯啉、噻喃、吡喃酮、四氢呋喃、四氢噻吩、奎宁环等。杂环(基)可以经环碳或杂原子连接于分子的其余部分。
术语“环烷基”是指具有指定环原子数(例如,C3-6环烷基)并且完全饱和的烃环。环烷基可以是一价或二价的。
术语“烷氧基”以其常规意义使用,指代分别经氧原子、氨基或硫原子连接于分子的其余部分的那些烷基。
除非另有表述,术语“卤代”或“卤素”本身或作为另一取代基的一部分是指氟、氯、溴、或碘原子。此外,诸如“卤代烷基”等术语表示包括单卤代烷基或多卤代烷基。例如,术语“C1-4卤代烷基”表示包括三氟甲基、2,2,2-三氟乙基、4-氯丁基、3-溴丙基等。
除非另有表述,术语“芳基”表示多不饱和的(通常芳香性)的烃基,其可以是单环或稠合在一起或共价连接的多环(最多三环)。术语"杂芳基"是指含有1至5个选自N、O、和S的杂原子的芳基(或环),其中氮和硫原子任选被氧化,氮原子任选被季铵化。杂芳基可通过杂原子连接于分子的其余部分。芳基的非限制性例子包括苯基、萘基和联苯基,而杂芳基的非限制性例子包括吡啶基、哒嗪基、吡嗪基、嘧啶基、三嗪基、喹啉基、喹喔啉基、喹唑啉基、噌啉基、酞嗪基、苯并三嗪基(benzotriazinyl)、嘌呤基、苯并咪唑基、苯并吡唑基、苯并三唑基、苯并异恶唑基、异苯并呋喃基(isobenzofuryl)、异吲哚基、中氮茚基、苯并三嗪基、噻吩并吡啶基、噻吩并嘧啶基、吡唑并嘧啶基、咪唑并吡啶、苯并噻唑基、苯并呋喃基、苯并噻吩基、吲哚基、喹啉基、异喹啉基、异噻唑基、吡唑基、吲唑基、蝶啶基、咪唑基、三唑基、四唑基、恶唑基、异恶唑基、噻二唑基、吡咯基、噻唑基、呋喃基、噻吩基等等。以上芳基和杂芳基环系统各自的取代基选自下述可接受的取代基的组。
在一些实施例中,上述术语(如“烷基”,“芳基”和“杂芳基”)将包括指定基团的取代和未取代形式。下面提供了每种类型基团的优选取代基。为简洁起见,术语芳基和杂芳基将指代如下文所提供的取代或未取代的形式,而术语“烷基”和相关的脂肪族
基团是指未取代的形式,除非指明被取代。
烷基(包括通常称为亚烷基,烯基,炔基和环烷基的那些基团)的取代基可以是选自下组的各种基团:-卤素、-OR'、-NR'R"、-SR'、-SiR'R"R"‘、-OC(O)R'、-C(O)R'、-CO2R'、-CONR'R"、-OC(O)NR'R"、-NR"C(O)R'、-NR'-C(O)NR"R"‘、-NR"C(O)2R'、-NH-C(NH2)=NH、-NR'C(NH2)=NH、-NH-C(NH2)=NR'、-S(O)R'、-S(O)2R'、-S(O)2NR'R"、-NR'S(O)2R"、-CN和-NO2,数量从零到(2M'+1),其中M'是这种基团中的碳原子总数。R'、R"和R"‘各自独立地表示氢,未取代的C1-8烷基,未取代的杂烷基,未取代的芳基,被1-3个卤素取代的芳基,未取代的C1-8烷基,C1-8烷氧基或C1-8硫代烷氧基,或未取代的芳基-C1-4烷基。当R'和R"连接到相同的氮原子时,它们可以与氮原子结合形成3-,4-,5-,6-或7-元环。例如,-NR'R"是指包括1-吡咯烷基和4-吗啉基。术语“酰基”,单独或作为另一基团的一部分使用,是指其中在最接近该基团的连接点的碳上两个取代基的被取代基=O取代(例如-C(O)CH3,-C(O)CH2CH2OR'等)。
类似地,芳基和杂芳基的取代基是多种的,并且通常选自:-卤素、-OR'、-OC(O)R'、-NR'R"、-SR'、-R'、-CN、-NO2、-CO2R'、-CONR'R"、-C(O)R'、-OC(O)NR'R"、-NR"C(O)R'、-NR"C(O)2R'、-NR'-C(O)NR"R"'、-NH-C(NH2)=NH、-NR'C(NH2)=NH、-NH-C(NH2)=NR'、-S(O)R'、-S(O)2R'、-S(O)2NR'R"、-NR'S(O)2R"、-N3、全氟(C1-C4)烷氧基和全氟(C1-C4)烷基,数量从零到芳香环体系上的开放化合价的总数;其中R'、R"和R"'独立地选自氢,C1-8烷基,C3-6环烷基,C2-8烯基,C2-8炔基,未取代的芳基和杂芳基,(未取代的芳基)-C1-4烷基和未取代的芳氧基-C1-4烷基。其它合适的取代基包括通过1-4个碳原子的亚烷基链连接到环原子上的每一个上述芳基取代基。
如本文所用,术语“杂原子”意在包括氧(O)、氮(N)、硫(S)和硅(Si)。
对于本文提供的化合物,从取代基(通常为R基团)到芳香环(例如苯,吡啶等)的中心的键将被理解为是指在芳香环的任何可用顶点提供连接的键。在一些实施例中,该描述也包括稠合在芳环上的环上的连接。例如,绘制到吲哚苯部分的中心的键将表示与吲哚的六元或五元环部分的任何可用顶点连接的键。
如本文所用,“衍生自……的部分”是指将活性物质(例如,诸如抗体等的多肽元件或靶向配体)通过一定手段(例如使其上活性基团反应,或引入活性基团进行反应)从而使活性物质与其他部分形成连接基团后余下的活性物质的部分或片段,该部分或片段保留了所述活性物质的功能(如靶向期望受体的能力)。具体的“衍生”形成的连接基团包括但不限于:-NH-、-CONH-、-CO-、-S-S-等等。
术语"药学上可接受的盐"意在包括活性化合物与相对无毒的酸或碱制备的盐,其取决于本文所述化合物上具体的取代基。当本发明化合物含有相对酸性的官能团时,可通过将中性形式的此类化合物与充足量的所需碱(无溶剂的或在合适的惰性溶剂中的)接触来获得碱加成盐。衍生自药学上可接受的无机碱的盐的例子包括铝、铵、钙、铜、铁,亚铁、锂、镁、锰,亚锰、钾、钠、锌等。衍生自药学上可接受的有机碱的盐包括伯胺、仲胺和叔胺的盐,包括取代的胺、环状胺、自然产生的胺等等,例如精氨酸、甜菜碱、咖啡因、胆碱、N,N’-二苄基乙二胺、二乙胺、2-二乙基氨基乙醇、2-二甲基氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、葡糖胺(glucamine)、葡萄糖胺(glucosamine)、
组氨酸、海巴明、异丙胺、赖氨酸、甲葡糖胺、吗啉、哌嗪、哌啶、聚胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺、氨基丁三醇等等。当本发明化合物含有相对碱性的官能团时,可通过将中性形式的此类化合物与充足量的所需酸(无溶剂的或在合适的惰性溶剂中的)接触来获得酸加成盐。药学上可接受的酸加成盐的例子包括衍生自无机酸的那些,例如盐酸、氢溴酸、硝酸、碳酸、单氢碳酸、磷酸、单氢磷酸、二氢磷酸、硫酸、单氢硫酸、氢碘酸、或亚磷酸等等;以及衍生自相对无毒的有机酸的盐,例如乙酸、丙酸、异丁酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、扁桃酸、苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸,酒石酸、甲磺酸等等。还包括氨基酸的盐,例如精氨酸盐等等,和有机酸的盐,例如葡萄糖醛酸(glucuronic acid)或半乳糖醛酸(galactunoric acid)等。本发明的某些具体化合物同时含有碱性和酸性官能团,从而能将化合物转换成碱加成盐或酸加成盐。
通过将盐与碱或酸接触并以常规方式分离母体化合物,可以再生该化合物的中性形式。化合物的母体形式与各种盐形式在某些物理性能(例如在极性溶剂中的溶解度)上不同,但除此之外,就本发明的目的而言,那些盐与母体形式化合物是等价的。
除盐形式外,本发明提供前药形式的化合物。本文所述的化合物的前药是在生理条件下很容易经历化学变化以提供本发明化合物的那些化合物。另外,前药可以在离体环境中通过化学或生物化学方法转变为本发明化合物。例如,当置于含合适的酶或化学试剂的经皮贴片贮器中时,前药可缓慢转变为本发明的化合物。
本发明的某些化合物可以非溶剂化形式以及溶剂化形式存在,包括水化形式。溶剂化形式通常与非溶剂化形式等价,应包括在本发明范围内。本发明的某些化合物可以多晶型或无定形形式存在。通常,就本发明所考虑的应用而言,所有物理形式是等价的,应包括在本发明范围内。
本发明的某些化合物拥有不对称碳原子(光学中心)或双键;消旋体、非对映体、几何异构体、区域异构体和单独的异构体(例如,分离的对映体)均应包括在本发明范围内。当本文提供的化合物具有确定的立体化学(表示为R或S,或具有虚线或楔形键指明)时,被本领域技术人员将理解那些化合物为基本上不含其他异构体(例如至少80%,90%,95%,98%,99%和至多100%不含其他异构体)。
本发明化合物还可在构成此类化合物的一个或多个同位素原子处含有非天然比例的原子同位素。某同位素的非天然比例可以定义为从所讨论原子的天然发现的量到100%该原子的量。例如,化合物可以掺入放射性同位素,例如氚(3H)、碘-125(125I)或碳-14(14C),或非放射性同位素,例如氘(2H)或碳-13(13C)。除了本申请所述的那些用途,此类同位素变体可提供额外的用途。例如,本发明化合物的同位素变体可以有额外的用途,包括但不限于作为诊断的和/或成像试剂,或作为细胞毒性/放射毒性治疗剂。另外,本发明化合物的同位素变体可具有改变的药代动力学和药效学特征,从而有助于增加治疗期间的安全性、耐受性或疗效。无论是否有放射性,本发明化合物的所有同位素变体均应包括在本发明范围内。
分子胶降解剂
目前研究发现,细胞周期蛋白依赖型激酶(cyclin-dependent kinases,CDK)抑制剂CR8
也是分子胶降解剂,CR8通过诱导CDK12/cyclin K与CUL4/DDB1直接形成复合物,使cyclin K发生泛素化并通过蛋白酶体系统降解,进而能更有效的杀死癌细胞。
进一步通过对蛋白-小分子-蛋白复合物CUL4-RBX1-DDB1-CR8-CDK12-cyclin的结构进行解析,发现CDK12扮演了类似于CRBN底物受体的角色,CDK12表面与CR8的2-吡啶部分的存在和正确的取向,使CR8的功能获得性增加,导致cyclin K的降解。即CR8-苯基吡啶赋予了它分子胶水的活性,诱导的cyclin K降解,增加了CR8的毒性。
通过对CR8结构进行改性,作者发现CR8分子胶水的活性很大程度上依赖于暴露在激酶表面的2-吡啶部分。他们得出结论,这个化学基团使得CR8像分子胶降解剂一样发挥功能。因此,对抑制剂的暴露在蛋白表面的部分进行化学修饰,可以将它们变成针对特定蛋白标靶的分子胶降解剂。
然而,发明人在研究中发现具有本发明、式(I)、式(I-1)、式(I-2)、式(I-3)、式(I-4)所示结构,尤其是式(I-1)所示结构的化合物在存在或不存在吡啶取代基(或其他含氮杂芳环类取代基)或者是否是吡啶取代基(或其他含氮杂芳环类取代基)的情况下依然具有优异的诱导细胞周期蛋白如细胞周期素K降解的效果,并基于此,发明人提供了一系列新颖的细胞周期蛋白调节剂(更具体地分子胶降解剂)。
在一个实施方案中,提供了一种如式(I)所示的化合物或其药学上可接受的盐,
其中,各基团如第一方面中定义。
在一个优选的实施方案中,提供了如式(I-1)、式(I-2)、式(I-3)或式(I-4)所示的化合物或其药学上可接受的盐;
其中,各基团如前定义。
在本发明的一个方面提供了如下任一所示的分子胶降解剂
其中,n2为2-4(即n2所在环为4至6元环),环Ar1还可任选地被n3个Ra取代基取代(未示出)和环Cr1还任选地被n4个Rb取代基取代(未示出);R1、R2、R3、X1、X2、X3、X4、X5、X6、X8、X9、下标n1、n3、n4、Ar1、Cr1、Ra和Rb如本文中其他部分定义。
在本发明的另一个方面提供了如下任一所示的分子胶降解剂
其中,n2为2-4(即n2所在环为4至6元环);环Ar1还可任选地被n3个Ra取代基取代(未示出)和环Ar2还任选地被n4个Rb取代基取代(未示出);;R1、R2、R3、X1、X2、X3、X4、X5、X6、X8、X9、下标n1、n3、n4、Ar1、Cr1、Ra和Rb如本文中其他部分定义。
活性成分
如本文所用,术语“本发明化合物”指如式(I)所示的化合物。该术语还包括及式I化合
物的各种晶型形式、或药学上可接受的盐。
在本文中,活性成分也可以是式(I)所示的化合物与抗体或多肽的形成的偶联物。
药物组合物和施用方法
由于本发明化合物具有优异的对诱导诱导细胞周期素K(Cyclin K)降解的活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物,或者由本发明化合物与抗体或多肽形成的偶联物可用于治疗、预防与细胞周期素K(Cyclin K)有关或细胞周期素K(Cyclin K)参与的的疾病。根据现有技术,本发明化合物可用于治疗以下疾病:癌症等。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。
“药学上可以接受的载体”指的是:一种或多种兼容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“兼容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、
二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物联合给药。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选20~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
多肽元件
如本文所用,术语“多肽元件”包括肽段(如3-20aa的短肽)或蛋白。此外,该术语还包括完整的蛋白或其片段。优选的多肽元件包括抗体(如完整抗体、单链抗体、纳米抗体、抗体片段),尤其是针对肿瘤细胞标志物(如位于肿瘤细胞表面的肿瘤标志物,如细胞表面的受体)或针对炎性因子(如与自身免疫疾病相关的炎性因子)的抗体。
如本文所用,术语“抗体”或“免疫球蛋白”是有相同结构特征的约150000道尔顿的异四聚糖蛋白,其由两个相同的轻链(L)和两个相同的重链(H)组成。每条轻链通过一个共价二硫键与重链相连,而不同免疫球蛋白同种型的重链间的二硫键数目不同。每条重链和轻链也有规则间隔的链内二硫键。每条重链的一端有可变区(VH),其后是多个恒定区。每条轻链的一端有可变区(VL),另一端有恒定区;轻链的恒定区与重链的第一个恒定区相对,轻链的可变区与重链的可变区相对。特殊的氨基酸残基在轻链和重链的可变区之间形成界面。
如本文所用,术语“单域抗体”、“纳米抗体”具有相同的含义,指克隆抗体重链的可变区,构建仅由一个重链可变区组成的单域抗体,它是具有完整功能的最小的抗原结合片段。通常先获得天然缺失轻链和重链恒定区1(CH1)的抗体后,再克隆抗体重链的可变区,构建仅由一个重链可变区组成的单域抗体。
如本文所用,术语“可变”表示抗体中可变区的某些部分在序列上有所不同,它形成了各种特定抗体对其特定抗原的结合和特异性。然而,可变性并不均匀地分布在整个抗体可变区中。它集中于轻链和重链可变区中称为互补决定区(CDR)或超变区中的三个片段中。可变区中较保守的部分称为构架区(FR)。天然重链和轻链的可变区中各自包含四个FR区,它们大致上呈β-折叠构型,由形成连接环的三个CDR相连,在某些情况下可
形成部分折叠结构。每条链中的CDR通过FR区紧密地靠在一起并与另一链的CDR一起形成了抗体的抗原结合部位。恒定区不直接参与抗体与抗原的结合,但是它们表现出不同的效应功能,例如参与抗体的依赖于抗体的细胞毒性。
脊椎动物抗体(免疫球蛋白)的“轻链”可根据其恒定区的氨基酸序列归为明显不同的两类(称为κ和λ)中的一类。根据其重链恒定区的氨基酸序列,免疫球蛋白可以分为不同的种类。主要有5类免疫球蛋白:IgA,IgD,IgE,IgG和IgM,其中一些还可进一步分成亚类(同种型),如IgG1,IgG2,IgG3,IgG4,IgA和IgA2。对应于不同类免疫球蛋白的重链恒定区分别称为α、δ、ε、γ、和μ。不同类免疫球蛋白的亚单位结构和三维构型是本领域人员所熟知的。
一般,抗体的抗原结合特性可由位于重链和轻链可变区的3个特定的区域来描述,称为可变区域(CDR),将该段间隔成4个框架区域(FR),4个FR的氨基酸序列相对比较保守,不直接参与结合反应。这些CDR形成环状结构,通过其间的FR形成的β折叠在空间结构上相互靠近,重链上的CDR和相应轻链上的CDR构成了抗体的抗原结合位点。可以通过比较同类型的抗体的氨基酸序列来确定是哪些氨基酸构成了FR或CDR区域。
本发明中,多肽元件不仅可包括完整的抗体,还包括具有免疫活性的抗体的片段(如如Fab或(Fab’)2片段;抗体重链;或抗体轻链)或抗体与其他序列形成的融合蛋白。因此,本发明还包括所述抗体的片段、衍生物和类似物。
靶向配体
靶向配体(或靶蛋白部分或靶蛋白配体或配体)是能够结合目标靶蛋白的小分子。
在本申请的一些实施方案中,靶向配体可以是(或源自)靶标分子。
本申请的一些实施方案涉及靶标分子,代表性的靶标分子其包括但不限于:叶酸、Hsp90抑制剂、激酶抑制剂、MDM2抑制剂、靶向含人BET溴结构域的蛋白的化合物、靶向胞质信号蛋白FKBP12的化合物、HDAC抑制剂、人赖氨酸甲基转移酶抑制剂、血管生成抑制剂、免疫抑制化合物、靶向芳基烃受体(AHR)和靶向肿瘤厌氧微环境的化合物。
在某些实施方案中,靶向配体是能够结合激酶、BET含溴结构域的蛋白、胞质信号蛋白(例如FKBP12)、核蛋白、组蛋白脱乙酰酶、赖氨酸甲基转移酶、调节血管生成的蛋白、调节免疫应答的蛋白、芳烃受体(AHR)、雌激素受体、雄激素受体、糖皮质激素受体或转录因子(例如,SMARCA4、SMARCA2、TRIM24)。
在某些实施方案中,靶向配体能够结合的激酶包括但不限于:酪氨酸激酶(例如,AATK、ABL、ABL2、ALK、AXL、BLK、BMX、BTK、CSF1R、CSK、DDR1、DDR2、EGFR、EPHA1、EPHA2、EPHA3、EPHA4、EPHA5、EPHA6、EPHA7、EPHA8、EPHA10、EPHB1、EPHB2、EPHB3、EPHB4、EPHB6、ERBB2、ERBB3、ERBB4、FER、FES、FGFR1、FGFR2、FGFR3、FGFR4、FGR、FLT1、FLT3、FLT4、FRK、FYN、GSG2、HCK、HRAS、HSP90、IGF1R、ILK、INSR、INSRR、IRAK4、ITK、JAK1、JAK2、JAK3、KDR、KIT、KRAS、KSP、KSR1、LCK、LMTK2、LMTK3、LTK、LYN、MATK、MERTK、MET、MLTK、MST1R、MUSK、NPR1、NRAS、NTRK1、NTRK2、NTRK3、PDGFRA、PDGFRB、PLK4、PTK2、PTK2B、PTK6、PTK7、RET、ROR1、ROR2、ROS1、RYK、SGK493、SRC、SRMS、STYK1、SYK、TEC、TEK、TEX14、TIE1、TNK1、TNK2、
TNNI3K、TXK、TYK2、TYRO3、YES1或ZAP70)、丝氨酸/苏氨酸激酶(例如酪蛋白激酶2、蛋白激酶A、蛋白激酶B、蛋白激酶C、Raf激酶、CaM激酶、AKT1、AKT2、AKT3、ALK1、ALK2、ALK3、ALK4、AuroraA、AuroraB、AuroraC、CHK1、CHK2、CLK1、CLK2、CLK3、DAPK1、DAPK2、DAPK3、DMPK、ERK1、ERK2、ERK5、GCK、GSK3、HIPK、KHS1、LKB1、LOK、MAPKAPK2、MAPKAPK、MEK、MNK1、MSSK1、MST1、MST2、MST4、NDR、NEK2、NEK3、NEK6、NEK7、NEK9、NEK11、PAK1、PAK2、PAK3、PAK4、PAK5、PAK6、PIM1、PIM2、PLK1、RIP2、RIP5、RSK1、RSK2、SGK2、SGK3、SIK1、STK33、TAO1、TAO2、TGF-β、TLK2、TSSK1、TSSK2、ΜLK1或ΜLK2)、周期素依赖性蛋白激酶(例如Cdk1-Cdk11)和富含亮氨酸的重复激酶(例如LRRK2)。
本发明的主要优点包括
(a)本发明的化合物具有优异的诱导胞周期素K(Cyclin K)降解的效果。
(b)深入研究发现,本发明的化合物还具有诱导其他细胞周期蛋白降解的功能,从而进一步增加了其细胞毒性。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数是重量百分比和重量份数。
A.制备实施例
通用合成方法
本发明的化合物可通过对本领域技术人员显而易见的任何方法制备、分离或获得。本发明的化合物也可以根据下面提供的示例性制备方案(如实施例中的方法)制备。示例性制备方案中未提供的反应条件、步骤和反应物对于本领域技术人员来说是显而易见的和是已知的。如本文所用,在这些过程中、方案和实施例中使用的符号和惯例,无论特定缩写是否被具体定义,都具有本领域技术人员所熟知的含义。具体地,但不限于,以下缩写可在实施例中和整个说明书中使用:g(克);mg(毫克);mL(毫升);μL(微升);毫米(毫摩尔);μM(微摩尔);MHz(赫兹);MHz(兆赫兹);mmol(毫摩尔);hr或hrs(小时);min(分钟);MS(质谱);ESI(电喷雾离子化);TLC(薄层色谱);HPLC(高效液相色谱);THF(四氢呋喃);CDCl3(氘代氯仿);AcOH(乙酸);DCM(二氯甲烷);DMSO(二甲基亚砜);EtOAc(乙酸乙酯);MeOH(甲醇);;和BOC(叔丁氧羰基)等。
除非另有说明,实施例中使用的原料可通过该市售获得或者以本领域技术人员已知的方式或实施例中记载的类似方法合成。
实施例1:化合物UB-001的合成
步骤1:UB-001c
将UB-001a(2000mg,13.6mol),UB-001b(2.32g,13.6mmol),pdCl2dppf(300mg),Na2CO3(2.8g)加入二氧六环(32mL)和水(8mL)中。反应体系在80℃搅拌16小时,反应完成后冷却至室温。将混合物加入水中,用乙酸乙酯萃取,盐水(30mL),硫酸钠干燥,过滤,浓缩后通过硅胶柱层析分离(二氯甲烷/甲醇=5%),得到黄色固体UB-001c(1.8g,收率55.5%)。LCMS[M+H]+=239.2
步骤2:UB-001d
LAH(4.2ml,1M in THF)滴加到UB-001c(500mg,2.1mmol)的无水THF(10mL)中。反应体系在20℃搅拌16小时,反应完成后用Na2SO4*10H2O淬灭。将混合物加入水中,用乙酸乙酯萃取,盐水(30mL),硫酸钠干燥,过滤,浓缩后通过硅胶柱层析分离(二氯甲烷/甲醇=2-20%),得到黄色固体UB-001d(200mg,收率44.5%)。LCMS[M+H]+=215.3
步骤3:UB-001f
把混合物UB-001d(100mg,0.47mmol),UB-001e(0.1g,0.47mmol)溶于正丁醇(2mL)120℃反应3小时。反应液浓缩,粗品用柱层析分离(PE/EA=30-70%)得到白色固体UB-001f(120mg,收率65.1%)。LCMS[M+H]+=394.2
步骤4:UB-001
把混合物UB-001f(30mg,0.08mmol),吗啡啉(33.12mg,0.38mmol),HCl(cat.)溶于正丁醇(2mL)180℃反应5小时。反应液浓缩,粗品用柱层析分离(DCM/MeOH=0-10%)得到白色固体UB-001(10mg,29.1%收率)。1H NMR(400MHz,DMSO-d6)δ8.06(s,1H),8.03–7.95(m,2H),7.89–7.73(m,3H),7.45(d,J=8.1Hz,2H),7.40(d,J=7.6Hz,1H),5.43(t,J=5.9Hz,1H),4.65(s,1H),4.61(d,J=5.8Hz,2H),4.02(q,J=7.2Hz,2H),3.61(s,8H),1.35(t,J=7.2Hz,3H).LCMS[M+H]+=446.6
实施例2:化合物UB-002的合成
步骤1:UB-002
把混合物UB-001f(30mg,0.08mmol),1-Boc-哌嗪(14mg,0.08mmol),HCl(cat.)溶
于正丁醇(2mL),180℃反应3小时。反应液浓缩,粗品用柱层析分离(DCM/MeOH=0-10%)得到黄色固体(5mg,14.8%收率)。1H NMR(400MHz,DMSO-d6)δ8.16(s,1H),7.99(d,J=8.0Hz,2H),7.88–7.81(m,2H),7.76(d,J=7.8Hz,1H),7.46(d,J=8.0Hz,2H),7.41(d,J=7.6Hz,1H),5.45(s,1H),4.67–4.58(m,3H),4.03(q,J=7.2Hz,2H),3.80(t,J=5.2Hz,4H),2.96(t,J=5.1Hz,4H),1.36(t,J=7.2Hz,3H),1.24(d,J=3.5Hz,1H).LCMS[M+H]+=445.6
实施例3:化合物UB-003的合成
步骤1:UB-003
把混合物UB-001f(30mg,0.08mmol),1-甲基-哌嗪(76mg,0.8mmol),HCl(cat.)溶于正丁醇(2mL),180℃反应3小时。反应液浓缩,粗品用制备板分离(DCM/MeOH=10%)得到黄色固体UB-003(5.9mg,16.9%收率)。1H NMR(400MHz,DMSO-d6)δ8.05(s,1H),8.01–7.96(m,2H),7.87–7.79(m,2H),7.75(d,J=7.8Hz,1H),7.45(d,J=8.1Hz,2H),7.40(d,J=7.5Hz,1H),5.45(t,J=5.9Hz,1H),4.62(t,J=8.0Hz,3H),4.02(q,J=7.2Hz,2H),3.70(s,4H),2.49–2.39(m,4H),2.24(s,3H),1.35(t,J=7.2Hz,3H).LCMS[M+H]+=459.3.
实施例4:化合物UB-004的合成
步骤1:UB-004c
把混合物UB-004a(100mg,0.47mmol),UB-004b(101mg,0.47mmol)DIPEA(95mg)溶于正丁醇(2mL)120℃反应3小时。反应液浓缩,粗品用柱层析分离(PE/EA=30-70%)得到白色固体UB-004c(120mg,收率60.4%)。LCMS[M+H]+=364.2
步骤2:UB-004
把混合物UB-004e(30mg,0.08mmol),哌嗪-1-羧酸叔丁酯(70.8mg,0.38mmol),HCl(cat.)溶于正丁醇(2mL)180℃反应5小时。反应液浓缩,粗品用柱层析分离(DCM/MeOH=0-10%)得到黄色固体UB-004(10mg,收率27.0%)。1H NMR(400MHz,DMSO-d6)δ7.78(s,1H),7.65–7.54(m,4H),7.48–7.40(m,4H),7.37–7.30(m,1H),4.63(s,2H),4.01(q,J=7.2Hz,2H),3.68–3.54(m,4H),2.75–2.63(m,4H),1.35(t,J=7.2Hz,3H).LCMS[M+H]+=414.4
实施例5:化合物UB-005的合成
步骤1:UB-005a
LAH(4.2ml,1M in THF)滴加到UB-005a(500mg,2.1mmol)的无水THF(10mL)中。反应体系在20℃搅拌16小时,反应完成后用Na2SO4*10H2O淬灭。将混合物加入水中,用乙酸乙酯萃取,盐水(30mL),硫酸钠干燥,过滤,浓缩后通过硅胶柱层析分离(二氯甲烷/甲醇=2-20%),得到黄色固体UB-005b(200mg,收率44.5%)。LCMS[M+H]+=214.2
步骤2:UB-005d
把混合物UB-005b(100mg,0.47mmol),UB-005c(101mg,0.47mmol),DIPEA(95mg)溶于正丁醇(2mL)120℃反应3小时。反应液浓缩,粗品用柱层析分离(PE/EA=30-70%)得到白色固体UB-005d(120mg,65.1%收率)。LCMS[M+H]+=394.3
步骤3:UB-005
把混合物UB-005e(30mg,0.08mmol),哌嗪-1-羧酸叔丁酯(70.8mg,0.38mmol),HCl(cat.)溶于正丁醇(2mL)180℃反应5小时。反应液浓缩,粗品用柱层析分离(DCM/MeOH=0-10%)得到黄色固体UB-005(10mg,29.5%收率)。1H NMR(400MHz,DMSO-d6)δ7.99(d,J=8.3Hz,3H),7.87–7.73(m,3H),7.45(d,J=8.1Hz,2H),7.40(d,J=7.6Hz,1H),5.41(s,1H),4.61(d,J=4.2Hz,4H),4.01(q,J=7.2Hz,2H),3.63(t,J=5.1Hz,4H),2.74(d,J=10.2Hz,4H),1.35(t,J=7.2Hz,3H).LCMS[M+H]+=444.6
实施例6:化合物UB-006的合成
步骤1:UB-006
把混合物UB-006a(50mg,0.14mmol),UB-006b(59.7mg,0.69mmol)溶于正丁醇(2mL)180℃反应16小时。反应液浓缩,粗品用柱层析分离(DCM/MeOH=0-10%)得到黄色固体UB-006(16mg,26.3%收率)。1H NMR(400MHz,DMSO-d6)δ8.67–8.60(m,1H),8.04–7.97(m,2H),7.93–7.82(m,2H),7.72(s,1H),7.45(d,J=8.0Hz,2H),7.35–7.28(m,1H),6.08(d,J=7.6Hz,1H),4.65(s,2H),4.48(d,J=4.5Hz,1H),3.97(q,J=7.2Hz,2H),3.61(s,1H),1.79(d,J=11.3Hz,4H),1.33(t,J=7.2Hz,3H),1.28–1.14(m,5H).LCMS[M+H]+=444.9
实施例7:化合物UB-007的合成方法
步骤1:UB-007b
将化合物UB-007a(35.8g,0.2mol)加入到三口反应瓶中,用四氢呋喃(360mL)溶解,在氩气保护下,分五批次加入四氢铝锂(17.6g,0.44mol)。反应液在16℃下反应2小时,反应液用饱和硫酸钠溶液(20g)淬灭,固体抽滤,滤饼用四氢呋喃(100mL)洗涤。滤液旋干得到产物(UB-007b,37g,100%收率)性状黄色固体.LCMS[M+1]+=184.3
步骤2:UB-007d
将化合物UB-007b(18.4g,0.1mol),UB-007c(18.9g,0.1mol),三乙胺(40.4g,0.4mol)溶解于叔丁醇(200mL)中在110℃下反应14小时。反应液降温到20℃,有大量固体析出来,抽滤,滤饼用乙醇/水(100mL/10mL)洗涤,真空干燥得到目标化合物(UB-007d,20.7g,80%收率)性状黄色固体。LCMS[M+1]+=336.8
步骤3:UB-007f
将化合物UB-007d(27g,0.08mol),K2CO3(55.2g,0.4mol)溶解于二甲亚砜(270mL)中,室温搅拌5分钟。化合物UB-007e(59.3g,0.48mol)滴加到反应液中。滴毕,反应液在30℃下反应14小时。反应液加水(1000ml)淬灭反应,用乙酸乙酯(200mL*3)萃取。有几层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=5/1)得到化合物(UB-007f,27g,90%收率)性状淡黄色固体。LCMS[M+1]+=378.9。1H NMR(400MHz,CDCl3)δ7.72(s,1H),7.62(dd,J=8.0,2.0Hz,4H),7.48(t,J=8.1Hz,4H),7.39(t,J=7.3Hz,1H),6.58(s,1H),5.04–4.80(m,3H),1.60(d,J=6.8Hz,6H).
步骤4:UB-007
将化合物UB-007f(110mg,0.29mmol),化合物UB-007g(446mg,1.45mmol)溶解于(2mL)二甲亚砜中,在145℃下反应14小时。反应液降温到20℃,用乙酸乙酯(20mL)萃取三次。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=1/2)得到化合物(UB-007,39mg,31.2%收率),淡黄色固体。LCMS[M+1]+=431.6.1H NMR(400MHz,CDCl3)δ7.66–7.58(m,4H),7.57(s,1H),7.53–7.44(m,4H),7.38(t,J=7.3Hz,1H),6.77(s,1H),5.00(d,J=6.0Hz,1H),4.83(s,2H),4.61(dt,J=13.5,6.8Hz,1H),4.01–3.91(m,1H),3.85(dd,J=10.7,2.3Hz,1H),3.67(dd,J=10.5,7.6Hz,1H),
1.73–1.57(m,2H),1.53(d,J=6.7Hz,6H),1.05(t,J=7.4Hz,3H).
实施例8:化合物UB-008的合成方法
步骤1:UB-008(LS22002-016)
将化合物UB-007f(185.15mg,0.49mmol),哌啶(200mg,2.35mmol)溶解于(2mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加入水(50ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=1/2)得到化合物(UB-007,31mg,14.8%收率)性状淡黄色固体。LCMS[M+1]+=427.5
实施例9:化合物UB-009的合成
步骤1:UB-009
将化合物UB-007f(200mg,0.53mmol),吗啡啉(416mg,5.3mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(50ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=1/2)得到化合物(UB-009,38.5mg,17%收率)性状淡黄色固体。LCMS[M+1]+=429.6.1H NMR(400MHz,CDCl3)δ7.68(s,1H),7.59(dd,J=15.8,7.8Hz,4H),7.51–7.43(m,4H),7.38(t,J=7.3Hz,1H),6.64(s,1H),4.85(s,2H),4.75–4.60(m,1H),3.80(d,J=3.4Hz,8H),1.56(d,J=6.7Hz,6H).
实施例10:化合物UB-010的合成
步骤1:UB-010
将化合物UB-007f(200mg,0.53mmol),哌嗪(461mg,5.3mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-010,85mg,37.5%收率)性状淡黄色固体。LCMS
[M+1]+=428.6。1H NMR(400MHz,CDCl3)δ7.80(s,1H),7.57(dd,J=12.3,7.9Hz,4H),7.45(dd,J=12.5,7.7Hz,4H),7.36(s,1H),4.79(s,2H),4.66(dt,J=12.9,6.3Hz,2H),4.11(s,4H),3.22(s,4H),1.55(d,J=6.7Hz,6H).
实施例11:化合物UB-011的合成
步骤1:UB-011
将化合物UB-007f(110mg,0.29mmol),N-甲基哌嗪(290mg,2.9mmol)溶解于(2mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-011,53.9mg,42%收率)性状淡黄色固体。LCMS[M+1]+=442.7。1H NMR(400MHz,CDCl3)δ7.59(dd,J=12.8,7.9Hz,5H),7.50–7.44(m,4H),7.37(t,J=7.3Hz,1H),6.43(s,1H),4.85(s,2H),4.73–4.63(m,1H),4.00(s,4H),2.67(s,4H),2.49(s,3H),1.56(d,J=6.8Hz,6H).
实施例12:化合物UB-012的合成
步骤1:UB-012b
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-012a(500mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,得到化合物(UB-012b,200mg,90.1%收率)性状淡黄色固体。LCMS[M+1]+=542.6
步骤2:UB-012
将化合物UB-012b(200mg,0.45mmol)溶解于(3mL)甲醇中,搅拌下加入1N盐酸甲醇气(3mL),在25℃下反应18小时。将反应液旋干,碳酸钠饱和溶液调节pH至9,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-012,131mg,66%收率)性状淡黄色固体。LCMS[M+1]+=442.7.1H NMR(500MHz,DMSO-d6)δ8.17(s,2H),7.81(s,1H),7.61(dd,J=15.5,7.7Hz,4H),7.44(t,J=7.8Hz,4H),7.34(t,J=7.3Hz,1H),6.17(s,1H),4.63(s,2H),4.57–4.44(m,1H),3.61(d,J=7.2Hz,1H),2.91(t,J=11.1Hz,1H),1.95(t,J=15.9Hz,4H),1.45(t,J=12.4Hz,7H),1.32–1.07(m,2H).
实施例13:化合物UB-013的合成
步骤1:UB-013b(LS22002-011-1)
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-012a(500mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,得到化合物(UB-013b,200mg,90.1%收率)性状淡黄色固体。LCMS[M+1]+=542.6
步骤2:UB-013(LS22002-011-2)
将化合物UB-013b(200mg,0.45mmol)溶解于(3mL)甲醇中,搅拌下加入1N盐酸甲醇气(3mL),在25℃下反应18小时。将反应液旋干,碳酸钠饱和溶液调节pH至9,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-013,77mg,38%收率)性状淡黄色固体。LCMS[M+1]+=442.71H NMR(500MHz,DMSO-d6)δ8.09(s,1H),7.89(s,1H),7.61(dd,J=18.2,7.8Hz,4H),7.50(d,J=7.7Hz,2H),7.44(t,J=7.7Hz,2H),7.34(t,J=7.3Hz,1H),4.75–4.56(m,3H),4.30(d,J=12.9Hz,1H),3.54–3.21(m,2H),3.09(dd,J=13.9,6.2Hz,2H),3.00(t,J=10.9Hz,1H),2.51(s,1H),2.01(d,J=10.0Hz,1H),1.73(dd,J=9.2,4.0Hz,1H),1.63–1.52(m,1H),1.47(t,J=10.0Hz,7H).
实施例14:化合物UB-014的合成
步骤1:UB-014b
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-014a(500mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,得到化合物(UB-014b,200mg,90.1%收率)性状淡黄色固体,粗品直接用于下一步。LCMS[M+1]+=542.6
步骤2:UB-014
将化合物UB-014b(200mg,0.45mmol)溶解于(3mL)甲醇中,搅拌下加入1N盐酸甲醇气(3mL),在25℃下反应18小时。将反应液旋干,碳酸钠饱和溶液调节pH至9,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯
化(二氯甲烷/甲醇=13/1)得到化合物(UB-014,35mg,17.6%收率)性状淡黄色固体。LCMS[M+1]+=442.5.1H NMR(400MHz,DMSO-d6)δ8.05(s,1H),7.90(s,1H),7.63(dd,J=14.2,8.0Hz,4H),7.48(dd,J=16.7,8.5Hz,4H),7.37(t,J=7.3Hz,1H),4.80–4.47(m,4H),4.31(d,J=12.9Hz,1H),3.03(d,J=7.5Hz,4H),2.02–1.92(m,1H),1.79–1.69(m,1H),1.51(d,J=6.8Hz,9H).
实施例15:化合物UB-015的合成
步骤1:UB-015b
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-015a(500mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,得到化合物(UB-015b,200mg,90.1%收率)性状淡黄色固体,粗品直接用于下一步。LCMS[M+1]+=542.5
步骤2:UB-015
将化合物UB-015b(200mg,0.45mmol)溶解于(3mL)甲醇中,搅拌下加入1N盐酸甲醇气(3mL),在25℃下反应18小时。将反应液旋干,碳酸钾饱和溶液调节pH至9,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-015,45mg,22.6%收率)性状淡黄色固体。LCMS[M+1]+=442.5
实施例16:化合物UB-016的合成
步骤1:UB-016c
N6-([1,1'-联苯]-4-基甲基)-9-异丙基-N2-(哌啶-4-基)-9H-嘌呤-2,6-二胺
向反应瓶中加入UB-016a(200mg,0.53mmol),UB-016b(318.4mg,1.59mmol),Pd2(dba)3(49mg,0.054mmol),Xphos(126mg,0.265mmol)and Cs2CO3(518mg,1.59mmol),和1,4-dioxane(10mL).将反应混合物置换氩气三次,然后升温至100℃搅拌过夜。将反应混合物用水(30mL)稀释,然后用乙酸乙酯(30mL*3)萃取,分离有机相,用盐水(50mL)洗涤并用无水硫酸钠干燥,然后浓缩并通过色谱法(二氯甲烷:二氯甲烷/甲醇10/1=40:60)纯化得到产物得到黄色固体化合物(UB-016c,369.6mg,粗品)LCMS[M+1]+
=542.3.
步骤2:UB-016
N6-([1,1'-联苯]-4-基甲基)-9-异丙基-N2-(哌啶-4-基)-9H-嘌呤-2,6-二胺
在室温下向100mL底部烧瓶中加入UB-016c(369.6mg,0.68mmol)、盐酸的1,4-二氧六环溶液(4mL)和二氯甲烷(8.0mL)。然后将溶液在室温搅拌2小时。过滤反应混合物,滤饼用二氯甲烷(5mL)洗涤,用碳酸氢钠饱和水溶液中和,并用二氯甲烷(3*50mL)萃取。将合并的有机相用盐水洗涤,用无水硫酸钠干燥并减压浓缩,然后加入甲醇和水,并冷冻干燥,得到黄色固体产物(UB-016,85.6mg,产率:28.4%)LCMS[M+1]+=442.2.1H NMR(400MHz,DMSO-d6)δ7.80(s,1H),7.59(dd,J=17.4,7.8Hz,4H),7.47–7.40(m,4H),7.33(t,J=7.3Hz,1H),6.17(d,J=7.2Hz,1H),4.64(s,2H),4.52(dt,J=13.2,6.5Hz,1H),3.72(s,1H),2.95(d,J=11.3Hz,2H),2.56(d,J=11.2Hz,1H),1.86(s,2H),1.78(s,2H),1.46(d,J=6.7Hz,6H),1.32(dd,J=16.4,8.8Hz,2H),1.24(d,J=6.1Hz,1H).
实施例17:化合物UB-017的合成
步骤1:UB-017
将化合物UB-007f(188.5mg,0.5mmol),4-氨基哌啶(250mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应18小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=1/2)得到化合物(UB-017,147mg,66%收率)性状淡黄色固体。LCMS[M+1]+=442.7。1H NMR(500MHz,DMSO-d6)δ8.09(s,1H),7.87(s,1H),7.78(s,2H),7.65–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.48–7.42(m,4H),7.34(t,J=7.4Hz,1H),4.68–4.54(m,4H),3.26–3.16(m,1H),2.86(t,J=11.7Hz,2H),2.54(s,1H),1.88(d,J=10.5Hz,2H),1.47(d,J=6.8Hz,6H),1.37(dd,J=19.5,10.2Hz,2H).
实施例18:化合物UB-018的合成
步骤1:UB-018
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-018a(285.5mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应14小时。反应液降温到20℃,加水(20ml)淬灭反
应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(石油醚/乙酸乙酯=1/2)得到化合物(UB-018,85mg,37%收率)性状淡黄色固体。LCMS[M+1]+=456.31H NMR(500MHz,DMSO-d6)δ8.08(s,1H),7.89(s,2H),7.62(d,J=7.3Hz,2H),7.59(d,J=8.2Hz,2H),7.48(d,J=7.9Hz,2H),7.44(t,J=7.7Hz,2H),7.34(t,J=7.3Hz,1H),4.79–4.49(m,4H),4.27(d,J=13.1Hz,1H),3.15–2.97(m,3H),2.54(s,1H),2.05–1.94(m,1H),1.73(dd,J=8.9,4.4Hz,1H),1.54(d,J=8.7Hz,1H),1.48(d,J=6.8Hz,8H).
实施例19:化合物UB-019的合成
步骤1:UB-019b
将化合物UB-007f(188.5mg,0.5mmol),化合物UB-019a(535.5mg,2.5mmol)溶解于(3mL)二甲亚砜中,在145℃下反应14小时。反应液降温到20℃,加水(20ml)淬灭反应,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,得到化合物(UB-019b,200mg,85.1%收率)性状淡黄色固体,粗品直接用于下一步。LCMS[M+1]+=556.6
步骤2:UB-019
将化合物UB-019b(200mg,0.45mmol)溶解于(3mL)甲醇中,搅拌下加入1N盐酸甲醇气(3mL),在25℃下反应14小时。将反应液旋干,碳酸钠饱和溶液调节pH至9,用乙酸乙酯(20mL*3)萃取。有机层用盐水洗,无水硫酸钠干燥,旋干,柱层析分离纯化(二氯甲烷/甲醇=13/1)得到化合物(UB-019,26mg,11.4%收率)性状淡黄色固体。LCMS[M+1]+=556.6
实施例20:化合物UB-020的合成
步骤1:UB-020c
叔丁基(R)-4-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-3-甲基哌嗪-1-羧酸酯
在Ar下向UB-007f(200mg,0.530mmol)和UB-020b(424mg,0.120mmol)的无水二氧六环溶液中(10mL)加入Pd2(dba)3(48mg,0.054mmol)、Cs2CO3(518mg,1.59mmol))和XPhos(126mg,0.265mmol)。将混合物在100℃下搅拌3小时。将反应液浓缩并通过快速色谱法纯化,用PE/EA=0-50%洗脱,得到白色固体化合物(UB-020c,110mg,
产率38.3%)。LCMS[M+1]+=542.4
步骤2:UB-020
(R)-N-([1,1'-联苯]-4-基甲基)-9-异丙基-2-(2-甲基哌嗪-1-基)-9H-嘌呤-6-胺
向反应瓶中加入UB-020c(110mg,0.203mmol)和8mL DCM溶液,加入HCl的二氧六环溶液(3mL)。将混合物在室温下搅拌1小时。将反应混合物用NaHCO3(5mL)淬灭并用DCM(10mL*3)萃取,分离有机相,用盐水(10mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱法纯化,用DCM:10%MeOH/DCM=0-100%洗脱,得到白色固体化合物(UB-020,42.5mg,产率47.5%)LCMS[M+1]+=442.31H NMR(400MHz,DMSO-d6)δ7.99(s,1H),7.84(s,1H),7.64–7.59(m,2H),7.58(d,J=8.2Hz,2H),7.47–7.40(m,4H),7.33(t,J=7.3Hz,1H),4.70(dd,J=15.0,11.6Hz,2H),4.56(dt,J=13.4,6.7Hz,2H),4.38–4.29(m,1H),3.00–2.83(m,2H),2.79(s,2H),1.47(dd,J=6.7,1.0Hz,6H),1.08(d,J=6.5Hz,3H).
实施例21:化合物UB-021的合成
步骤1:UB-021c
(S)-4-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-3-甲基哌嗪-1-羧酸叔丁酯
将化合物UB-021b(637mg,3.18mmol),化合物UB-007f(200mg,0.53mmol),碳酸铯(519mg,1.59mmol),Pd2(dba)3(73mg,0.08mmol)和Xphos(142mg,0.30mmol)溶解于(6mL)超干-二氧六环中,在100℃下反应过夜。反应完成后,反应液降温到室温,将反应液浓缩并且通过硅胶柱纯化(EA/PE=40%),得到化合物(UB-021c,280mg,97%产率)性状黄色固体。LCMS[M+1]+=542.3.
步骤2:UB-021
(S)-N-([1,1'-联苯]-4-基甲基)-9-异丙基-2-(2-甲基哌嗪-1-基)-9H-嘌呤-6-胺
将化合物UB-021c(280mg,0.52mmol)溶于二氯甲烷(6mL),加入盐酸-1,4-二氧六环(6mmol,1.5mL)。反应在40℃下搅拌4小时。反应完成后,向反应液中加入碳酸氢钠饱和溶液调节PH至8~9,并且用DCM萃取(40mL*3)。合并有机相并用饱和食盐水洗,用无水硫酸钠干燥。将萃取液浓缩并通过硅胶柱纯化(DCM/MeOH=30%)并且冻干,得到想要的化合物UB-021(40mg,24%产率)性状白色固体。LCMS[M+1]+=442.3.1H NMR(400MHz,DMSO-d6)δ8.11(s,1H),7.88(s,1H),7.60(dd,J=13.8,8.0Hz,4H),7.47–7.42(m,4H),7.34(t,J=7.3Hz,1H),4.87(s,1H),4.56(ddd,J=33.3,26.3,16.3Hz,4H),3.15(d,J=12.0Hz,1H),3.09–2.90(m,3H),2.74(t,J=22.8Hz,1H),1.47(d,J=6.7Hz,6H),1.24(d,J=6.0Hz,1H),1.12(d,J=6.5Hz,3H).
实施例22:化合物UB-022的合成
步骤1:UB-022h
向三口烧瓶中依次加入化合物UB-007f(270mg,0.72mmol),UB-022g(416mg,2.34mmol),Cs2CO3(624mg,2.15mmol),Pd2(dba)3(90mg,0.10mmol)和XPhos(234mg,0.49mmol)。将混合物用氩气置换三次,然后加入无水1,4-二氧六环(16mL),将混何物于100℃下搅拌19小时。将混何物冷却至室温,减压浓缩后通过硅胶色谱柱纯化(DCM:10%MeOH in DCM=0-78%),得到产物UB-022h(65mg,产率:16%)。LCMS[M+1]+=558.3
步骤2:UB-022
向化合物UB-022h(65mg,0.12mmol)在CH2Cl2(3mL)中的混合物加入HCl/二氧六环(4N,1.5mL)。将反应混合物在25℃下搅拌17小时。将反应混合物浓缩,用饱和Na2CO3水溶液调节至pH=8-9。用CH2Cl2(20mL*3)萃取后,将合并的有机层用盐水洗涤,用无水Na2SO4干燥,然后将混合物减压浓缩,通过反相柱纯化得到产物UB-022(15.7mg,产率:29%),为白色固体。LCMS[M+1]+=458.3.1H NMR(400MHz,DMSO-d6)δ8.00(s,1H),7.84(s,1H),7.65–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.48–7.40(m,4H),7.33(t,J=7.3Hz,1H),4.67–4.51(m,4H),4.43(d,J=12.9Hz,1H),3.79(t,J=9.3Hz,1H),3.42(dd,J=9.8,4.7Hz,2H),3.23(d,J=12.3Hz,2H),3.00–2.87(m,2H),2.68(dd,J=12.3,4.0Hz,1H),2.64–2.54(m,1H),1.46(d,J=6.2Hz,6H).
实施例23:化合物UB-023的合成
步骤1:UB-023c
叔丁基(R)-4-(6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-3-(羟甲基)哌嗪-1-羧酸盐
在Ar下向反应瓶中加入UB-007f(300mg,0.8mmol)、UB-023b(520mg,2.4mmol)和无水二氧六环溶液(18mL),加入Pd2(dba)3(80mg,0.08mmol)、Cs2CO3(800mg,2.4mmol))和XPhos(200mg,0.4mmol)。将混合物在100℃下搅拌3小时。将反应浓缩并通过快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=0-40%洗脱,得到黄色油状化合物(UB-023c,200mg,产率44.8%)。LCMS[M+1]+=558.3
步骤2:UB-023
(R)-(1-(6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-2-基)甲醇
在反应瓶中加入UB-023c(200mg,0.359mmol)、8mL DCM溶液和HCl的二氧六环溶液(2mL)。将混合物在室温下搅拌1小时。将反应混合物用NaHCO3(4mL)淬灭并用DCM(20mL*3)萃取,分离有机相,用盐水(20mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱纯化,用DCM/(DCM:MeOH=10:1)=0-100%洗脱,得到浅黄色固体状化合物(UB-023,25.5mg,产率15.5%)LCMS[M+1]+=458.3。1H NMR(400MHz,DMSO-d6)δ8.09(s,1H),7.87(s,1H),7.65–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.48–7.41(m,4H),7.34(t,J=7.3Hz,1H),4.70(s,1H),4.67–4.58(m,2H),4.54(dd,J=13.3,5.7Hz,2H),3.78(t,J=9.2Hz,1H),3.49(dd,J=10.1,4.8Hz,1H),3.37(s,1H),3.07(dd,J=24.9,12.1Hz,2H),2.84(dd,J=12.3,3.7Hz,1H),2.71(dd,J=23.4,11.4Hz,1H),1.50–1.44(m,6H).
实施例24:化合物UB-024的合成
步骤1:UB-024i
在室温下向K2CO3(8.39g,60.17mmol)在MeCN(100mL)中的搅拌悬浮液中加入化合物UB-024g(4.00g,20.24mmol)。将所得混合物搅拌15分钟,然后加入苄基溴(2.6mL,21.89mmol)。将反应混合物在回流温度下搅拌14小时。将反应混合物浓缩并通过硅胶色谱法纯化(40g,45mL/min;DCM:10%MeOH的DCM溶液=0-6-30%),得到产物UB-024i(3.95g,产率:77%),为白色固体。LCMS[M+1]+=252.1
步骤2:UB-024k
向搅拌的化合物UB-024i(3.95g,15.73mmol)在DCM(80mL)中的冷却溶液中加入Et3N(3.3mL,23.74mmol),然后缓慢加入溴乙酰溴(3.81g,18.88mmol)。将反应混合物
升至室温搅拌过夜。将混合物减压浓缩并通过硅胶色谱法纯化(PE:EA=0-15-30%),得到产物UB-024k(4.62g,产率:79%),为无色液体。LCMS[M+1]+=372.1&374.1
步骤3:UB-024l
将化合物UB-024k(4.62g,12.43mmol)溶解在CH3OH(20mL)中,然后加入NH3在CH3OH中的溶液(7N,1.5mL)并将混合物在室温下搅拌17h。然后减压除去溶剂并用硅胶柱色谱法纯化(25g,45mL/min;CH2Cl2/10%CH3OH in CH2Cl2=0-30%),得到产物UB-024l(2.18g,产率:64%),为白色固体。LCMS[M+1]+=277.1
步骤4:UB-024m
向在冰浴中冷却至0℃的UB-024l(2.18g,7.92mmol)在无水四氢呋喃(30mL)中的搅拌溶液中,缓慢加入LiAlH4在THF中的溶液(48mL,48mmol)。将所得悬浮液在0℃下保持10分钟,然后回流1.5小时。然后将反应冷却下来并将水和硫酸钠直接加入混合物中直到气体释放完成。然后将混合物通过硅藻土过滤,滤饼用MeOH洗涤,除去溶剂,得到产物UB-024m(1.70g,75%产率),为浅橙色油。LCMS[M+1]+=221.2
步骤5:UB-024n
在室温下,向化合物UB-024m(1.74g,7.90mmol)在(40mL)的溶液中加入碳酸氢钠(1.99g,23.69mmol)的水(20mL)溶液。向上述混合物中缓慢加入二碳酸二叔丁酯(2.59g,11.87mmol),并将混合物在室温下搅拌17小时。将混合物减压浓缩并通过硅胶色谱法纯化(25g,45mL/min;DCM:10%MeOH的DCM溶液=0-10%),得到产物UB-024n(1.78g,产率:71%),为浅黄色液体。LCMS[M+1]+=321.2
步骤6:UB-024o
在室温下将Pd/C加入到化合物UB-024n(1.78g,5.56mmol)在EtOH(40mL)的溶液中。将混合物脱气并用H2重新填充三次。然后将混合物在室温下搅拌24小时。混合物通过硅藻土垫过滤,并用MeOH洗涤,滤液浓缩得到产物UB-024o(1.28g,产率100%)。LCMS[M+1]+=231.2
步骤7:UB-024p
向三颈圆底烧瓶中加入化合物UB-007f(170mg,0.45mmol)、UB-024o(225mg,0.98mmol)、Cs2CO3(440mg,1.35mmol)、Pd2(dba)3(43mg,0.05mmol)和XPhos(112毫克,0.23毫摩尔)。将混合物脱气并用氩气重新填充3次。并且通过注射器将干燥的二恶烷(14mL)添加到混合物中。然后将混合物在100℃下搅拌4小时。将反应混合物浓缩并通过硅胶色谱法纯化(DCM:10%MeOH in DCM=0-24%),得到产物UB-024p(158mg,产率:61%),为黄色固体。LCMS[M+1]+=572.3
步骤8:UB-024
向化合物UB-024p(158mg,0.28mmol)在CH2Cl2(6mL)中的混合物加入HCl/二氧六环(4N,1.5mL)。将反应混合物在25℃搅拌17小时。将反应混合物浓缩,用Na2CO3水溶液调节至pH=8-9。然后将混合物减压浓缩并通过硅胶色谱法纯化(DCM:10%MeOH in DCM=0-33%),得到产物UB-024(41mg,产率:32%),为白色固体。LCMS[M+1]+=472.31H NMR(400MHz,DMSO-d6)δ7.97(s,1H),7.83(s,1H),7.62(dd,J=5.2,3.3Hz,2H),7.58(d,J=8.3Hz,2H),7.44(dd,J=8.0,6.8Hz,4H),7.37–7.29(m,1H),4.65(s,3H),4.53(m,1H),4.44(d,J=11.2Hz,1H),3.36(t,J=6.9Hz,2H),2.91–2.77(m,3H),2.69–
2.60(m,1H),1.84(d,J=6.6Hz,2H),1.46(dd,J=6.7,3.4Hz,6H).
实施例25:化合物UB-025的合成
步骤1:UB-025c
二甲基苄基-L-天冬氨酸
在室温下向反应瓶中加入K2CO3(6.29g,45.54mmol)和20mL MeCN,在搅拌的悬浮液中加入UB-025a(3.0g,15.18mmol)。将反应液搅拌15分钟。加入UB-025b(2.726g,15.94mmol)。将反应混合物在回流温度下搅拌16小时。蒸发溶剂并用DCM(3×50mL)萃取残余物并Na2SO4干燥。减压蒸发溶剂。将残余物通过柱色谱DCM:(DCM:MeOH=10:1)=0-10%纯化,得到无色油状化合物(UB-025c,3.0g,产率78.7%)。LCMS[M+1]+=252.1
步骤2:UB-025e
N-苄基-N-(2-溴乙酰基)-L-天冬氨酸二甲酯
在反应瓶中加入UB-025c(3.0g,12mmol)、无水DCM(15mL)溶液和Et3N(1.82g,18mmol)。将混合物冷却至0℃并缓慢加入UB-025d(1.89g,14.3mmol)的5mL无水DCM的溶液。将反应在室温搅1小时。棕色溶液用1M HCl溶液洗涤两次,用饱和NaHCO3溶液洗涤两次,用盐水洗涤一次。有机相用Na2SO4干燥,然后浓缩并用快速色谱法纯化PE/EA=0-20%,得到淡黄色油状化合物(UB-025e,3.1g,产率69.6%)。LCMS[M+1]+=372.0;374.0
步骤3:UB-025f
S)-2-(1-苄基-3,6-二氧代哌嗪-2-基)乙酸甲酯
在反应瓶中加入UB-025e(3.1g,8.36mmol)和CH3OH(10mL)中,搅拌均匀,然后加入6mL7M的NH3/CH3OH溶液并将混合物在室温下搅拌7小时。然后除去溶剂并用快速色谱法(DCM/MeOH=0-30%)纯化残余物,得到白色固体状的化合物(UB-025f,1.6g,产率69.3%)。LCMS[M+1]+=277.1
步骤4:UB-025g
(S)-2-(1-苄基哌嗪-2-基)乙烷-1-醇
在冰浴下向反应瓶中加入UB-025f(500mg,1.81mmol)和10mL无水THF溶液,然后缓慢滴加LiAlH4/THF(10.9mL,1mmol/mL)溶液。将所得悬浮液在0℃下搅拌10分钟,然后回流90分钟。用Na2SO4和H2O淬灭反应混合物。混合物通过硅藻土过滤,然后浓缩,得到黄色油状化合物(UB-025g,400mg,产率100%),直接用于下一步反应。LCMS[M+1]+=221.2
步骤5:UB-025h
(S)-4-苄基-3-(2-羟乙基)哌嗪-1-羧酸叔丁酯
在室温将NaHCO3(1570mg,18.7mmol)和水(10mL)加入到溶有UB-025g(380mg,1.7mmol)的1,4-二氧六环(10mL)溶液中。加入(Boc)2O(524mg,2.4mmol)并将混合物在室温下搅拌1小时。反应完成后加入水(20mL)和EA(20mL)并分离各层。用EA(20mL)再次萃取水层。合并的有机物用水(30mL)和饱和氯化钠水溶液(20mL)洗涤,用硫酸钠干燥,过滤,真空浓缩。将所得油状物通过硅胶快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=10-30%洗脱,得到黄色油状化合物(UB-025h,500mg,产率91.9%)。LCMS[M+1]+=321.3
步骤6:UB-025i
(S)-3-(2-羟乙基)哌嗪-1-羧酸叔丁酯
将Pd/C(50mg,10%wt)加入到用氮气吹扫的容器中。加入EtOH(5mL),然后加入UB-025h(500mg)的EtOH(5mL)溶液。将容器密封,用氮气吹扫,用氢气吹扫,并在氢气加压下室温反应过夜。将反应混合物过滤并真空浓缩,得到黄色油状化合物(1246i,200mg,产率58.2%)。LCMS[M+1]+=231.2
步骤7:UB-025k
叔丁基(S)-4-(6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-3-(2-羟乙基)哌嗪-1-羧酸盐
在Ar下向反应瓶中加入UB-025i(156mg,0.413mmol)、UB-007f(190mg,0.825mmol)、Pd2(dba)3(38mg,0.041mmol)、Cs2CO3(404mg,1.24mmol)、XPhos(100mg,0.21mmol)和无水二氧六环(10mL)溶液。将混合物在100℃下搅拌3小时。将反应浓缩并通过快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=0-40%洗脱,得到黄色固体状化合物(UB-025k,90mg,产率38%)。LCMS[M+1]+=572.3
步骤8:UB-025047
(S)-2-(1-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-2-基)乙-1-醇
在反应瓶中加入UB-025k(90mg,0.16mmol)和6mL DCM溶液,搅拌均匀,加入TFA(1mL)。将混合物在室温下搅拌1小时。将反应混合物用NaHCO3淬灭并用DCM(10mL*3)萃取,分离有机相,用盐水(10mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=0-100%得到白色固体状化合物(UB-025,25mg,产率33.8%)。LCMS[M+1]+=472.2。1H NMR(400MHz,DMSO-d6)δ8.00(s,1H),7.84(s,1H),7.64–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.47–7.41(m,4H),7.34(d,J=7.4Hz,1H),4.66(d,J=30.1Hz,3H),4.54(dd,J=13.5,6.8Hz,1H),4.50–
4.44(m,1H),3.37(t,J=6.7Hz,3H),2.91(t,J=10.9Hz,3H),2.75–2.64(m,1H),1.93–1.80(m,2H),1.46(dd,J=6.7,3.2Hz,6H).
实施例26:化合物UB-026的合成
步骤1:UB-026h
将化合物UB-007f(80mg,0.11mmol)、UB-026g(210mg,1.05mmol)溶解于N-甲基吡咯烷酮(2mL)中,加入N,N-二异丙基乙按(216mg,1.68mmol),然后在微波中180℃下反应3小时。将反应混合物冷却至室温并加入水(10mL),沉淀出固体,过滤沉淀物,用水(20mL)洗涤,固体用二氯甲烷溶解,然后浓缩,残留物用硅胶纯化凝胶柱层析(石油醚/乙酸乙酯=2/1)得到所需产物(UB-026h,84mg,产率74%),性状黄色液体。LCMS[M+1]+=542.
步骤2:UB-026
将化合物UB-026h(84mg,0.15mmol)溶于二氯甲烷(4mL)和盐酸/二氧六环在二恶烷(1mL)中,然后在40℃下搅拌1小时。将反应混合物浓缩,用饱和碳酸氢钠水溶液调节至pH=8-9。用二氯甲烷(20mL*3)萃取后,将合并的有机层用食盐水洗涤,经无水硫酸钠干燥,过滤,浓缩,并将残留的水溶液冻干,得到所需产物(UB-026,20.2mg,产率30%),性状白色固体。LCMS[M+1]+=442.1H NMR(400MHz,CDCl3)δ7.99(s,1H),7.84(s,1H),7.65–7.54(m,4H),7.44(dt,J=7.8,3.6Hz,4H),7.38–7.29(m,1H),4.57(td,J=13.5,13.0,6.2Hz,3H),4.44(dd,J=12.7,3.0Hz,2H),2.86(d,J=11.1Hz,1H),2.68(td,J=12.0,2.7Hz,1H),2.57(td,J=11.4,4.7Hz,3H),2.31(dd,J=12.5,10.3Hz,1H),1.46(d,J=6.7Hz,6H),0.98(d,J=6.2Hz,3H).
实施例27:化合物UB-027的合成
步骤1:UB-027c
(R)-4-(6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-2-甲基哌嗪-1-羧酸叔丁酯
将化合物UB-027b(2650mg,13.26mmol),化合物UB-007f(1000mg,2.65mmol)溶解于(7mL)NMP中,在微波180℃下反应3小时。反应液降温到室温,加水至溶液析出固体,过滤。将滤渣溶解并且通过硅胶柱纯化(DCM/MeOH=10%),得到化合物(UB-027c,712mg,50%收率和470mg的产物掉Boc)性状黄色油。LCMS[M+1]+=542.3.
步骤2:UB-027
(R)-N-([1,1'-联苯]-4-基甲基)-9-异丙基-2-(3-甲基哌嗪-1-基)-9H-嘌呤-6-胺
将化合物UB-027c(712mg,1.32mmol)溶于二氯甲烷(16mL),加入盐酸-1,4-二氧六环(16mmol,4mL)。反应在40℃下搅拌4小时。反应完成后,向反应液中加入碳酸氢钠饱和溶液调节PH至8~9,并且用DCM萃取(40mL*3)。合并有机相并用饱和食盐水洗,用无水硫酸钠干燥。将萃取液浓缩并且冻干,得到想要的化合物UB-027(525.9mg,45%产率)性状白色固体。LCMS[M+1]+=442.31H NMR(400MHz,DMSO-d6)δ7.98(s,1H),7.84(s,1H),7.64–7.55(m,4H),7.47–7.41(m,4H),7.33(t,J=7.3Hz,1H),4.56(dt,J=13.4,6.7Hz,3H),4.44(d,J=12.3Hz,2H),2.85(d,J=11.3Hz,1H),2.67(t,J=12.0Hz,1H),2.61–2.53(m,2H),2.30(dd,J=12.3,10.4Hz,1H),1.46(d,J=6.7Hz,6H),0.97(d,J=6.2Hz,3H).
实施例28:化合物UB-028的合成
步骤1:UB-028c
(R)-叔丁基4-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)-2-(羟甲基)哌嗪-1-羧酸盐
将化合物UB-028b(287mg,1.33mmol),化合物UB-007f(100mg,0.27mmol)溶解于(3mL)NMP中,在微波180℃下反应3小时。反应液降温到室温,加水至溶液析出固体,过滤。将滤渣溶解并且通过硅胶柱纯化(DCM/MeOH=30%),得到化合物(UB-028c,42mg,59%收率)性状黄色油。LCMS[M+1]+=558.3.
步骤2:UB-028
(R)-(4-(6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-2-基)甲醇
将化合物UB-028c(42mg,0.07mmol)溶于二氯甲烷(2mL),加入盐酸-1,4-二氧六环(2mmol,0.5mL)。反应在40℃下搅拌4小时。反应完成后,向反应液中加入碳酸氢钠饱和溶液调节PH至8~9,并且用DCM萃取(40mL*3)。合并有机相并用饱和食盐水洗,用无水硫酸钠干燥。将萃取液浓缩并且冻干,得到想要的化合物UB-028(17.5mg,54%产率)性状白色固体。LCMS[M+1]+=458.2.1H NMR(400MHz,DMSO-d6)δ8.06(s,1H),7.87(s,1H),7.60(dd,J=16.3,7.7Hz,4H),7.48–7.41(m,4H),7.33(t,J=7.3Hz,1H),4.87(s,1H),4.69–4.42(m,5H),3.42(d,J=3.4Hz,2H),3.01(d,J=11.4Hz,1H),2.85(t,J=11.2Hz,1H),2.79–2.54(m,3H),1.47(d,J=6.7Hz,6H).
实施例29:化合物UB-029的合成
步骤1:UB-029b
(S)-哌嗪-2-基甲醇
向反应瓶中加入UB-029a(250mg,1.16mmol)和8mL DCM中的溶液,搅拌均匀,加入TFA(2mL)。将混合物在室温下搅拌1小时。将反应混合物浓缩,得到白色固体状化合物(UB-029b,400mg,产率100%)直接用于下一步反应。LCMS[M+1]+=117.1
步骤2:UB-029
(S)-(4-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-2-基)甲醇
在微波管中加入UB-029b(153mg,1.323mmol)、UB-007f(100mg,0.265mmol)、DIPEA(274mg,2.12mmol)和NMP(4mL)溶液。将混合物在微波条件下180℃搅拌3小时。将反应混合物倒入H2O中。过滤收集所得沉淀,滤液用EA萃取3次,合并有机相,过滤通过硅胶柱色谱纯化[洗脱液:DCM/(10%MeOH/DCM)=0-100%],得到白色固体状化合物(UB-029,62mg,产率51%)。LCMS[M+1]+=458.3。1H NMR(400MHz,DMSO-d6)δ8.00(s,1H),7.85(s,1H),7.64–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.49–7.41(m,4H),7.33(t,J=7.3Hz,1H),4.68(t,J=5.1Hz,1H),4.61(d,J=6.3Hz,1H),4.56(dd,J=13.4,6.8Hz,2H),4.45(d,J=12.6Hz,1H),3.38–3.34(m,2H),2.93(d,J=11.5Hz,1H),2.76(t,J=12.0Hz,1H),2.60(t,J=9.8Hz,2H),2.48–2.39(m,1H),1.46(d,J=6.7Hz,6H).
实施例30:化合物UB-030的合成
步骤1:UB-030b
(S)-2-(哌嗪-2-基)乙烷-1-醇
向反应瓶中加入UB-030a(460mg,2mmol)和8mL DCM溶液,搅拌均匀,加入TFA(2mL)。将混合物在室温下搅拌1小时。将反应混合物浓缩,得到白色固体状化合物(UB-030b,300mg,产率100%)。直接用于下一步反应。LCMS[M+1]+=131.2
步骤2:UB-030
(S)-2-(4-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-2-基)乙-1-醇
在微波管中加入UB-030b(138mg,1.058mmol)、UB-007f(80mg,0.0.212mmol)、DIPEA(220mg,1.7mmol)和NMP(4mL)溶液。将混合物在微波条件下180℃搅拌3小时。将反应混合物倒入H2O中。过滤收集所得沉淀,滤液用EA萃取3次,合并有机相,过滤通过硅胶柱色谱纯化[洗脱液:DCM/(10%MeOH/DCM)=0-100%],得到白色固体状化合物(UB-030,59mg,产率59.0%)。LCMS[M+1]+=472.3。1H NMR(400MHz,DMSO-d6)δ8.01(s,1H),7.84(s,1H),7.64–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.44(t,J=8.1Hz,4H),7.33(t,J=7.3Hz,1H),4.57(td,J=13.3,6.5Hz,3H),4.48(d,J=10.8Hz,1H),4.42(d,J=12.8Hz,1H),3.53(td,J=6.4,2.2Hz,2H),2.90(d,J=11.8Hz,1H),2.76(d,J=11.5Hz,1H),2.62(dd,J=16.8,10.5Hz,2H),2.45(d,J=10.3Hz,1H),1.54–1.48(m,2H),1.46(d,J=6.8Hz,6H).
实施例31:化合物UB-031的合成
步骤1:UB-031h
向化合物UB-031h(313mg,1.36mmol)在CH2Cl2(3mL)中的混合物加入HCl/二氧六环(4N,3.5mL)。将反应混合物在25℃下搅拌17小时。将反应混合物浓缩,用饱和Na2CO3水溶液调节至pH=8-9。用CH2Cl2(20mL*3)萃取后,将合并的有机层用盐水洗涤,用无水Na2SO4干燥,然后将混合物减压浓缩,得到产物UB-031h(177mg,产率:100%),为白色固体。LCMS[M+1]+=131.2步骤2:UB-031
向微波管中分别加入化合物UB-007f(70mg,0.19mmol),化合物UB-031h(177mg,0.47mmol),DIPEA(192mg,1.48mmol)和N-甲基吡咯烷酮(3mL),将混何用微波在180℃下加热6小时。将混何物冷却至室温,减压浓缩后通过硅胶柱层析法纯化(4g,40mL/min;DCM:10%MeOH in DCM=0-33%),得到产物粗(48mg,产率:55%),为棕黄色液体。粗产物进一步通过制备液相色谱(Prep.HPLC,流动相:HCl/水/乙腈)纯化,得到产物UB-031(31.5mg,产率:36%),为黄色固体。LCMS[M+1]+=472.3。1H NMR(400MHz,DMSO-d6)δ8.19(s,1H),7.91(s,1H),7.64–7.56(m,5H),7.47–7.41(m,5H),7.33(dd,J=10.4,4.3Hz,2H),4.65–4.45(m,6H),3.56(dd,J=11.3,5.8Hz,2H),3.18(d,J=12.1Hz,1H),3.09(d,J=11.0Hz,3H),2.87(s,3H),1.67(td,J=14.5,7.0Hz,3H),1.47(d,J=6.8Hz,8H).
实施例32:化合物UB-032的合成
步骤1:UB-032
N-([1,1'-联苯]-4-基甲基)-9-环丁基-2-(哌嗪-1-基)-9H-嘌呤-6-胺
在10mL的微波管中加入UB-007f(60mg,0.16mmol),UB-032b(148mg,0.80mmol),DIPEA(164mg,1.27mmol),NMP(3mL),所得混合物微波在180℃下反应3小时,反应结束后加入30mL的水,固体析出过滤,滤饼经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~30/70)分离得到白色固体化合物UB-032(30mg,产率42%)。LCMS[M+H]+=456.3.1H NMR(400MHz,DMSO-d6)δ8.03(s,1H),7.84(s,1H),7.65–7.60(m,2H),7.57(d,J=8.2Hz,2H),7.48–7.40(m,4H),7.34(d,J=7.3Hz,1H),4.56(dt,J=13.4,6.7Hz,3H),3.76(dd,J=12.7,3.0Hz,2H),3.41(dd,J=12.8,6.2Hz,3H),3.15(s,2H),1.46(dd,J=6.7,4.7Hz,6H),1.01(d,J=6.3Hz,6H).
实施例33:化合物UB-033的合成
步骤1:UB-033h
向三口烧瓶中依次加入化合物UB-007f(270mg,0.72mmol),UB-033g(416mg,2.34mmol),Cs2CO3(624mg,2.15mmol),Pd2(dba)3(90mg,0.10mmol)和XPhos(234mg,0.49mmol)。将混合物用氩气置换三次,然后加入无水1,4-二氧六环(16mL),将混何物于100℃下搅拌19小时。将混何物冷却至室温,减压浓缩后通过硅胶色谱柱纯化(DCM:10%MeOH in DCM=0-78%),得到产物UB-033h(109mg,产率:27%)。LCMS[M+1]+=558.3
步骤2:UB-033
向化合物UB-033h(109mg,0.20mmol)在CH2Cl2(3mL)中的混合物加入HCl/二氧六环(4N,1.5mL)。将反应混合物在25℃下搅拌17小时。将反应混合物浓缩,用饱和Na2CO3水溶液调节至pH=8-9。用CH2Cl2(20mL*3)萃取后,减压浓缩后通过硅胶色谱柱纯化(DCM:10%MeOH in DCM=0-100%),得到产物UB-033(59.3mg,产率:60%),为浅黄色固体。LCMS[M+1]+=458.3。1H NMR(400MHz,DMSO-d6)δ7.94(s,1H),7.82
(s,1H),7.65–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.48–7.41(m,4H),7.33(t,J=7.3Hz,1H),4.62(s,2H),4.55(m,3H),4.37(d,J=12.5Hz,1H),3.80(t,J=9.4Hz,1H),3.42–3.35(m,2H),3.16(d,J=12.0Hz,1H),2.86(t,J=12.8Hz,2H),2.58(dd,J=12.1,3.8Hz,1H),1.46(dd,J=6.7,0.9Hz,6H).
实施例34:化合物UB-034的合成
步骤1:UB-034c
叔丁基(R)-3-(((6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氧基)甲基)哌嗪-1-羧酸盐
在Ar下向反应瓶中加入UB-007f(300mg,0.8mmol)、UB-034b(520mg,2.4mmol)和无水二氧六环溶液(18mL),加入Pd2(dba)3(80mg,0.08mmol)、Cs2CO3(800mg,2.4mmol))和XPhos(200mg,0.4mmol)。将混合物在100℃下搅拌3小时。将反应浓缩并通过快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=0-40%洗脱,得到黄色油状化合物(UB-034c,200mg,产率44.8%)。LCMS[M+1]+=558.3
步骤2:UB-034
(R)-N-([1,1'-联苯]-4-基甲基)-9-异丙基-2-(哌嗪-2-基甲氧基)-9H-嘌呤-6-胺
在反应瓶中加入UB-034c(200mg,0.359mmol)、8mL DCM溶液和HCl的二氧六环溶液(2mL)。将混合物在室温下搅拌1小时。将反应混合物用NaHCO3(4mL)淬灭并用DCM(20mL*3)萃取,分离有机相,用盐水(20mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱纯化,用DCM/(DCM:MeOH=10:1)=0-100%洗脱,得到浅黄色固体状化合物(UB-034,80.5mg,产率49%)。LCMS[M+1]+=458.3。1H NMR(400MHz,DMSO-d6)δ8.39(s,1H),8.05(s,1H),7.61(dd,J=11.1,7.8Hz,4H),7.43(dd,J=11.9,5.2Hz,4H),7.35(d,J=7.3Hz,1H),4.80–4.50(m,3H),4.06(d,J=5.6Hz,2H),2.86(d,J=9.2Hz,2H),2.77(d,J=10.6Hz,1H),2.70(d,J=11.1Hz,1H),2.61–2.55(m,1H),2.32(d,J=10.7Hz,1H),1.49(d,J=6.7Hz,6H).
实施例35:化合物UB-035的合成
步骤1:UB-035c
叔丁基4-(9-异丙基-6-((2-丙氧基-[1,1'-联苯]-4-基)甲基)氨基)-9H-嘌呤-2-基)哌嗪-1-羧酸盐
在100ml圆底烧瓶中加入UB-007f(80mg,0.147mmol),UB-035b(54mg,0.439mmol),碳酸铯(142mg,0.436mmol),DMF(5mL),所得混合物常温下反应1小时,反应结束后加入20mL的水,用乙酸乙酯萃取三次,有机溶剂用无水硫酸钠干燥,旋干得到黄色固体化合物UB-035c(70mg,产率81%)。LCMS[M+H]+=586.2
步骤2:UB-035
9-异丙基-2-(哌嗪-1-基)-N-(2-丙氧基-[1,1'-联苯]-4-基)甲基)-9H-嘌呤-6-胺
在50mL圆底烧瓶中加入UB-035c(70mg,0.11mmol),二氯甲烷(3mL)和盐酸二氧六环(2mL,8mmol),所得混合物在室温反应2个小时,反应用饱和碳酸氢钠溶液淬灭至pH为中性,用二氯甲烷萃取,有机相减压浓缩,残留物经制备得到白色固体化合物UB-035(14mg,产率25%)。LCMS[M+1]+=428.3。1H NMR(400MHz,DMSO-d6)δ7.93(s,1H),7.80(s,1H),7.66–7.55(m,4H),7.51–7.40(m,4H),7.33(t,J=7.3Hz,1H),4.65(s,1H),4.56(dt,J=13.4,6.7Hz,1H),3.66(t,J=5.4Hz,1H),3.59(dd,J=11.5,5.7Hz,2H),3.53–3.44(m,2H),3.27–3.18(m,2H),2.06(td,J=13.1,6.8Hz,1H),1.90(s,2H),1.73(dd,J=12.4,6.4Hz,1H),1.47(d,J=6.8Hz,6H).
实施例36:化合物UB-036的合成
步骤1:UB-036c
(R)-(1-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)吡咯烷-3-基)氨基甲酸叔丁酯
将化合物UB-036b(198mg,1.06mmol),化合物UB-007f(80mg,0.21mmol)溶解于(2mL)NMP中,在微波180℃下反应3小时。反应液降温到室温,加水至溶液析出固体,过滤。将滤渣溶解并且通过硅胶柱纯化(DCM/MeOH=10%),得到化合物(UB-036c,25mg,57%产率)性状黄色油。LCMS[M+1]+=528.3.
步骤2:UB-036
(R)-N-([1,1'-联苯]-4-基甲基)-2-(3-氨基吡咯烷-1-基)-9-异丙基-9H-嘌呤-6-胺
将化合物UB-036c(25mg,0.05mmol)溶于二氯甲烷(2mL),加入盐酸-1,4-二氧六环(2mmol,0.5mL)。反应在40℃下搅拌4小时。反应完成后,向反应液中加入碳酸氢钠饱和溶液调节PH至8~9,并且用DCM萃取(40mL*3)。合并有机相并用饱和食盐水洗,用无水硫酸钠干燥。将萃取液浓缩并且冻干,得到想要的化合物UB-036(3.5mg,10%产率)性状白色固体。LCMS[M+1]+=428.2。1H NMR(400MHz,DMSO-d6)δ7.88(s,1H),7.79(d,J=5.9Hz,1H),7.64–7.56(m,4H),7.45(dd,J=14.6,7.5Hz,4H),7.33(t,J=7.3Hz,1H),4.78–4.50(m,3H),3.53(dddd,J=17.9,15.8,14.0,10.9Hz,4H),3.13(dd,J=10.8,5.0Hz,1H),1.99(dt,J=12.3,6.7Hz,1H),1.63(td,J=13.1,6.6Hz,1H),1.47(d,J=6.8
Hz,6H).
实施例37:化合物UB-037的合成
步骤1:UB-037c
(S)-3-((6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)吡咯烷-1-羧酸叔丁酯
向反应瓶中加入UB-007f(100mg,0.265mmol),UB-037b(160mg,0.8mmol),Pd2(dba)3(146.6mg,0.16mmol),Cs2CO3(172.7mg,0.53mmol),X-phos(380.8mg,0.8mmol)和1,4-dioxane(10mL).将反应混合物置换氩气三次,然后升温至100℃搅拌过夜。将反应混合物用水(30mL)稀释,然后用乙酸乙酯(30mL*3)萃取,分离有机相,用盐水(50mL)洗涤并用无水硫酸钠干燥,然后浓缩并通过色谱法(二氯甲烷:二氯甲烷/甲醇10/1=75:25)纯化得到产物得到黄色固体化合物(UB-037c,120mg,产率35.58%).LCMS[M+1]+=528.2
步骤2:UB-037
N6-([1,1'-联苯]-4-基甲基)-9-异丙基-N2-(吡咯烷-3-基)-9H-嘌呤-2,6-二胺
在室温下向100mL底部烧瓶中加入UB-037c(121.2mg,0.23mmol)、盐酸的1,4-二氧六环溶液(4mL)和二氯甲烷(8.0mL)。然后将溶液在室温搅拌2小时。过滤反应混合物,滤饼用二氯甲烷(5mL)洗涤,用碳酸氢钠饱和水溶液中和,并用二氯甲烷(3*50mL)萃取。将合并的有机相用盐水洗涤,用无水硫酸钠干燥并减压浓缩,然后加入甲醇和水,并冷冻干燥,得到黄色固体产物(UB-037,54.7mg,产率:56.3%)。LCMS[M+1]+=428.2.1H NMR(400MHz,DMSO-d6)δ7.79(s,1H),7.60(dd,J=15.0,7.9Hz,4H),7.44(t,J=7.6Hz,4H),7.33(t,J=7.3Hz,1H),6.28(d,J=6.6Hz,1H),4.67(s,1H),4.53(dt,J=13.6,6.7Hz,1H),4.20(d,J=6.2Hz,1H),2.90(dd,J=11.4,6.6Hz,1H),2.87–2.81(m,1H),2.73–2.64(m,1H),2.57(dd,J=11.0,4.2Hz,1H),1.91(dd,J=12.8,6.3Hz,1H),1.63–1.50(m,1H),1.47(d,J=6.7Hz,6H).
实施例38:化合物UB-038的合成
步骤1:UB-038c
(R)-叔丁基-3-(6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)吡咯烷
-1-羧酸盐
在100mL的圆底烧瓶中依次加入化合物UB-038a(400mg,1.06mmol),UB-038b(1.18g,6.36mmol),Pd2(dba)3(97mg,0.106mmol),XPhos(252mg,0.53mmol),Cs2CO3(1.03g,3.18mmol),1,4-二氧六环(10mL),所得混合物用氩气置换三次后加热至100℃反应24h,反应结束后,减压浓缩,残留物经柱层析(洗脱剂:DCM:PE:EA=100/0~80/20)分离得到淡黄色固体化合物UB-038c(200mg,产率36%)。LCMS[M+H]+=528.3.
步骤2:UB-038
(R)-N6-([1,1'-联苯]-4-基甲基)-9-异丙基-N2-(吡咯烷-3-基)-9H-嘌呤-2,6-二胺
在50mL圆底烧瓶中加入UB-038c(80mg,0.15mmol),二氯甲烷(3mL)和三氟乙酸(128mg,1.13mmol),所得混合物在室温反应2个小时,反应用饱和碳酸氢钠溶液淬灭至pH为中性,用二氯甲烷萃取,有机相减压浓缩,残留物经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~90/10)分离得到白色固体化合物UB-038(42mg,产率87%)。LCMS[M+1]+=428.3。1H NMR(400MHz,DMSO-d6)δ8.71(s,1H),8.07(s,1H),7.91(s,1H),7.69–7.55(m,2H),7.48–7.39(m,2H),7.34(t,J=7.3Hz,1H),6.73(s,1H),4.67(s,1H),4.56(dt,J=13.5,6.8Hz,1H),4.39(d,J=4.8Hz,1H),3.40–3.27(m,2H),3.28–3.16(m,1H),3.12(s,1H),2.12(dd,J=13.4,7.0Hz,1H),1.97(d,J=5.7Hz,1H),1.48(d,J=6.8Hz,6H).
实施例39:化合物UB-039的合成
步骤1:UB-039c
叔丁基((1R,3S)-3-((6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)环戊基)氨基甲酸酯
向反应瓶中加入UB-007f(100mg,0.265mmol),UB-039b(160mg,0.8mmol),Pd2(dba)3(146.6mg,0.16mmol),Cs2CO3(172.7mg,0.53mmol),X-phos(380.8mg,0.8mmol)和1,4-dioxane(10mL).将反应混合物置换氩气三次,然后升温至100℃搅拌过夜。反应完成将反应液旋干拌样,通过硅胶柱纯化DCM/MeOH=0-25%(10%MeOH)得到黄色固体化合物UB-039c(40mg,产率28%).LCMS[M+1]+=542.3.
步骤2:UB-039
N6-([1,1'-联苯]-4-基甲基)-N2-((1S,3R)-3-氨基环戊基)-9-异丙基-9H-嘌呤-2,6-二胺
将UB-039c(50mg,0.09mmol)溶于3mL THF中,再加入HCl/二氧六环(1mL)。反应液再室温下搅拌过夜。反应液通过过硅胶色谱法纯化得到白色固体化合物UB-039(3.3mg,产率8%)。LCMS[M+1]+=442.3.1H NMR(400MHz,DMSO-d6)1H NMR(400MHz,)δ7.88(s,1H),7.82(s,1H),7.61(dd,J=13.6,7.8Hz,4H),7.44(dd,J=11.9,5.3Hz,
4H),7.34(t,J=7.3Hz,1H),6.44(d,J=7.1Hz,1H),4.66(s,2H),4.53(dt,J=13.4,6.8Hz,1H),4.18(d,J=7.0Hz,1H),2.43–2.30(m,1H),2.00(dd,J=14.8,7.0Hz,1H),1.89(s,2H),1.65(d,J=4.8Hz,2H),1.47(d,J=6.7Hz,6H),1.36–1.28(m,2H),1.25(s,2H),1.22–1.22(m,1H).
实施例40:化合物UB-040的合成
步骤1:UB-040c
叔丁基((1S,3S)-3-((6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)环戊基)氨基甲酸酯
向反应瓶中加入UB-007f(50mg,0.13mmol),UB-040b(96.1mg,0.48mmol),Pd2(dba)3(18.3mg,0.02mmol),Xphos(38.2mg,0.08mmol)and Cs2CO3(156.4mg,0.48mmol),和1,4-dioxane(10mL).将反应混合物置换氩气三次,然后升温至100℃搅拌过夜。然后将反应混合物在100℃搅拌24小时。将反应混合物用水(30mL)稀释,然后用乙酸乙酯(30mL*3)萃取,分离有机相,用盐水(50mL)洗涤并用无水硫酸钠干燥,然后浓缩并通过色谱法(二氯甲烷:二氯甲烷/甲醇10/1=75:25)纯化得到产物得到黄色固体化合物(UB-040c,38mg,收率:21.9%).LCMS[M+1]+=542.3.
步骤2:UB-040
N6-([1,1'-联苯]-4-基甲基)-N2-((1S,3S)-3-氨基环戊基)-9-异丙基-9H-嘌呤-2,6-二胺
在室温下向100mL底部烧瓶中加入UB-040c(37.9mg,0.07mmol)、盐酸的1,4-二氧六环溶液(2mL)和二氯甲烷(4.0mL)。然后将溶液在室温搅拌2小时。过滤反应混合物,滤饼用二氯甲烷(5mL)洗涤,用碳酸氢钠饱和水溶液中和,并用二氯甲烷(3*50mL)萃取。将合并的有机相用盐水洗涤,用无水硫酸钠干燥并减压浓缩,然后加入甲醇和水,并冷冻干燥,得到黄色固体产物(UB-040,13.9mg,产率:44.8%)。LCMS[M+1]+=428.2.1H NMR(400MHz,DMSO-d6)δ7.78(s,1H),7.64–7.61(m,2H),7.58(d,J=8.2Hz,2H),7.47–7.40(m,5H),7.33(t,J=7.3Hz,1H),6.19(d,J=7.0Hz,1H),4.67(s,2H),4.53(dt,J=13.3,6.6Hz,1H),4.31(dd,J=14.1,7.1Hz,1H),2.07–2.00(m,1H),1.90–1.82(m,1H),1.68(dd,J=13.1,6.6Hz,1H),1.64–1.56(m,1H),1.47(d,J=6.7Hz,6H),1.43–1.34(m,2H),1.25–1.14(m,2H).
实施例41:化合物UB-041的合成
步骤1:UB-041c
叔丁基2-((1s,3s)-3-((6-(([1,1'-联苯基]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)
将化合物UB-041b(158mg,0.85mmol),化合物UB-007f(80mg,0.21mmol),碳酸铯(207mg,0.64mmol),Pd2(dba)3(25mg,0.02mmol)和Xphos(51mg,0.11mmol)溶解于(5mL)超干-二氧六环中,在100℃下反应过夜。反应完成后,反应液降温到室温,将反应液浓缩并且通过硅胶柱纯化(EA/PE=50%),得到化合物(UB-041c,30mg,5%产率)性状黄色固体。LCMS[M+1]+=528.3.
步骤2:UB-041
(1s,3s)-3-((6-(([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)环丁-1-氯化铵.
将化合物UB-041c(30mg,0.06mmol)溶于二氯甲烷(2mL),加入盐酸-1,4-二氧六环(2mmol,0.5mL)。反应在40℃下搅拌4小时。反应完成后,向反应液中加入碳酸氢钠饱和溶液调节PH至8~9,并且用DCM萃取(40mL*3)。合并有机相并用饱和食盐水洗,用无水硫酸钠干燥。将萃取液浓缩并且冻干,得到想要的化合物UB-041(14.9mg,55%产率)性状白色固体。LCMS[M+1]+=428.3。1H NMR(400MHz,DMSO-d6)δ9.60(d,J=117.0Hz,1H),8.73(s,1H),8.31(s,3H),7.64(d,J=7.7Hz,4H),7.55–7.44(m,4H),7.36(t,J=7.3Hz,1H),5.30(d,J=16.8Hz,1H),4.86–4.62(m,3H),4.13(s,1H),2.67(s,2H),2.13(d,J=7.7Hz,2H),1.53(d,J=6.3Hz,6H),1.23(s,1H).
实施例42:化合物UB-042的合成
步骤1:UB-042c
2-羟基-[1,1'-联苯]-4-腈
在100mL的圆底烧瓶中依次加入化合物UB-042a(1.55g,7.57mmol),UB-042b(1.85g,15.14mmol),Pd(dppf)Cl2(550mg,0.757mmol),K2CO3(3.13g,22.71mmol),1,4-二氧六环(45mL)和水(10mL),所得混合物用氩气置换三次后加热至100℃反应过夜,反应结束后,减压浓缩,残留物经柱层析(洗脱剂:DCM:PE:EA=100/0~30/70)分离得到淡黄色固体化合物UB-042c(1.1g,产率78%)。LCMS[M+H]+=196.1.
步骤2:UB-042d
4-(氨甲基)-[1,1'-联苯]-2-醇
在100mL圆底烧瓶中加入UB-042c(1.1g,5.64mmol),雷尼镍(110mg),胺甲醇(10mL),所得混合物用氢气置换三次常温下反应1小时,反应结束后用硅藻土过滤,滤液减压浓缩,残留物经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~50/50)分离得到白色固体化合物UB-042d(840mg,产率63%)。LCMS[M+H]+=200.1.
步骤3:UB-042f
4-((2-氯-9-异丙基-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-醇
在100mL圆底烧瓶中加入UB-042d(840mg,4.22mmol),UB-042e(1.02g,4.43mmol),三乙胺(1.28g,12.66mmol),异丙醇(15mL),所得混合物用在110℃下反应3小时,反应结束后冷却到室温,固体析出过滤,滤饼用乙醇和水10:1洗涤,得到白色固体化合物UB-042f(1.3g,产率78%)。LCMS[M+H]+=394.1.
步骤4:UB-042h
叔丁基4-(6-((2-羟基-[1,1'-联苯]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
在20mL的微波管中加入UB-042f(1.0g,2.54mmol),UB-042g(2.36g,12.72mmol),DIPEA(2.62g,20.35mmol),NMP(8mL),所得混合物微波在180℃下反应3小时,反应结束后加入30mL的水,固体析出过滤,滤饼经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~30/70)分离,得到白色固体化合物UB-042h(900mg,产率65%)。LCMS
[M+H]+=544.3
步骤5:UB-042
4-(9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-醇
在50mL圆底烧瓶中加入UB-042h(60mg,0.11mmol),二氯甲烷(3mL)和盐酸二氧六环(2mL,8mmol),所得混合物在室温反应4个小时,反应用饱和碳酸氢钠溶液淬灭至pH为中性,用二氯甲烷萃取,有机相减压浓缩,残留物经制备得到白色固体化合物UB-042(14mg,产率29%)。LCMS[M+1]+=444.1。1H NMR(400MHz,DMSO-d6)δ9.42(s,1H),8.85(s,2H),8.16(d,J=14.5Hz,1H),7.93(s,1H),7.56–7.44(m,2H),7.36(t,J=7.6Hz,2H),7.26(t,J=7.3Hz,1H),7.16(d,J=7.8Hz,1H),6.94(s,1H),6.87(d,J=7.9Hz,1H),4.73–4.32(m,3H),3.87(d,J=4.8Hz,4H),3.08(s,4H),1.48(d,J=6.8Hz,6H).
实施例43:化合物UB-043的合成
步骤1:UB-043c
叔丁基4-(6-(((2-(2-羟基乙氧基)-[1,1'-联苯基]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
向微波管中加入化合物UB-043a(100mg,0.18mmol),化合物UB-043b(112.6mg,0.90mmol),K2CO3(124.2mg,0.90mmol)和5mL N-甲基吡咯烷酮,反应液在微波管中加热至150℃反应4小时。将反应液倒入水中,过滤得滤饼,滤液用乙酸乙酯萃取2次,合并有机相和滤饼,除去溶剂后,浓缩物通过快速色谱法纯化((甲醇:二氯甲烷(1:10)/二氯甲烷=0-70%)得到白色固体化合物UB-043c(73.0mg,产率66.7%)。LCMS[M+1]+=588.3.
步骤2:UB-043
2-((4-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-基)氧基)乙醇
将化合物UB-043c(73.0mg,0.12mmol)溶于4mL的二氯甲烷中,加入盐酸二氧六环溶液(1mL),室温搅拌3小时。反应液用碳酸氢钠溶液中和,用二氯甲烷萃取,收集有机相,干燥,除去溶剂后,浓缩物通过快速色谱法纯化((甲醇:二氯甲烷(1:10)/二氯甲烷=0-100%)得到白色固体化合物UB-043(29.7mg,产率49.0%)。LCMS[M+1]+=488.3。1H NMR(400MHz,DMSO-d6)δ7.97(s,1H),7.85(s,1H),7.56–7.48(m,2H),7.36(t,J=7.5Hz,2H),7.31–7.24(m,1H),7.24–7.15(m,2H),7.02(d,J=7.7Hz,1H),4.76(s,1H),4.57(dt,J=13.5,6.7Hz,3H),3.98(t,J=5.2Hz,2H),3.62(dd,J=12.8,8.1Hz,6H),2.71(dd,J=8.3,3.4Hz,4H),1.46(d,J=6.8Hz,6H).
实施例44:化合物UB-044的合成
步骤1:UB-044c
(S)-叔丁基(1-(6-([1,1'-联苯]-4-基甲基)氨基)-9-异丙基-9H-嘌呤-2-基)吡咯烷-3-基)氨基甲酸酯
在10mL的微波管中加入UB-044a(80mg,0.212mmol),UB-044b(197mg,1.06mmol),DIPEA(218mg,1.69mmol),NMP(3mL),所得混合物微波在180℃下反应3小时,反应结束后加入30mL的水,固体析出过滤,滤饼经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~30/70)分离,得到白色固体化合物UB-044c(60mg,产率54%)。LCMS[M+H]+=528.3
步骤2:UB-044
(S)-N-([1,1'-联苯]-4-基甲基)-2-(3-氨基吡咯烷-1-基)-9-异丙基-9H-嘌呤-6-胺
在50mL圆底烧瓶中加入UB-044c(60mg,0.11mmol),二氯甲烷(3mL)和盐酸二氧六环(2mL,8mmol),所得混合物在室温反应4个小时,反应用饱和碳酸氢钠溶液淬灭至pH为中性,用二氯甲烷萃取,有机相减压浓缩,残留物经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~90/10)分离得到白色固体化合物UB-044(14mg,产率29%)。LCMS[M+1]+=486.2。1H NMR(400MHz,DMSO-d6)δ8.24(s,1H),8.04(s,1H),7.87(s,1H),7.46(d,J=7.2Hz,2H),7.37(t,J=7.6Hz,2H),7.28(t,J=7.3Hz,1H),7.20(d,J=7.7Hz,1H),7.15(s,1H),7.01(d,J=7.0Hz,1H),4.57(dd,J=13.5,6.8Hz,3H),3.89(t,J=6.4Hz,2H),3.70(s,5H),2.83(s,4H),1.64(dd,J=13.9,6.7Hz,2H),1.47(d,J=6.8Hz,6H),0.89(t,J=7.4Hz,3H).
实施例45:化合物UB-045的合成
步骤1:UB-045c
叔丁基4-(6-(((2-(4-((叔丁基二甲基甲硅烷基)氧基)丁氧基)-[1,1'-联苯]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
向100mL的反应瓶中加入化合物UB-045a(80mg,0.147mmol),碳酸铯(96mg,0.294mmol)和5mL N,N-二甲基甲酰胺,反应液搅拌至微黄色,然后加入化合物UB-045b(80mg,0.294mmol),反应液加热至80℃反应18小时。冷却至室温,除去溶剂后,浓缩物通过快速色谱法纯化(乙酸乙酯/石油醚=0-50%)得到白色固体化合物1225c(110.0mg,
产率97%)。LCMS[M+1]+=616.4.
步骤2:UB-045
4-((4-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-基)氧基)丁-1-醇
将化合物UB-045c(110.0mg,0.179mmol)溶于4mL的二氯甲烷中,加入盐酸二氧六环溶液(1mL),室温搅拌3小时。反应液用碳酸氢钠溶液中和,用二氯甲烷萃取,收集有机相,干燥,除去溶剂后,浓缩物通过快速色谱法纯化((甲醇:二氯甲烷(1:10)/二氯甲烷=0-100%)得到白色固体化合物UB-045(41.7mg,产率48.1%)。LCMS[M+1]+=516.3。1H NMR(400MHz,DMSO-d6)δ8.14(s,1H),7.91(s,1H),7.48–7.42(m,2H),7.36(dd,J=15.2,7.4Hz,2H),7.28(t,J=7.3Hz,1H),7.19(dd,J=14.0,7.2Hz,2H),7.01(d,J=7.0Hz,1H),4.58(dd,J=13.5,6.7Hz,3H),3.94(t,J=6.5Hz,2H),3.82(d,J=3.8Hz,4H),3.39(d,J=6.4Hz,2H),3.00(s,4H),1.66(dd,J=14.6,6.7Hz,2H),1.48(t,J=6.8Hz,8H).
实施例46:化合物UB-046的合成
步骤1:UB-046c
2'-羟基-[1,1'-联苯]-4-腈
向UB-046a(3.0g,16.5mmol)和UB-046b(3.4g,24.7mmol)在1,4-二氧六环(60mL)和H2O(20mL)中的溶液中加入(dppf)PdCl2(600mg,0.82mmol)、K2CO3(6.8g,49.4mmol)在N2下。将混合物回流搅拌4小时,混合物逐渐变浑浊。将反应混合物浓缩并通过硅胶柱色谱法纯化残余物[洗脱液:PE/EA=0-40%],得到黄色固体状的化合物(UB-046c,3.26g,产率100%)。LCMS[M+1]+=177.1
步骤2:UB-046d
4'-(氨基甲基)-[1,1'-联苯]-2-醇
在H2下加入UB-046c(2.8g,14.36mmol)、Raney Ni(280mg)、NH3的甲醇溶液(15mL)。将混合物在室温搅拌过夜。将混合物通过硅藻土过滤,将滤液浓缩并通过硅胶柱色谱法纯化[洗脱液:DCM/10%MeOH/DCM=0-50%],得到白色固体状的化合物(UB-046d,1.4g,产率49%)。LCMS[M+1]+=200.1
步骤3:UB-046f
4'-(((2-氯-9-异丙基-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-醇
向反应瓶中加入UB-046d(1090mg,5.48mmol)、UB-046e(1290mg,5.58mmol)、Et3N(1660mg,16.44mmol)和异丙醇(20mL)。将混合物在80℃下搅拌4小时。将混合物浓缩并通过硅胶柱色谱法纯化[洗脱液:DCM/10%MeOH/DCM=0-50%],得到黄色固体状的化合物(1218f,1.8g,产率83.4%)。LCMS[M+1]+=394.2
步骤4:UB-046h
4-(6-(((2'-羟基-[1,1'-联苯]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸叔丁酯
在微波管中加入UB-046f(1500mg,3.807mmol)、UB-046g(3.54g,19.03mmol)、DIPEA(3.93g,30.4mmol)和NMP(6mL)。将混合物在微波条件下180℃搅拌3小时。将反应混合物倒入H2O中。过滤收集所得沉淀,滤液用EA萃取3次,合并有机相,将滤液浓缩并通过硅胶柱色谱纯化[洗脱液:DCM/10%MeOH/DCM=0-20%],得到白色固体状的化合物(UB-046h,1.11g,产率53.2%)。LCMS[M+1]+=544.3
步骤5:UB-046
4'-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-醇
向UB-046h(50mg,0.09mmol)的3mL DCM溶液中加入HCl在二恶烷(1mL)中的溶液。将混合物在室温搅拌2小时。将反应混合物用NaHCO3淬灭并用DCM(10mL*3)萃取,分离有机相,用盐水(10mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱纯化[洗脱液:DCM/10%MeOH/DCM=0-100%]得到白色固体状的化合物(UB-046,13.5mg,产率33.9%)。LCMS[M+1]+=444.3。1H NMR(400MHz,DMSO-d6)δ9.44(s,1H),7.96(s,1H),7.84(s,1H),7.44(d,J=8.2Hz,2H),7.37(d,J=8.1Hz,2H),7.20(dd,J=7.6,1.6Hz,1H),7.15–7.09(m,1H),6.91(d,J=8.0Hz,1H),6.84(t,J=7.4Hz,1H),4.69–4.47(m,3H),3.61(d,J=5.0Hz,4H),2.71(d,J=4.5Hz,4H),1.46(d,J=6.7Hz,6H).
实施例47:化合物UB-047的合成
步骤1:UB-047c
叔丁基4-(6-(((2'-(2-羟基乙氧基)-[1,1'-联苯基]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
在微波管中加入UB-047a(80mg,0.147mmol)、UB-047b(92mg,0.737mmol)、K2CO3(102mg,0.737mmol)在NMP(3mL)中的溶液。将混合物在微波条件下150℃搅拌4
小时。将反应混合物倒入H2O中。过滤收集所得沉淀,滤液用EA萃取3次,合并有机相,将滤液浓缩并通过硅胶柱色谱纯化[洗脱液:DCM:10%MeOH/DCM=0-70%],得到白色固体状的化合物(UB-047c,60mg,产率69.5%)。LCMS[M+1]+=588.3
步骤2:UB-047
2-((4'-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-基)氧)乙烷-1-醇
在反应瓶中加入UB-047c(60mg,0.102mmol)和3mL DCM溶液,加入HCl的二氧六环溶液(2mL)。将混合物在室温搅2小时。将反应混合物用NaHCO3淬灭并用DCM(10mL*3)萃取,分离有机相,用盐水(10mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱纯化,用DCM:10%MeOH/DCM=0-100%]得到浅黄色固体状的化合物(UB-047,39mg,产率78.5%)。LCMS[M+1]+=488.1。1H NMR(400MHz,DMSO-d6)δ8.04(d,J=19.2Hz,1H),7.86(s,1H),7.48(d,J=8.2Hz,2H),7.37(d,J=8.2Hz,2H),7.29(dd,J=13.3,4.8Hz,2H),7.09(d,J=8.0Hz,1H),6.99(t,J=7.0Hz,1H),4.58(td,J=13.8,7.1Hz,3H),4.01(t,J=5.1Hz,2H),3.68–3.62(m,6H),2.81–2.72(m,4H),1.47(d,J=6.8Hz,6H).
实施例48:化合物UB-048的合成
步骤1:UB-048h
将化合物UB-048f(80mg,0.15mmol)和Cs2CO3(384mg,1.18mmol)在DMF(3mL)中的混合物在室温下搅拌5分钟,然后将化合物UB-048g(264mg,1.18mmol)加入混合物中并在60℃下搅拌2.5小时。将混何物冷却至室温,减压浓缩后通过硅胶色谱柱纯化[二氯甲烷(二氯甲烷:甲醇=10:1)=0-21%],得到产物UB-048h(64mg,产率:63%),为白色固体。LCMS[M+1]+=687.2。
步骤2:UB-048
向化合物UB-048h(64mg,0.09mmol)在CH2Cl2(3mL)中的混合物加入HCl/二氧六环(4N,1.5mL)。将反应混合物在25℃下搅拌17小时。将反应混合物浓缩,用饱和Na2CO3水溶液调节至pH=8-9。用CH2Cl2(20mL*3)萃取后,将合并的有机层用盐水洗涤,用无水Na2SO4干燥,然后将混合物减压浓缩,得到产物UB-048(29.3mg,产率:65%),为白色固体。LCMS[M+1]+=487.3。1H NMR(400MHz,DMSO-d6)δ7.97(s,1H),7.86–7.81(s,1H),7.44(d,J=8.2Hz,2H),7.38(d,J=8.2Hz,2H),7.27(dt,J=7.7,4.5Hz,2H),7.08(d,J=7.9Hz,1H),7.00(t,J=7.1Hz,1H),4.57(td,J=13.6,6.8Hz,3H),3.93(t,J=5.6Hz,2H),3.70(d,J=24.2Hz,1H),3.65–3.55(m,4H),2.81(t,J=5.6Hz,2H),2.70(s,4H),1.46(d,J=6.8Hz,6H).
实施例49:化合物UB-049的合成
步骤1:UB-049h
将化合物UB-049f(100mg,0.18mmol)和Cs2CO3(180mg,0.55mmol)在DMF(3mL)中的混合物在室温下搅拌5分钟,然后将化合物UB-049g(86mg,0.70mmol)加入混合物中并在室温下搅拌1小时。将H2O(20mL)添加到反应混合物中,然后将水层用二氯甲烷(30mL×4)萃取。合并有机层,用无水Na2SO4干燥,然后将混合物减压浓缩,得到粗产物UB-049h(89mg,产率:83%),为淡黄色液体,其不经纯化直接用于下一步反应。LCMS[M+1]+=586.4
步骤2:UB-049
向化合物UB-049h(89mg,0.15mmol)在CH2Cl2(3mL)中的混合物加入HCl/二氧六环(4N,1.5mL)。将反应混合物在25℃下搅拌17小时。将反应混合物浓缩,用饱和Na2CO3水溶液调节至pH=8-9。用CH2Cl2(20mL*3)萃取后,将合并的有机层用盐水洗涤,用无水Na2SO4干燥,然后将混合物减压浓缩,得到产物UB-049(54mg,产率:70%),为白色固体。LCMS[M+1]+=486.3。1H NMR(400MHz,DMSO-d6)δ7.97(s,1H),7.84(s,2H),7.42(d,J=8.2Hz,3H),7.37(d,J=8.2Hz,3H),7.32–7.23(m,3H),7.06(d,J=8.1Hz,1H),6.98(t,J=7.3Hz,2H),4.68–4.50(m,4H),3.92(t,J=6.3Hz,3H),3.65–3.54(m,6H),2.70(s,6H),1.65(dd,J=13.8,6.6Hz,3H),1.46(d,J=6.8Hz,9H),0.91(t,J=7.4Hz,5H).
实施例50:化合物UB-050的合成
步骤1:UB-050b
(4-溴丁氧基)(叔丁基)二甲基硅烷
在冰浴下向反应瓶中加入UB-050a(500mg,3.268mmol)和DCM(10mL)溶液,加入咪唑(666mg,9.8mmol),搅拌10分钟。缓慢加入TBSCl(738mg,4.9mmol)并搅拌3小时。浓缩DCM,用30mL EA稀释,用10%NaHCO3溶液和盐水(30x2mL)洗涤。有机溶剂经Na2SO4干燥并真空蒸发,得到无色油状化合物(UB-050b,620mg,产率71%),直接用于下一步反应。
步骤2:UB-050e
叔丁基4-(6-(((2'-(4-((叔丁基二甲基甲硅烷基)氧基)丁氧基)-[1,1'-联苯]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
向反应瓶中加入UB-050c(80mg,0.147mmol)和Cs2CO3(96mg,0.294mmol)及DMF溶液(5mL)。真空换氮三次。在室温下搅拌,反应液变成黄色。然后加入UB-050d(80mg,0.294mmol)并将反应液在80℃下加热18小时。然后将反应液冷却至室温,过滤。浓缩溶剂,得到的残余物通过硅胶柱色谱法纯化[洗脱液:PE/EA=0-50%],得到浅黄色固体化合物(UB-050e,110mg,产率97%)。LCMS[M+1]+=616.4
步骤3:UB-050
4-((4'-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-基)氧)丁烷-1-醇
向反应瓶中加入UB-050e(100mg,0.162mmol)和8mL DCM溶液,加入HCl的二氧六环溶液(3mL)。将混合物在室温搅拌过夜。将反应混合物用NaHCO3(5mL)淬灭并用DCM(10mL*3)萃取,分离有机相,用盐水(10mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱法纯化,用DCM:10%MeOH/DCM=0-100%,得到白色固体化合物(UB-050,14mg,产率16.7%)。LCMS[M+1]+=516.3。1H NMR(400MHz,DMSO-d6)δ7.97(s,1H),7.84(s,1H),7.42(d,J=8.3Hz,2H),7.37(d,J=8.3Hz,2H),7.31–7.22(m,2H),7.07(d,J=7.8Hz,1H),7.02–6.95(m,1H),4.73–4.50(m,3H),3.97(t,J=6.6Hz,2H),3.65–3.57(m,4H),3.40(t,J=6.4Hz,2H),2.77–2.66(m,4H),1.68(s,2H),1.48(dd,J=14.1,7.5Hz,8H).
实施例51:化合物UB-051的合成
步骤1:UB-051c
叔丁基4-(6-(((2'-(3-氰基丙氧基)-[1,1'-联苯]-4-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)哌嗪-1-羧酸盐
在N2下,向反应瓶中加入UB-051a(100mg,0.185mmol)、Cs2CO3(120mg,0.925mmol)和DMF溶液(5mL)。在室温下搅拌,反应液变成黄色。然后加入UB-051b(55mg,0.925mmol)并将反应液在80℃加热3小时。然后将反应液冷却至室温,然后过滤。蒸发掉溶剂,得到的残余物通过硅胶柱色谱法纯化[洗脱液:PE/EA=0-80%],得到无色油状物化合物(UB-051c,100mg,产率88.6%)。LCMS[M+1]+=611.3
步骤2:UB-051
4-((4'-(((9-异丙基-2-(哌嗪-1-基)-9H-嘌呤-6-基)氨基)甲基)-[1,1'-联苯]-2-基)氧)丁腈
向反应瓶中加入UB-051c(100mg,0.16mmol)、6mL DCM溶液和三氟乙酸(2mL)。将混合物在室温下搅拌1小时。将反应混合物用NaHCO3(4mL)淬灭并用DCM(20mL*3)
萃取,分离有机相,用盐水(20mL*3)洗涤并用Na2SO4干燥,然后浓缩并通过快速色谱法纯化,用DCM/(DCM:MeOH=10:1)=0-100%洗脱,得到白色固体状化合物(UB-051,11.4mg,产率14%)。LCMS[M+1]+=511.2。1H NMR(400MHz,DMSO-d6)δ7.99(s,1H),7.85(s,1H),7.44–7.37(m,4H),7.34–7.24(m,2H),7.10(d,J=8.2Hz,1H),7.02(t,J=7.5Hz,1H),4.78–4.43(m,3H),4.03(t,J=6.0Hz,2H),3.62(s,4H),2.73(s,4H),2.53(d,J=5.2Hz,2H),1.95(p,J=6.6Hz,2H),1.47(d,J=6.8Hz,6H).
实施例52:化合物UB-052的合成
步骤1:UB-052c
N-([1,1'-联苯]-4-基甲基)-2-氯-9-环丁基-9H-嘌呤-6-胺
在100mL的圆底烧瓶中依次加入化合物UB-052a(100mg,0.298mmol),UB-052b(60mg,0.446mmol),(dppf)PdCl2(22mg,0.029mmol),Cs2CO3(386mg,1.19mmol),DMF(5mL),所得混合物用氩气置换三次后加热至100℃反应5h,反应结束后,减压浓缩,残留物经柱层析(洗脱剂:DCM:PE:EA=100/0~80/20)分离得到淡黄色固体化合物UB-052c(80mg,产率46%)。LCMS[M+1]+=390.1.
步骤2:UB-052
N-([1,1'-联苯]-4-基甲基)-9-环丁基-2-(哌嗪-1-基)-9H-嘌呤-6-胺
在10mL的微波管中加入UB-052c(60mg,0.15mmol),UB-052d(66mg,0.77mmol),DIPEA(158mg,1.23mmol),NMP(3mL),所得混合物微波在180℃下反应3小时,反应结束后加入30mL的水,固体析出过滤,滤饼经柱层析(洗脱剂:DCM/(10%MeOH in DCM)=100/0~30/70)分离得到白色固体化合物UB-052(30mg,产率45%)。LCMS[M+H]+=440.2.1H NMR(400MHz,DMSO-d6)δ8.01(s,1H),7.94(s,1H),7.66–7.60(m,2H),7.58(d,J=8.2Hz,2H),7.49–7.39(m,4H),7.33(t,J=7.3Hz,1H),4.92–4.75(m,1H),4.63(s,2H),3.72–3.49(m,5H),2.71(dd,J=14.2,9.6Hz,4H),2.59(ddd,J=19.3,9.7,2.5Hz,2H),2.42–2.27(m,2H),1.92–1.73(m,2H).
实施例53:化合物UB-053的合成
步骤1:UB-053c
2,6-二氯-9-苯基-9H-嘌呤叔丁基
向UB-053a(519.40mg,2.65mmol)的二氯甲烷(20mL)溶液中加入UB-053b(645.01mg,5.29mmol)、Cu(OAc)2(960.82mg,5.29mmol)、TEA(804.46mg,7.95mmol),将混
合物在室温搅拌1小时。将反应混合物浓缩并通过色谱法(二氯甲烷)纯化,得到白色固体(UB-053c,63.1mg,产率:7.5%)LCMS[M+1]+=265.0;267.0.
步骤2:UB-053e
N-([1,1'-联苯]-4-基甲基)-2-氯-9-苯基-9氢-嘌呤-6-胺
向UB-053c(43.55mg,0.24mmol)的叔丁醇(4mL)溶液中加入UB-053d(63.07mg,0.24mmol),TEA(96.33mg,0.95mmol),混合物在110℃下搅拌过夜。反应结束后过滤,并用乙醇:水(10:1)(20mL)洗涤滤饼,并将滤饼抽干得到白色固体(UB-053e,67.6mg,产率:69%).LCMS[M+1]+=412.1.
步骤3:UB-053
N-([1,1'-联苯]-4-基甲基)-9-苯基-2-(哌嗪-1-基)-9H-嘌呤-6-胺
向微波管中加入UB-053e(41.2mg,0.10mmol),UB-053f(41.3mg,0.48mmol),DIPEA(98.2mg,0.76mmol)和NMP(3mL)并在180℃下微波反应3h.将反应混合物用水(200mL)稀释并用二氯甲烷(3×70mL)萃取。合并的有机相用盐水洗涤,用无水硫酸钠干燥并减压浓缩。粗产物经硅胶色谱纯化(二氯甲烷:二氯甲烷/甲醇:10/1=10:90)得到白色固体(UB-053,34.0mg,产率:51.15%).LCMS[M+1]+=462.2.1H NMR(400MHz,DMSO-d6)δ9.07(s,2H),8.50(s,1H),8.43(s,1H),7.88(d,J=7.8Hz,2H),7.65–7.60(m,4H),7.57(t,J=7.9Hz,2H),7.50–7.39(m,5H),7.35(t,J=7.3Hz,1H),4.69(s,2H),3.89(d,J=4.7Hz,4H),3.08(s,4H).
实施例54:化合物UB-054的合成
步骤1:UB-054c
2,6-二氯-9-(3-氟苯基)-9H-嘌呤
将化合物UB-054b(740mg,5.29mmol),化合物UB-054a(500mg,2.64mmol),溶解于(10mL)二氯甲烷中,再加入醋酸铜(961mg,5.29mmol)和三乙胺(804mg,7.96mmol)。在室温下反应3小时。反应完成后,将反应液浓缩并且通过硅胶柱纯化(二氯甲烷),得到化合物(UB-054c,200mg,26%产率)性状黄色固体。LCMS[M+1]+=283.0&284.9.
步骤2:UB-054e
N-([1,1'-联苯]-4-基甲基)-2-氯-9-(3-氟苯基)-9H-嘌呤-6-胺
将化合物UB-054c(200mg,0.71mmol),UB-054d(120mg,0.68mmol)和三乙胺(206mg,2.04mmol)溶于异丙醇(3mL)。反应在80℃下搅拌2小时。反应完成后,将反应液冷却至室温。将反应液过滤得到想要的化合物UB-054e(75mg,53%产率)性状白色固体。LCMS[M+1]+=430.1。
步骤3:UB-054
N-([1,1'-联苯基]-4-基甲基)-9-(3-氟苯基)-2-(哌嗪-1-基)-9H-嘌呤-6-胺
将化合物UB-054f(40mg,0.47mmol),UB-054e(40mg,0.09mmol)和DIPEA(96mg,0.74mmol)溶解于NMP(3mL)。反应在微波180℃下搅拌3小时。反应完成后,将反应液冷却至室温。加水至反应液固体析出并过滤。溶解滤渣并通过硅胶柱纯化(DCM/MeOH=30%),并冻干得到想要的化合物UB-0450(16mg,20%产率)性状白色固体。LCMS[M+1]+=480.2。1H NMR(400MHz,DMSO-d6)δ8.34(s,1H),8.25(s,1H),7.92(dt,J=10.8,2.2Hz,1H),7.88–7.83(m,1H),7.65–7.56(m,5H),7.48–7.41(m,4H),7.34(t,J=7.3Hz,1H),7.22(td,J=8.5,2.2Hz,1H),4.67(s,2H),3.70–3.57(m,4H),2.81–2.66(m,4H),1.29(d,J=49.5Hz,3H).
实施例55:化合物UB-055的合成
步骤1:UB-055c
2,6-二氯-9-(1-甲基-1H-吡唑-4-基)-9H-嘌呤
将化合物UB-055b(666mg,5.29mmol),化合物UB-055a(500mg,2.64mmol),溶解于(10mL)二氯甲烷中,再加入醋酸铜(961mg,5.29mmol)和三乙胺(804mg,7.96mmol)。在室温下反应3小时。反应完成后,将反应液浓缩并且通过硅胶柱纯化(二氯甲烷),得到化合物(UB-055c,120mg,16.9%产率)性状黄色固体。LCMS[M+1]+=269.1.
步骤2:UB-055e
N-([1,1'-联苯]-4-基甲基)-2-氯-9-(1-甲基-1H-吡唑-4-基)-9H-嘌呤-6-胺
将化合物UB-055c(120mg,0.45mmol),UB-055d(80mg,0.43mmol)和三乙胺(130mg,1.29mmol)溶于异丙醇(2mL)。反应在80℃下搅拌2小时。反应完成后,将反应液冷却至
室温。将反应液过滤得到想要的化合物UB-055e(95mg,53%产率)性状白色固体。LCMS[M+1]+=416.2。
步骤3:UB-055
N-([1,1'-联苯]-4-基甲基)-9-(1-甲基-1H-吡唑-4-基)-2-(哌嗪-1-基)-9H-嘌呤-6-胺
将化合物UB-055f(99mg,1.15mmol),UB-055e(95mg,0.23mmol)和DIPEA(238mg,1.84mmol)溶解于NMP(3mL)。反应在微波180℃下搅拌3小时。反应完成后,将反应液冷却至室温。加水至反应液固体析出并过滤。溶解滤渣并通过硅胶柱纯化(DCM/MeOH=60%)并且冻干,得到想要的化合物UB-055(64mg,59%产率)性状白色固体。LCMS[M+1]+=466.2。1H NMR(400MHz,DMSO-d6)δ8.29(s,1H),8.29(s,1H),8.28–8.12(m,2H),8.15(d,J=4.4Hz,1H),7.98(s,1H),7.98(s,1H),7.68–7.55(m,4H),7.66–7.58(m,4H),7.48–7.42(m,4H),7.52–7.39(m,4H),7.34(t,J=7.3Hz,1H),7.34(t,J=7.3Hz,1H),4.66(s,2H),4.66(s,2H),3.92(s,3H),3.92(s,3H),3.69–3.61(m,4H),3.75–3.58(m,4H),2.74(s,4H),2.74(s,4H).
实施例59-63:化合物UB-056到UB-063的合成
UB-059,UB-060的合成方法,类似UB-032的合成。
UB-061的合成方法,类似UB-041的合成。
UB-062、UB-063的合成方法,类似UB-043的合成。
表A1
表A2
表A3
表A4
B.测试实施例
测试实施例1:细胞增殖实验
试剂:RPMI-1640培养基、McCoy's5A培养基、IMDM培养基、MEM培养基、L-15培养基、胎牛血清、青-链双抗、胰蛋白酶等、2-mercaptoethanol、NEAA、pyruvate等。
测试用细胞进行常规培养,细胞铺板前至少传2代以上。
将25uL1000个HT-29、N87、SKOV3、Colo-205和MDA-MB-231细胞接种于黑色壁
透明底384孔板中,加入25uL不同浓度化合物,在37℃、5%CO2条件下培养过夜,
将25uL1500个H82和H69细胞接种于黑色壁透明底384孔板中,加入25uL不同浓度化合物在37℃、5%CO2条件下培养细胞72小时。室温平衡384孔板,每孔加入25μL Cell试剂,在水平振荡摇床上振荡混匀2分钟使细胞裂解,室温孵育10分钟稳定发光信号,然后使用Envision检测化学发光信号。
所有细胞都进行相对应受试样品的IC50测定。
使用Alarm blue法检测各孔荧光强度,并计算IC50。
IC50由以下公式计算:
Y=Max+(Min-Max)/[1+(X/IC50)×Slope]
Y=Max+(Min-Max)/[1+(X/IC50)×Slope]
其中Min、Max和Slope分别表示最小值、最大值和斜率。
结果如表1所示,本发明的化合物在多个肿瘤细胞系上进行了细胞抑制实验,结果显示,大多数化合物在多个肿瘤细胞中都表现出很强的细胞杀伤作用,具有作为抗肿瘤药物开发的潜力。
表1
测试实施例2:免疫组织化学染色(Immunohistochemistry,IHC)
培养的细胞中,加入适量的化合物。在37℃组织培养箱中,孵育2小时。
培养的细胞用PBS洗涤两次后,加入100μL10%中性缓冲福尔马林,固定20分钟。
PBS洗洗涤3次之后,用CCNK抗体和通用二步法检测试剂盒(小鼠/兔增强聚合物法检测系统,PV-9000,Zsbio Inc,Beijing)进行免疫组织化学染色。
具体地,加入试剂盒中的内源性过氧化物酶阻断剂100μL,室温孵育10分钟;PBS缓冲液冲洗3分钟×3次。
加入100μL CCNK抗体1:5000稀释液,37℃孵育60分钟;PBS缓冲液冲洗3分钟×3次。
加入100μL反应增强液,37℃孵育20分钟;PBS缓冲液冲洗3分钟×3次。
加入100μL增强酶标羊抗小鼠/兔IgG聚合物,37℃孵育20分钟;PBS缓冲液冲洗3分钟×3次。
置于75%乙醇中,浸泡3分钟×2次;置于95%乙醇中,浸泡3分钟×2次;去除多余的液体后,置于无水乙醇中,浸泡3分钟×3次;去除多余的液体后,风干,封片后显微镜观察、拍照。
结果如图1和表2所示,可以看出本发明的化合物能够快速有效的降解Cyclin K蛋白,且大多化合物降解Cyclin K的活性显著优于CR8。
测试实施例3:蛋白质印迹
用500uL0.01mg/mL聚-D-赖氨酸氢溴酸盐包被透明12孔板,37℃放置1h,去除包被液,用1mL PBS清洗2遍,接种40万个HEK293细胞于12孔板中。细胞用化合物处理24h,去除培养基,用PBS清洗后,加入RIPA buffer裂解细胞;细胞裂解液加入Loading buffer后取适量体积缓慢加到胶板对应的孔中,跑SDS-PAGE胶(4%-12%)。跑胶结束后转到PVDF膜上,用5%脱脂奶粉室温封闭1小时。将膜放到用5%脱脂奶粉稀释的抗-细胞周期素K(Cyclin K)一抗中,4度慢摇过夜。一抗孵育结束后,用TBST摇床洗膜3次;加入与一抗对应的用5%脱脂奶粉稀释的抗兔HRP二抗,室温慢摇1小时。二抗孵育结束后,再次用TBST摇床洗膜3次。将PVDF膜平放到暗盒中,用ECL显影液均匀浸润条带,置于ChemDoc XRS+凝胶成像仪中拍照。使用ImageJ软件定量分析蛋白条带强度。
结果如图2和表2所示,可见本发明的化合物能够快速有效的降解Cyclin K蛋白,且大多化合物降解Cyclin K的活性显著优于CR8。
表2
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (15)
- 一种如式(I)所示的化合物或其药学上可接受的盐,
其中,R1各自独立地为H或C1-4烷基;下标n1为1、2或3;环Ar1选自下组:C6-10芳环、5至10元杂芳环、5至10元桥环;环Cr1选自下组:H、C3-10碳环基、3至10元杂环基、C6-10芳基、和5至10元杂芳基;Ra和Rb各自独立地选自下组:H、Re或R;或者Ra和Rb与环Ar1和环Cr1共同形成其中,X7各自独立地选自下组:-O-、-S-、-N(Rc)-、-C(Rc)2-、-C(Rc)2-C(Rc)2-;下标n5和n6各自独立地为0、1、2或3;Re各自独立地选自下组:羟基、C1-6烷基、-O-C1-6烷基、-O-C1-6亚烷基-Rf;其中,Rf选自下组:-CN、-OH、-NH2、-NH(C1-6烷基)、-N(C1-6烷基)2;下标n3和n4各自独立地为0、1、2、3或4;R2选自下组:H、CN、任选取代的C1-6烷基、任选取代的C2-6烯基、任选取代的C2-6炔基、任选取代的C3-8环烷基、任选取代的3至8元杂环基;X1、X2和X6各自独立地为N或C(Rc);X3、X4和X5各自独立地为N或C;M1选自下组:无、X8、(M4)s;其中,X8为N(Rc)或C(Rc)2;M4各自独立地选自下组:O、S、C(O)O、C(O)、N(Rc)和C1-4亚烷基;s为1、2或3;M2为无或如式A所示的环;
式A中,X9是与M1连接的位置,X10是与M3连接的位置;X9为N或C(Rm),X10选自下 组:O、S、N或C(Rm);X11和X12各自独立地选自下组:-C(Rm)2-、-N(Rm)-;下标m1和m2各自独立地为0、1、2或3,并且m1+m2≥2;其中,Rm各自独立地为Rc或Rm1;其中,Rm1各自独立地选自下组:羟基、任选取代的C1-6烷基、任选取代的C1-6羟基烷基、任选取代的C1-6卤代烷基;或者,两个Rm1共同形成单键、任选取代的C1-4亚烷基或任选取代的1至4元杂亚烷基;M3选自下组:无、R3、-NH-R3;其中,R3选自下组:H、任选取代的C1-6烷基、任选取代的C1-6-羟烷基、任选取代的C1-6-卤代烷基;Rc各自独立地为H或C1-4烷基;除非特别定义,所述任选取代是指未取代的或基团中一个或多个(如1、2、3或4个)氢被取代基R所取代,并且R选自下组:D、卤素、C1-6烷基、C1-6卤代烷基、C1-6羟烷基、C2-6烯基、C2-6炔基、-CN、-OR'、-NO2、-NR'R"、-SR'、-OC(O)R'、-C(O)R'、-CO2R'、-CONR'、-OC(O)NR'R"、-NR"C(O)R'、-NR"-C(O)NR'R"、-NR"C(O)2R'、-S(O)R'、-S(O)2R'、-S(O)2NR'R"、-NR"S(O)2R'、任选被一个或多个R'"所取代的C3-10环烷基、任选被一个或多个R'"所取代的4至10元杂环烷基、任选被一个或多个R'"所取代的C6-10芳基、任选被一个或多个R'"所取代的5至10元杂芳基、任选被一个或多个R'"所取代的-C1-4亚烷基-C3-10环烷基、任选被一个或多个R'"所取代的-C1-4亚烷基-4至10元杂环烷基、任选被一个或多个R'"所取代的-C1-4亚烷基-C6-10芳基、任选被一个或多个R'"所取代的-C1-4亚烷基-5至10元杂芳基;各个R'各自独立地为H、D、任选被一个或多个R'"所取代的选自下组的基团:C1-6烷基、C3-10环烷基、4至10元杂环烷基、C6-10芳基、5至10元杂芳基、-C1-4亚烷基-C3-10环烷基、-C1-4亚烷基-4至10元杂环烷基、-C1-4亚烷基-C6-10芳基-C1-4亚烷基-5至10元杂芳基;各个R"选自下组:H、D、C1-4烷基、C1-4卤代烷基、和C3-4环烷基;各个R"'独立地选自下组:D、卤素、羟基、硝基、CN、C1-6烷基、C1-6卤代烷基。 - 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,环Ar1选自下组:
其中,*代表与环Cr1连接的位置;Xa、Xb、Xc和Xd各自独立地为CH和N;Xg选自下组:NH、O、S;Xh、Xi和Xj各自独立为-CH2-或-CH2-CH2-;和/或,环Cr1选自下组:
其中,Xd和Xe各自独立地为N或CH;Xf为NH、S、O;Xg为N或CH。 - 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,选自下组:
- 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,环Cr1为环Ar2;并且环Ar2为C6-10芳基。
- 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,环Ar2为苯基。
- 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,所述的化合物如式I-1所示
或者,所述的化合物如式I-2所示
或者,所述的化合物如式I-3所示
或者,所述的化合物如式I-4所示
- 如权利要求6所述的化合物或其药学上可接受的盐,其特征在于,所述化合物为式I-1化合物,其中,为m3为0、1或2。
- 如权利要求6所述的化合物或其药学上可接受的盐,其特征在于,环Cr1为环Ar2;并且环Ar2为苯基。
- 如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,所述的化合物为选自表A1、A2、A3和表A4的化合物。
- 一种药物组合物,其特征在于,所述的药物组合物包括:(i)如权利要求1所述的化合物或其药学上可接受的盐;以及(ii)药学上可以接受的载体。
- 一种如权利要求1所述的化合物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
- 一种偶联物或其药学上可接受的盐,其特征在于,所述偶联物是由如权利要求1所述的化合物与多肽元件或靶向配体形成的偶联物。
- 如权利要求12所述的偶联物或其药学上可接受的盐,其特征在于,所述偶联物如式II所示
MD-ML-MP (II)其中,MD是衍生自如第一方面所述的如式(I)所示的化合物的部分;ML为无或用于连接MD和MP的连接部分;MP为衍生自多肽元件或靶向配体的部分。 - 一种药物组合物,所述的药物组合物包括:(i)如权利要求12所述的偶联物或其药学上可接受的盐;以及(ii)药学上可以接受的载体。
- 一种如权利要求12所述的偶联物或其药学上可接受的盐在制备用于治疗癌症的药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211037727.8 | 2022-08-26 | ||
CN202211037727.8A CN117659016A (zh) | 2022-08-26 | 2022-08-26 | 细胞周期蛋白调节剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024041661A1 true WO2024041661A1 (zh) | 2024-02-29 |
Family
ID=90012601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/115312 WO2024041661A1 (zh) | 2022-08-26 | 2023-08-28 | 细胞周期蛋白调节剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117659016A (zh) |
WO (1) | WO2024041661A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1231611A (zh) * | 1996-08-02 | 1999-10-13 | Cv治疗公司 | 依赖细胞周期蛋白的激酶2和IKB-α的嘌呤抑制剂 |
US20020091263A1 (en) * | 1999-03-17 | 2002-07-11 | Trova Michael Peter | Biaryl substituted purine derivatives as potent antiproliferative agents |
US20030087906A1 (en) * | 2001-09-11 | 2003-05-08 | Trova Michael Peter | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
US20030092909A1 (en) * | 2001-09-11 | 2003-05-15 | Trova Michael Peter | Heterocycle substituted purine derivatives as potent antiproliferative agents |
US20030125342A1 (en) * | 1999-03-17 | 2003-07-03 | Trova Michael Peter | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
CN105026396A (zh) * | 2013-02-08 | 2015-11-04 | 奥洛穆茨帕拉茨基大学 | 2-取代-6-联芳基甲基氨基-9-环戊基-9h-嘌呤衍生物、其作为药物的用途及药物组合物 |
WO2023059609A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
-
2022
- 2022-08-26 CN CN202211037727.8A patent/CN117659016A/zh active Pending
-
2023
- 2023-08-28 WO PCT/CN2023/115312 patent/WO2024041661A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1231611A (zh) * | 1996-08-02 | 1999-10-13 | Cv治疗公司 | 依赖细胞周期蛋白的激酶2和IKB-α的嘌呤抑制剂 |
US20020091263A1 (en) * | 1999-03-17 | 2002-07-11 | Trova Michael Peter | Biaryl substituted purine derivatives as potent antiproliferative agents |
US20030125342A1 (en) * | 1999-03-17 | 2003-07-03 | Trova Michael Peter | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
US20030087906A1 (en) * | 2001-09-11 | 2003-05-08 | Trova Michael Peter | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
US20030092909A1 (en) * | 2001-09-11 | 2003-05-15 | Trova Michael Peter | Heterocycle substituted purine derivatives as potent antiproliferative agents |
CN105026396A (zh) * | 2013-02-08 | 2015-11-04 | 奥洛穆茨帕拉茨基大学 | 2-取代-6-联芳基甲基氨基-9-环戊基-9h-嘌呤衍生物、其作为药物的用途及药物组合物 |
WO2023059609A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Non-Patent Citations (1)
Title |
---|
KRAJČOVIČOVÁ SOŇA, GUCKÝ TOMÁŠ, HENDRYCHOVÁ DENISA, KRYŠTOF VLADIMÍR, SOURAL MIROSLAV: "A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 82, no. 24, 15 December 2017 (2017-12-15), pages 13530 - 13541, XP093142317, ISSN: 0022-3263, DOI: 10.1021/acs.joc.7b02650 * |
Also Published As
Publication number | Publication date |
---|---|
CN117659016A (zh) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7057798B2 (ja) | mTORC1阻害剤 | |
JP7394074B2 (ja) | 治療用化合物 | |
WO2020073930A1 (zh) | 靶向蛋白酶降解平台(ted) | |
AU2016262107B2 (en) | Silicon based drug conjugates and methods of using same | |
AU2020205339A1 (en) | Macrocyclic compounds as Trk kinase inhibitors | |
CN105198908B (zh) | 新型苯并二氮杂*衍生物 | |
CN107335061B (zh) | 细胞毒性苯并二氮杂䓬衍生物 | |
CN115873020A (zh) | Ras抑制剂 | |
JP2019517564A (ja) | シラノール系治療的ペイロード | |
CN102971329A (zh) | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 | |
WO2021205391A1 (zh) | 靶向蛋白酶降解(ted)平台 | |
JP2023511337A (ja) | ピリミジン-4(3h)-オンヘテロ環式化合物、その調製方法、およびその医薬的使用 | |
WO2023116934A1 (zh) | Kras g12d蛋白水解调节剂及其制备方法和应用 | |
WO2022161222A1 (zh) | 一类杂环类shp2抑制剂、其制备方法及用途 | |
WO2022117075A1 (zh) | 氮杂并环化合物、其制备方法及其用途 | |
WO2020238776A1 (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
WO2024041661A1 (zh) | 细胞周期蛋白调节剂 | |
US20230312601A1 (en) | Thiazolo[5,4-b]pyridine malt-1 inhibitors | |
WO2021057867A1 (zh) | 一类基于有机胂的cdk抑制剂及其制备方法和用途 | |
WO2022078356A1 (zh) | 杂芳环类AhR抑制剂 | |
WO2023056981A1 (zh) | 靶向蛋白酶降解(ted)平台 | |
WO2023098831A1 (zh) | 靶向蛋白酶降解(ted)平台 | |
WO2023246371A1 (zh) | 具有嘧啶并噻吩结构的小分子化合物及其应用 | |
WO2023151635A1 (zh) | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 | |
WO2023147328A1 (en) | Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23856746 Country of ref document: EP Kind code of ref document: A1 |